Elovl1 inhibitors
Compounds of formula (I) and (I¹) with specific ring structures inhibit ELOVL1 activity, addressing the challenge of developing therapeutic inhibitors for VLCFA-related disorders by modulating VLCFA levels and improving lipid metabolism and skin barrier function.
Patent Information
- Application Number
- PCT/US2026/028567
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-18
- Publication Date
- 2026-11-19
AI Technical Summary
The development of selective and efficacious ELOVL1 inhibitors is challenging due to the structural and functional complexity of the enzyme, necessitating compounds that demonstrate high potency, selectivity, and pharmacokinetic properties suitable for therapeutic applications to address conditions associated with dysregulated lipid metabolism and skin barrier function.
Development of compounds of formula (I) or (I¹) and their pharmaceutically acceptable salts, which modulate ELOVL1 activity, forming spiro or fused ring moieties with specific substituents, to inhibit ELOVL1 activity and treat conditions like X-linked adrenoleukodystrophy and other VLCFA-related disorders.
The compounds effectively inhibit ELOVL1 activity, providing therapeutic benefits for conditions such as X-linked adrenoleukodystrophy and other VLCFA-related disorders by modulating VLCFA levels and improving lipid metabolism and skin barrier function.
Smart Images

Figure US2026028567_19112026_PF_FP_ABST
Abstract
Description
Series 1 / 5 33827 / 50003 / PCELOVL1 INHIBITORSBACKGROUND
[0001] ELOVL fatty acid elongase 1 (ELOVL1) plays a crucial role in the elongation of long-chain fatty acids, particularly in the biosynthesis of very long-chain fatty acids (VLCFAs). VLCFAs serve as essential components of various cellular structures, including cell membranes and lipid droplets, and are involved in diverse physiological processes such as lipid metabolism, skin barrier function, and neurological development, especially as a major lipid component of myelin.
[0002] ELOVL1 (Elongation of Very Long Chain Fatty Acids Protein 1) is a ubiquitously expressed enzyme responsible for the elongation of saturated and monounsaturated fatty acids into very long chain fatty acids (VLCFAs). VLCFAs are synthesized predominantly via endogenous pathways, as dietary contribution is minimal, and their production is largely cell-autonomous. The homeostasis of VLCFAs across both central and peripheral tissues is critical for maintaining normal physiological function.
[0003] VLCFA levels are regulated by a balance between biosynthesis— primarily through ELOVL1— and peroxisomal degradation. Notably, ELOVL1 activity does not appear to be subject to feedback inhibition by its VLCFA products. As such, when degradation pathways are compromised, VLCFAs can accumulate unchecked. Reduced expression or activity of ELOVL1 has been linked to impaired lipid metabolism and skin barrier function.
[0004] Accumulation of VLCFAs is associated with several deleterious outcomes, most notably in X-linked adrenoleukodystrophy (X-ALD), a neurodegenerative disorder characterized by acute inflammatory demyelination, neuropathy, and adrenal insufficiency. X-ALD is frequently caused by mutations in the ABCD1 (ATP-binding cassette sub-family D member 1) gene, which encodes a peroxisomal transporter essential for VLCFA degradation. In these patients, elevated VLCFA levels are strongly implicated in disease pathogenesis. Therefore, selective inhibition of ELOVL1 offers a promising therapeutic strategy to mitigate VLCFA accumulation in conditions where peroxisomal degradation is impaired.
[0005] Given the significance of ELOVL1 in health and disease, there is a growing interest in the development of inhibitors targeting this enzyme as potential therapeutic agents. Inhibition of ELOVL1 activity presents a promising approach for modulating VLCFA levels and addressing conditions associated with dysregulated lipid metabolism and skin barrier function. However, the development of selective and efficacious ELOVL1 inhibitors presents a significant challenge due to the structural and functional complexity of the enzyme.
[0006] Thus, there is a need for ELOVL1 inhibitors that demonstrate high potency, selectivity, and pharmacokinetic properties suitable for therapeutic applications. Such inhibitors have the potential to address unmet medical needs and improve the treatment outcomes of conditions associated with dysregulated ELOVL1 activity.Series 1 / 5 33827 / 50003 / PCSUMMARY
[0007] The disclosure provides a compound of formula (I) or (I1):pharmaceutically acceptable salt thereof, wherein Ring A is C6-10aryl, 5-6 membered heteroaryl having 1, 2, or 3 ring heteroatoms independently selected from N, O, and S, indolyl, isoindolyl, indolinyl, or isoindolinyl; or each R1is independently halogen, CN, oxo, Ci-salkyl, C1-3alkoxy, Ci-ahaloalkyl, C1-3haloalkoxy, -S(O)2R3, C0-2alkylene-C(O)R4, C0-2alkylene-Cyc, C(O)-Cyc, N(RN)2, NRNC(O)-Cyc, or C(O)NRN-Cyc; or one R1taken together with Ring A and themorpholine ring forms (a) a spiro ring moiety having a structurefused ring moietyhaving a structuresubstituted with 0 to 4 R1; n is 0, 1, 2, 3, 4, or 5; each of R2and R2Ais H, or R2and R2A, together with the atoms to which they are attached, form a fused cyclopropyl ring;Cyc is Cs-ecycloalkyl, C6-10aryl, 5-6-membered heterocycle, or 5-6 membered heteroaryl, wherein the heterocycle and heteroaryl have 1 to 3 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc; each RCycis independently halogen, oxo, OH, C1-4 alkyl, C0-2alkylene-C(O)R4, or -S(O)2R3; each R3is independently N(RN)2, Ci-galkyl, or Cs-ecycloalkyl; each R4is independently OH, N(RN)2, phenyl, C1-3 alkyl, C1.3 alkoxy, Ci-3haloalkyl, Cishaloalkyoxy, Ci^hydroxyalkyl, or Ci-shydroxyalkoxy; each RNis independently H, phenyl, C1-4 alkyl, or -S(O)2Ci-3alkyl; and Het is pyrazolyl or triazolyl and is substituted with 0, 1, or 2 halogens, with the proviso that when n is 0, Ring A is phenyl, and R2Aand R2are H, then Het is substituted with 1 or 2 halogens.
[0008] In some cases, e.g., for Formula (I), each R1is independently halogen, -CN, Ci-salkyl, Cvsalkoxy, Ci. ahaloalkyl, C1-3haloalkoxy, phenyl, -SO2R3, 5-membered heterocycle having 1 to 3 heteroatoms independently selected from N, O, and S, or an R1can comprise an Cisalkylene such that when taken together with the phenyl ringand morpholine ring forms a spiro ring moiety having a structurethe phenyl ring is furtherSeries 1 / 5 33827 / 50003 / PCsubstituted with 0 to n-1 R1, or an R1can comprise -O-CH2- such that when taken together with the phenyl ring andmorpholine ring forms a moiety having a structurethe phenyl is further substituted with 0 to n-1R1; each of R2and R2Ais H, or R2and R2A, together with the atoms to which they are attached, form a fused cyclopropyl ring; R3is Ci-salkyl or Cs-ecycloalkyl; Het is pyrazolyl or triazolyl; and n is 1, 2, 3, 4, or 5.
[0009] The disclosure also provides pharmaceutical compositions comprising a compound or a salt thereof, as disclosed herein, and methods of using the disclosed compounds, such as methods of treating disorders, diseases, or conditions associated with, or caused by the accumulation of Very Long Chain Fatty Acids (VLCFAs).DETAILED DESCRIPTION
[0010] Provided herein are compounds, and pharmaceutically acceptable salts thereof, that modulate ELOVL1 activity and methods of using the same. The compounds disclosed herein inhibit ELOVL1 activity and are suitable for treating various disorders, diseases, or conditions associated with, or caused by, the accumulation of Very Long Chain Fatty Acids (VLCFAs). For example, the disclosed compounds advantageously provide a method for modulating ELOVL1 activity in diseases such as (but not limited to) X-linked adrenoleukodystrophy, (X-ALD or ALD), cerebral adrenoleukodystrophy (cALD), childhood onset cerebral adrenoleukodystrophy (CCALD), adolescent onset cerebral adrenoleukodystrophy, adult onset cerebral adrenoleukodystrophy, cerebello-brainstem form of ALD (CBALD), adrenomyeloneuropathy (AMN) or adrenal insufficiency (Addison only) form of ALD., conditions characterized by mutations in ABCD1, ACOX1, ACOX2, HSD17B4, AMACR, PHYH, or a combination thereof (e.g., Zellweger Spectrum Disorder and presentations thereof, including Zellweger Syndrome (ZSD), Neonatal Adrenoleukodystrophy (NALD), Infantile Refsum Disease (IRD), Adult Refsum Disease (ARD), Heimler Syndrome, mitochondrial disorders, and peripheral neuropathies), and Multiple Sclerosis (MS).
[0011] In some embodiments, the disclosure provides the disclosed compounds in the form of a salt. As used herein, the terms "salt" or "salts" refers to an acid addition or base addition salt of a compound of the invention. " Salts" include in particular "pharmaceutical acceptable salts". The term "pharmaceutically acceptable salts" refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable. In many cases, the compounds of the present invention are capable of forming acid and / or base salts by virtue of the presence of amino and / or carboxyl groups or groups similar thereto.
[0012] Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuricSeries 1 / 5 33827 / 50003 / PCacid, nitric acid, and phosphoric acid. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, benzenesuflonic acid, toluenesulfonic acid, and sulfosalicylic acid.
[0013] Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper. In certain other embodiments, the salts are selected from ammonium, potassium, sodium, calcium and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
[0014] In another aspect, the present invention provides compounds as disclosed herein in acetate, ascorbate, adipate, aspartate, benzoate, besylate, bromide / hydrobromide, bicarbonate / carbonate, bisulfate / sulfate, camphorsulfonate, caprate, chloride / hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide / iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, mucate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate / hydrogen phosphate / dihydrogen phosphate, polygalacturonate, propionate, sebacate, stearate, succinate, sulfosalicylate, sulfate, tartrate, tosylate trifenatate, trifluoroacetate or xinafoate salt form. In yet another aspect, the present invention provides compounds as disclosed herein in Ci-C4alkyl sulfonic acid, benzenesulfonic acid or mono-, di- or tri-Ci-C4alkyl substituted benzene sulfonic acid addition salt form.
[0015] Compounds of the disclosure can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof. It is understood that for any compound provided herein, including any compound of formulae (I') or (I), or any embodiment thereof, or a salt of any of the foregoing, the compound may exist in any stereochemical form, such as a single enantiomer, diastereomer, or tautomer or a mixture of one or more enantiomers, diastereomers, and tautomers in any ratio.
[0016] For example, any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the ( / ?)-, (S)- or (R, S)-configuration. In certain embodiments, each asymmetric atom has at least 50% enantiomeric excess (ee), at least 60% ee, at least 70% ee, at least 80% ee, at least 90% ee, at least 95% ee, or at least 99% ee in the ( / ?)- or (S)-configuration. Substituents at atoms with unsaturated bonds may, if possible, be present in c / s-(Z)- or trans-(E)-form. If the compound contains aSeries 1 / 5 33827 / 50003 / PCdisubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration.
[0017] As used herein, the term "isomers" refers to different compounds that have the same molecular formula but differ in arrangement and configuration of the atoms. Also as used herein, the term "an optical isomer" or "a stereoisomer" refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. " Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic" mixture. The term is used to designate a racemic mixture where appropriate. The use of "rel" indicates that the diastereomeric orientation is known but the absolute stereochemistry is not. In cases where the absolute stereochemistry has not been determined the optical rotation and / or chiral chromatography conditions will indicate which isomer is present.
[0018] " Diastereoisomers" are stereoisomers that have at least two asymmetric atoms, but which are not mirrorimages of each other. The absolute stereochemistry is specified according to the Cahn-lngold-Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line or retention time on chiral chromatography separation. Certain of the compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-, or with the (+) or (-) sign. The present invention is meant to include all such possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures. Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration, for instance, 1,3- disubstituted cyclobutanes can be either of the following geometric isomers, cis
[0019] Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and / or fractional crystallization.
[0020] Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base,Series 1 / 5 33827 / 50003 / PCand liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O, O'-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic products can also be resolved by chiral chromatography, e.g., high performance liquid chromatography (HPLC) or supercritical fluid chromatography (SFC) using a chiral adsorbent.
[0021] Mixtures of isomers obtainable according to the invention can be separated in a manner known to those skilled in the art into the individual isomers; diastereoisomers can be separated, for example, by partitioning between polyphasic solvent mixtures, recrystallization and / or chromatographic separation, for example over silica gel or by e.g. medium pressure liquid chromatography over a reversed phase column, and racemates can be separated, for example, by the formation of salts with optically pure salt-forming reagents and separation of the mixture of diastereoisomers so obtainable, for example by means of fractional crystallization, or by chromatography over optically active column materials. Certain compounds disclosed herein are named using pseudoasymmetric descriptors (r / s) by compound-naming programs such as ChemDraw (e.g., see Stereochemistry of organic compounds by E. L. Eliel and S. H. Wilen. John Wiley & Sons: 1994, pages 666-668).COMPOUNDS OF THE DISCLOSURE
[0022] The disclosure provides compounds, or a pharmaceutically acceptable salt thereof, wherein the compoundwherein
[0023] Ring A is Ce- aryl, 5-6 membered heteroaryl having 1, 2, or 3 ring heteroatoms independently selected from N, 0, and S, indolyl, isoindolyl, indolinyl, or isoindolinyl;
[0024] each R1is independently halogen, CN, oxo, Ci-3alkyl, C1-3alkoxy, C1-3haloalkyl, Ci-ahaloalkoxy, -S(O)2R3,C0-2alkylene-C(O)R4, C0-2alkylene-Cyc, C(O)-Cyc, N(RN)2, NRNC(O)-Cyc, or C(O)NRN-Cyc; orone R1taken together with Ring A and the morpholine ring forms(a) a spiro ring moiety having a structureSeries 1 / 5 33827 / 50003 / PC(b) a fused ring moiety having a structureRing A is further substituted with 0 to 4 R1;
[0025] n is 0, 1, 2, 3, 4, or 5;
[0026] each of R2and R2Ais H, or R2and R2A, together with the atoms to which they are attached, form a fused cyclopropyl ring;
[0027] Cyc is C3-6cycloalkyl, C6-10aryl, 5-6-membered heterocycle, or 5-6 membered heteroaryl, wherein the heterocycle and heteroaryl have 1 to 3 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc;
[0028] each RCycis independently halogen, oxo, OH, CM alkyl, C0-2alkylene-C(O)R4, or -S(O)2R3;
[0029] each R3is independently N (RN)2, Ci-3alkyl, or Cs-ecycloalkyl;
[0030] each R4is independently OH, N(RN)2, phenyl, C1-3 alkyl, C1.3 alkoxy, C1-3haloalkyl, Ci-shaloalkyoxy, Ci. shydroxyalkyl, or Ci-shydroxy alkoxy;
[0031] each RNis independently H, phenyl, C1-4 alkyl, or -S(O)2Ci-3alkyl; and
[0032] Het is pyrazolyl or triazolyl and is substituted with 0, 1, or 2 halogens,with the proviso that when n is 0, Ring A is phenyl, and R2Aand R2are H, then Het is substituted with 1 or 2 halogens.
[0033] The disclosure also provides compounds, or a pharmaceutically acceptable salt thereof, wherein the compound has a structure of formula (I):wherein
[0034] each R1is independently halogen, -CN, Ci-3alkyl, C1-3alkoxy, C1-3haloalkyl, C1-3haloalkoxy, phenyl, -SO2R3, 5-membered heterocycle having 1 to 3 heteroatoms independently selected from N, O, and S, or an R1can comprise an Ci-3al ky lene such that when taken together with the phenyl ring and morpholine ring forms a spiro ring moietySeries 1 / 5 33827 / 50003 / PChaving a structurethe phenyl ring is further substituted with 0 to n-1 R1, or an R1can comprise -O-CH2- such that when taken together with the phenyl ring and morpholine ring forms a moiety having astructurethe phenyl is further substituted with 0 to n-1 R1;
[0035] each of R2and R2Ais H, or R2and R2A, together with the atoms to which they are attached, form a fused cyclopropyl ring;
[0036] R3is Ci.3alkyl or Cs-ecycloalkyl;
[0037] Het is pyrazolyl or triazolyl; and
[0038] n is 1, 2, 3, 4, or 5.
[0039] As used herein, the term "halogen" or “halo” refers to fluoro, chloro, bromo, and / or iodo.
[0040] As used herein, the term "alkyl" refers to a fully saturated branched or unbranched hydrocarbon moiety having up to 20 carbon atoms. Unless otherwise provided, alkyl refers to hydrocarbon moieties having 1 to 20 carbon atoms, 1 to 16 carbon atoms, 1 to 10 carbon atoms, 1 to 7 carbon atoms, 1 to 6 carbon atoms, 1 to 5 carbon atoms, 1 to 4 carbon atoms, or 1 to 3 carbon atoms. More particularly, the term Cnmeans the alkyl group has “n” carbon atoms. For example, C4 alkyl refers to an alkyl group that has 4 carbon atoms. Accordingly, the term C alkyl refers to an alkyl group having a number of carbon atoms encompassing the entire range (e.g., 1, 2, and / or 3 carbon atoms). Suitable representative examples of Ci-3alkyl groups include methyl, ethyl, n-propyl, and isopropyl.
[0041] As used herein, the term "cycloalkyl" refers to a saturated carbocyclic group containing from 3 to 8 carbon atoms (e.g., 3 to 8, 3 to 7, 3 to 6, 3 to 5 carbon atoms), such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, and cyclooctyl. In some embodiments, cycloalkyl is cyclopropyl.
[0042] As used herein, the term "alkylene" refers to divalent alkyl group as defined herein above having 1 to 20 carbon atoms. Unless otherwise provided, alkylene refers to moieties having 1 to 20 carbon atoms, 1 to 16 carbon atoms, 1 to 10 carbon atoms, 1 to 7 carbon atoms, 1 to 6 carbon atoms, 1 to 5 carbon atoms, 1 to 4 carbon atoms, or 1 to 3 carbon atoms. The term Cnmeans the alkylene group has “n” carbon atoms. For example, C2 alkylene refers to an alkylene group that has 2 carbon atoms. C1-2alkylene refers to an alkylene group having a number of carbon atoms encompassing the entire range (e.g., 1 to 2 carbon atoms). Moreover, the term Coalkylene refers to 0 carbonSeries 1 / 5 33827 / 50003 / PCatoms, that is, the Coalkylene moiety is a direct bond. Representative examples of alkylene include, but are not limited to, methylene, ethylene, n-propylene, iso-propylene, n-butylene, sec-butylene, iso-butylene, tert-butylene, n-pentylene, isopentylene, neopentylene, n-hexylene, 3-methylhexylene, 2,2-dimethylpentylene, 2,3-dimethylpentylene, n-heptylene, n-octylene, n-nonylene, and n-decylene. Ci-2alkylene includes methylene and ethylene.
[0043] As used herein, the term “alkoxy” refers to the group R'-O-, wherein R' is alkyl having the previously given meaning. Suitable examples of Ci-3alkoxy groups include methoxy, ethoxy, n-propoxy, and isopropoxy.
[0044] As used herein, the term “haloalkyl” refers to an alkyl group, as previously defined, substituted with at least one halogen, particularly substituted with one to five halogens, particularly one to three halogens. Haloalkyl also includes perhalogenated species, wherein all hydrogens are substituted with halogen. Some non-limiting “haloalkyl'' are fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, fluoropropyl, and fluorobutyl.
[0045] As used herein, the term “hydroxyalkyl” refers to an alkyl group, as previously defined, substituted with at least one hydroxy group (OH), particularly substituted with one to three hydroxy groups, particularly one hydroxy group. Some non-limiting “hydroxyalkyl” are hydroxymethyl, hydroxyethyl, hydroxypropyl, and hydroxybutyl.
[0046] As used herein, the term “haloalkoxy” refers to an alkoxy group, as previously defined, substituted with at least one halogen, particularly substituted with one to five halogens, particularly one to three halogens. Haloalkoxy includes perhalogenated species wherein all hydrogens are substituted with halogen. Particular “haloalkyl” are fluoromethoxy, fluoroethoxy, fluoropropoxy, and fluorobutoxy.
[0047] As used herein, the term “hydroxyalkoxy” refers to an alkoxy group, as previously defined, substituted with at least one hydroxy group, particularly substituted with one to three hydroxy groups, particularly one hydroxy group. Some non-limiting “hydroxyalkoxy” are hydroxyethoxy, hydroxypropoxy, and hydroxybutoxy.
[0048] As used herein, the term “heterocycle” or "heterocyclyl" refers to a saturated or partly unsaturated 3-, 4-, 5-, 6- or 7- membered ring which can comprise one, two, three, or four ring heteroatoms independently selected from N, O and S. Examples of heterocyclyl rings include piperidinyl, piperazinyl, azetidinyl, azepinyl, pyrrolidinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, oxiranyl, thiadiazolylidinyl, oxetanyl, dioxolanyl, dihydrofuryl, tetrahydrofuryl, dihydropyranyl, tetrahydropyranyl, and thiomorpholinyl. The term 5-membered heterocycles refers to those heterocycles having 5-membered rings.
[0049] As used herein, the term “heteroaryl” refers to an aromatic heterocyclic group, e.g., 5-, 6- 7- 8-, 9-, 10-, 11-, or 12-membered ring which can comprise one, two, three, or four ring heteroatoms independently selected from N, O and S. Examples of heteroaryl rings include pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiophenyl, indolyl, benzimidiazolyl, purinyl, benzofuranyl, quinolinyl, isoquinolinyl, indolizinyl, indazolyl, and quinazolinyl. The term 5-membered heteroaryl refers to those heteroaryls having 5-membered rings.Series 1 / 5 33827 / 50003 / PC
[0050] As used herein, the term “aryl’’ refers to an aromatic 6- 7- 8-, 9- 10-, 11-, or 12-membered ring comprising carbon atoms. Examples of aryl rings include phenyl, naphthyl (e.g., 1 -naphthyl or 2-naphthyl), azulenyl, and acenaphthylenyl. The term 10-membered or C10 aryl refers to those aryls having 10-membered rings (e.g., naphthyl).
[0051] " Oxo” refers to a double-bonded oxygen (=0) as a substituent.Ring A
[0052] The compounds of formula (I1) comprising Ring A, wherein Ring A is C6-10aryl, 5-6 membered heteroaryl having 1, 2, or 3 ring heteroatoms independently selected from N, O, and S, indolyl, isoindolyl, indolinyl, or isoindolinyl. In some embodiments, Ring A is Ce- aryl or 5-6 membered heteroaryl having 1, 2, or 3 ring heteroatoms independently selected from N, O, and S. In some embodiments, Ring A is indolyl, isoindolyl, indolinyl, or isoindolinyl. In some embodiments, Ring A is Ce-waryl. In some embodiments, Ring A is 5-6 membered heteroaryl having 1, 2, or 3 ring heteroatoms independently selected from N, 0, and S. In some embodiments, Ring A is 6-membered heteroaryl having 1, or 2 ring nitrogens. In some embodiments, Ring A is 5-membered heteroaryl having 1, or 2 ring nitrogens. In some embodiments, Ring A is pyridinyl, pyrazolyl, pyrimidinyl or phenyl. In some embodiments, Ring A is pyridinyl, pyrazolyl, or pyrimidinyl. In some embodiments, Ring A is phenyl or naphthyl.In some embodiments, Ring A is phenyl or pyridinyl. In some embodiments, Ring A is phenyl or pyrazolyl. In some embodiments, Ring A is phenyl or pyrimidinyl. In some embodiments, Ring A is naphthyl. In some embodiments, Ring A is pyridinyl. In some embodiments, Ring A is pyrazolyl. In some embodiments, Ring A is pyrimidinyl. In some embodiments, Ring A is phenyl. In some embodiments, Ring A is indolinyl.(R1)nand R3
[0053] The compounds of formulae (I’) or (I) comprising a (R1)nmoiety, wherein n is 0, 1, 2, 3, 4, or 5. In some embodiments, n is 0 such that R1is absent (i.e., Ring A or the phenyl ring is unsubstituted). In some embodiments, n is 1. In some embodiments, n is 2 or more (i.e., 2, 3, 4 or 5). In some embodiments, n is 1, 2, or 3. In some embodiments, n is 1 or 2.
[0054] In some embodiments, at least one R1is halogen (i.e., F, Cl, Br, or I). In some embodiments, at least one R1is fluoro (i.e., F) In some embodiments, n is 1 and R1is F. In some embodiments, at least one R1is chloro (i.e., Cl). In some embodiments, n is 1 and R1is Cl. In some embodiments, at least two R1are F. In some embodiments, n is 2 and each R1is F.
[0055] In some embodiments, at least one R1is cyano (i.e., -CN). In some embodiments, n is 1 and R1is -CN.
[0056] In some embodiments, at least one R1is C1-3alkyl (e.g., methyl, ethyl, propyl, or isopropyl). In some embodiments, at least one R1is methyl. In some embodiments, n is 1 and R1is C1-3alkyl (e.g., methyl).
[0057] In some embodiments, at least one R1is C1-3alkoxy (e.g., methoxy, ethoxy, propoxy, or isopropoxy). InSeries 1 / 5 33827 / 50003 / PCsome embodiments, at least one R1is methoxy. In some embodiments, n is 1 and R1is C1-3alkoxy (e.g., methoxy).
[0058] In some embodiments, at least one R1is C1-3haloalkyl. In some embodiments, at least one R1is fluoromethyl (-CH2F), difluoromethyl (-CHF2), or trifluoromethyl (-CF3). In some embodiments, n is 1 and R1is C1-3haloalkyl. In some embodiments, n is 1 and R1is fluoromethyl (-CH2F), difluoromethyl (-CHF2), or trifluoromethyl (-CF3).
[0059] In some embodiments, at least one R1is C1-3haloalkoxy. In some embodiments, at least one R1is difluoromethoxy or trifluoromethoxy. In some embodiments, n is 1 and R1is Ci-3haloalkoxy. In some embodiments, n is 1 and R1is difluoromethoxy or trifluoromethoxy.
[0060] In some embodiments, at least one R1is oxo. In some embodiments, n is 1 and R1is oxo. In some embodiments, n is 2 and one R1is oxo and the other is methyl.
[0061] In some embodiments, at least one R1is -SO2R3, wherein R3is N(RN)2, C1-3alkyl, or C3-6cycloalkyl. In some embodiments, at least one R1is -SO2CH3. In some embodiments, n is 1 and R1is -SO2R3. In some embodiments, n is 1 and R1is -SO2CH3. In some embodiments, at least one R1is -SO2N(RN)2. In some embodiments, n is 1 and R1is - SO2N(RN)2. In some embodiments, n is 1 and R1is -SO2NH2. In some embodiments, n is 1 and R1is -SO2NHMe. In some embodiments, n is 1 and R1is -SO2NMe2.
[0062] In some embodiments, at least one R1is -SO2R3, wherein R3is C1-3alkyl or C3-6cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl). In some embodiments, at least one R1is -SO2CH3. In some embodiments, n is 1 and R1is -SO2R3. In some embodiments, n is 1 and R1is -SO2CH3.
[0063] In some embodiments, at least one R1is C0-2alkylene-C(O)R4, wherein R4is OH, N (RN)2, phenyl, C1.3 alkyl, C1-3alkoxy, C1-3haloalkyl, C1-3haloalkyoxy, C1-3hydroxyalkyl, or C1-3hydroxyalkoxy. In some embodiments, at least one R1is C0-1alkylene-C(O)R4, wherein R4is OH. In some embodiments, at least one R1is C0-1alkylene-C(O)R4, wherein R4is N(RN)2and at least one RNis H. In some embodiments, at least one R1is C0-1alkylene-C(O)R4, wherein R4is N(RN)2and at least one RNis Me. In some embodiments, n is 1 and R1is CO2H. In some embodiments, n is 1 and R1is CH2CO2H. In some embodiments, n is 1 and R1is CH2C(O)NHMe. In some embodiments, n is 1 and R1is C(O)NHMe In some embodiments, n is 1 and R1is CH2CO2NH2. In some embodiments, n is 1 and R1is C(O)NH2. In some embodiments, n is 1 and R1is CH2C(O)NMe2. In some embodiments, n is 1 and R1is -CO2NMe2. In some embodiments, n is 1 and R1is C(O)NHS(O)2Me2. In some embodiments, n is 2, one R1is C0-1alkylene-CO2H and the other R1is F. In some embodiments, n is 2, one R1is C0-1alkylene-C(O)NH2and the other R1is F. In some embodiments, n is 2, one R1is C0-1alkylene-C(O)NHMe and the other R1is F. In some embodiments, n is 2, one R1is C0-1alkylene-C(O)NMe2and the other R1is F.
[0064] In some embodiments, at least one R1is phenyl. In some embodiments, n is 1 and R1is phenyl.
[0065] In some embodiments, at least one R1is a 5-membered heterocycle having 1 to 3 heteroatomsSeries 1 / 5 33827 / 50003 / PCindependently selected from N, 0, and S. In some embodiments, n is 1 and R1is a 5-membered heterocycle having 1 to 3 heteroatoms independently selected from N, 0, and S. In some embodiments, at least one R1is pyrrolidinyl. In some embodiments, n is 1 and R1is pyrrolidinyl. In some embodiments, at least one R1is pyrrolidinyl. In some embodiments, n is 1 and R1is pyrrolidinyl.
[0066] In some embodiments, at least one R1is N(RN)2. In some embodiments, n is 1 and R1is N(RN)2, wherein one RNis H, and the other RNis selected from phenyl, C1-4 alkyl, or -S(O)2Ci-3alkyl. In some embodiments, n is 1 and R1is N(RN)2, wherein one RNis methyl, and the other RNis selected from phenyl, C1.4 alkyl, or -S(O)2Ci-3alkyl. In some embodiments, n is 1 and R1is N(Me)2. In some embodiments, n is 1 and R1is NH2. In some embodiments, n is 1 and R1is NHMe.
[0067] In some embodiments, n is1, R1is C0-2alkylene-Cyc, and Cyc is C3-6cycloalkyl, C6-10aryl, 5-6-membered heterocycle, or 5-6 membered heteroaryl, wherein the heterocycle and heteroaryl have 1 to 3 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is1, R1is Cyc, and Cyc is C6-10aryl, 5-6-membered heterocycle, or 5-6 membered heteroaryl, wherein the heterocycle and heteroaryl have 1 to 3 ring heteroatoms independently selected from N, O, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is1, R1is Cyc, and Cyc is C6-10aryl substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is1, R1is Cyc, and Cyc is 5-6-membered heterocycle having 1 to 3 ring heteroatoms independently selected from N, 0, and S, and is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is1, R1is Cyc, and Cyc is 6-membered heterocycle having 1 or 2 ring heteroatoms independently selected from N, 0, and S, and is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is1, R1is Cyc, and Cyc is 5-membered heterocycle having 1 or 2 ring heteroatoms independently selected from N, 0, and S, and is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is1, R1is Cyc, and Cyc is 5-6 membered heteroaryl having 1 to 3 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is1, R1is Cyc, and Cyc is 6 membered heteroaryl having 1 to 3 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is1, R1is Cyc, and Cyc is 5 membered heteroaryl having 1 to 3 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, at least one R1is Cyc, and Cyc is substituted with 1 RCyc. In some embodiments, at least one R1is Cyc, and Cyc is substituted with 0 RCyc. In some embodiments, n is 1, R1is Cyc, and Cyc is substituted with 1, 2, or 3 RCyc. In some embodiments, n is 1, R1is CH2-Cyc, and Cyc is phenyl substituted with 1 F. In some embodiments, n is 1, R1is Cyc, and Cyc is phenyl substituted with 1 F. In some embodiments, n is 1, R1is Cyc, and Cyc is phenyl substituted with 0 RCyc. In some embodiments, n is 1, R1is Cyc, and Cyc is pyrazolyl. In some embodiments, n is 1, R1is Cyc, and Cyc is pyrazolyl substituted with 1 methyl. In some embodiments, n is 1, R1is Cyc, and Cyc is pyridinyl. In some embodiments, n is 1, R1is Cyc, and Cyc is 1-pyridinyl substituted with 0 RCyc. In some embodiments, n is 1, R1is Cyc, and Cyc is 2-pyridinyl substituted with 0 RCyc. In some embodiments, n is 1, R1Series 1 / 5 33827 / 50003 / PCis Cyc, and Cyc is 3-pyridinyl substituted with 0 RCyc. In some embodiments, n is 1, R1is Cyc, and Cyc is morpholinyl. In some embodiments, n is 1, R1is Cyc, and Cyc is morpholinyl substituted with 0 RCyc. In some embodiments, n is 1, R1is Cyc, and Cyc is thiomorpholinyl. In some embodiments, n is 1, R1is Cyc, and Cyc is thiomorpholinyl substituted with at least one oxo. In some embodiments, n is 1, R1is Cyc, and Cyc is piperazinyl substituted with 1, 2, or 3 RCyc. In some embodiments, n is 1, R1is Cyc, and Cyc is piperazinyl substituted with 0 RCyc. In some embodiments, n is 1, R1is Cyc, and Cyc is piperazinyl substituted with 1 C1-4 alkyl. In some embodiments, n is 1, R1is Cyc, and Cyc is piperazinyl substituted with 1 oxo. In some embodiments, n is 1, R1is Cyc, and Cyc is piperazinyl substituted with 1 OH. In some embodiments, n is 1, R1is Cyc, and Cyc is piperazinyl substituted with 1 -C(O)R4, wherein R4is selected from N(RN)2, phenyl, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, C1-3haloalkyoxy, C1-3hydroxyalkyl, and C1-3hydroxyalkoxy. In some embodiments, n is 1, R1is Cyc, and Cyc is piperazinyl substituted with 1 -C(O)R4, wherein R4is selected from methyl, NHMe, NMe2, isobutyl, CF3, CH2OH, NHPh, phenyl, and methoxy. In some embodiments, n is 1, R1is Cyc, and Cyc is piperazinyl substituted with 1 -S(O)2R3, wherein R3is selected from (RN)2, C1-3alkyl, or C3-6cycloalkyl. In some embodiments, n is 1, R1is Cyc, and Cyc is piperazinyl substituted with 1 -S(O)2R3, wherein R3is selected from methyl, NHMe, NMe2, and NHPh.
[0068] In some embodiments, n is1, R1is C(O)-Cyc, and Cyc is C3-6cycloalkyl, C6-10aryl, 5-6-membered heterocycle, or 5-6 membered heteroaryl, wherein the heterocycle and heteroaryl have 1 to 3 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is1, R1is C(O)-Cyc, and Cyc is 5-6-membered heterocycle or 5-6 membered heteroaryl, wherein the heterocycle and heteroaryl have 1 to 3 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is1, R1is C(O)-Cyc, Cyc is 5-6-membered heterocycle having 1 to 3 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is1, R1is C(O)-Cyc, Cyc is 5-6 membered heteroaryl having 1 to 3 ring heteroatoms independently selected from N, O, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is1, R1is C(O)-Cyc, Cyc is a 5 membered heterocycle having 1 or 2 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is1, R1is C(O)-Cyc, Cyc is a 6 membered heterocycle having 1 or 2 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is1, R1is C(O)-Cyc, and Cyc is morpholinyl. In some embodiments, n is 1, R1is C(O)-Cyc, and Cyc is morpholinyl substituted with 0 RCycIn some embodiments, n is 1, R1is C(O)-Cyc, and Cyc is piperidinyl. In some embodiments, n is 1, R1is C(O)-Cyc, and Cyc is piperidinyl substituted with 0 RCyc. In some embodiments, n is 1, R1is C(O)-Cyc, and Cyc is piperazinyl. In some embodiments, n is 1, R1is C(O)-Cyc, and Cyc is piperazinyl substituted with 0 RCyc. In some embodiments, n is 1, R1is C(O)-Cyc, and Cyc is piperazinyl substituted with 1 C1-3 alkyl. In some embodiments, n is 1, R1is C(O)-Cyc, and Cyc is piperazinyl substituted with 1 methyl. In some embodiments, n is 1, R1is C(O)-Cyc, and Cyc is piperazinyl substituted with 1 -C(O)R4, wherein R4is selected from N(RN)2, phenyl, C1-3 alkyl, C1-3 alkoxy, C1-3haloalkyl, C1-3haloalkyoxy, C1-3hydroxyalkyl, and C1-3hydroxyalkoxy. InSeries 1 / 5 33827 / 50003 / PCsome embodiments, n is1, R1is C(O)-Cyc, and Cyc is piperazinyl substituted with 1 -C(O)R4, wherein R4is methyl.
[0069] In some embodiments, at least one R1is NRNC(O)-Cyc or C(O)NRN-Cyc, and Cyc is C3-6cycloalkyl, C6-10aryl, 5-6-membered heterocycle, or 5-6 membered heteroaryl, wherein the heterocycle and heteroaryl have 1 to 3 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, at least one R1is NHC(O)-Cyc or C(O)NH-Cyc, and Cyc is C3-6cycloalkyl, C6-10aryl, 5-6-membered heterocycle, or 5-6 membered heteroaryl, wherein the heterocycle and heteroaryl have 1 to 3 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, at least one R1is C(O)NRN-Cyc and Cyc is C3-6cycloalkyl, C6-10aryl, 5-6-membered heterocycle, or 5-6 membered heteroaryl, wherein the heterocycle and heteroaryl have 1 to 3 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 R^ In some embodiments, at least one R1is NRNC(O)-Cyc and Cyc is C3-6cycloalkyl, C6-10aryl, 5-6-membered heterocycle, or 5-6 membered heteroaryl, wherein the heterocycle and heteroaryl have 1 to 3 ring heteroatoms independently selected from N, O, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is 1, R1is C(O)NH-Cyc, and Cyc is C3-6cycloalkyl substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is 1, R1is C(O)NH-Cyc, and Cyc is C3-6cycloalkyl substituted with 1, 2, or 3 RCyc. In some embodiments, n is 1, R1is C(O)NH-Cyc, and Cyc is C3-6cycloalkyl substituted with 0 RCyc. In some embodiments, n is 1, R1is C(O)NH-Cyc, and Cyc is cyclohexyl substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is 1, R1is C(O)NH-Cyc, and Cyc is cyclohexyl substituted with 1, 2, or 3 RCyc. In some embodiments, n is 1, R1is C(O)NH-Cyc, and Cyc is cyclohexyl substituted with 0 RCyc. In some embodiments, n is 1, R1is C(O)NH-Cyc, Cyc is 5-6-membered heterocycle having 1 to 3 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, n is 1, R1is C(O)NH-Cyc, Cyc is 6-membered heterocycle having 1 or 2 ring heteroatoms independently selected from N or O, and Cyc is substituted with 1, 2, or 3 RCyc. In some embodiments, n is 1, R1is C(O)NH-Cyc, Cyc is 6-membered heterocycle having 1 or 2 ring heteroatoms independently selected from N or 0, and Cyc is substituted with 0 RCyc. In some embodiments, n is 1, R1is C(O)NH-Cyc, Cyc is tetrahydropyranyl and substituted with 0 RCyc. In some embodiments, n is 1, R1is C(O)NH-Cyc, Cyc is piperidinyl and substituted with 0 RCyc. In some embodiments, n is 1, R1is C(O)NH-Cyc, Cyc is piperidinyl and substituted with 1 methyl or acetyl.
[0070] Each R1of formula (I1), when present, can be attached to any suitable position on Ring A (e.g., o-, m-, p-substituted for a 6-membered heteroaryl / aryl or 1,2- or 1,3- substituted for a 5-membered heteroaryl), including any suitable di-, tri-, or tetra- substituted regioisomers. Each R1of formula (I), when present, can be attached to any suitable position on the phenyl ring (e.g., o-, m-, p- substituted), including any suitable di-, tri-, or tetra- substituted regioisomers.
[0071] In some embodiments of formula (I’), one R1taken together with Ring A and the morpholine ring forms aSeries 1 / 5 33827 / 50003 / PCspiro ring moiety having a structure, wherein Ring A is further substituted with 0 to 4 R1. In some embodiments, the spiro ring moiety is formed via a methylene bridge between Ring A and the morpholine ring. In some embodiments, the spiro ring moiety is formed via an ethylene bridge between Ring A and the morpholine ring. In some embodiments, the spiro ring moiety is formed via an n-propylene bridge between Ring A and the morpholine ring. In some embodiments, Ring A of the spiro ring moiety is further substituted with 0 R1. In some embodiments, Ring A of the spiro ring moiety is further substituted with 1 or 2 R1. In some embodiments, one R1taken together with Ring A and the morpholine ring forms a spiro ring moiety having the structure ofwhich is unsubstituted (i.e., no further R1are present).
[0072] In some embodiments of formula (I'), one R1taken together with Ring A and the morpholine ring forms afused ring moiety having a structurewherein Ring A is further substituted with 0 to 4 R1. In some embodiments, Ring A of the fused ring moiety is further substituted with 0 R1. In some embodiments, Ring A of the fused ring moiety is further substituted with 1 or 2 R1. In some embodiments, one R1taken together with Ring Aand the morpholine ring forms a fused ring moiety having the structure, which is unsubstituted (i.e., no further R1are present).
[0073] In some embodiments, one R1forms a spiro ring moiety or a fused ring moiety as described herein. For example, in some embodiments, one R1comprises an C1-3alkylene is such that when taken together with the phenylring and morpholine ring forms a spiro ring moiety having a structurethe phenyl ring is further substituted with 0 to n-1 R1. In some embodiments, R1is ethylene such that the moiety of formulaSeries 1 / 5 33827 / 50003 / PC
[0074] In some other embodiments, one R1comprises -O-CH2- such that when taken together with the phenyl ringand morpholine ring forms a moiety having a structurethe phenyl is further substituted with 0 ton-1 R1. In some embodiments, the moiety of structureunsubstituted (i.e., no further R1are present).Cyc, RCyc, R3, R4and RN
[0075] In some embodiments, at least one Cyc is C3-6cycloalkyl, C6-10aryl, 5-6-membered heterocycle, or 5-6 membered heteroaryl, wherein the heterocycle and heteroaryl have 1 to 3 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 RcvcIn some embodiments, at least one Cyc is C6-10aryl substituted with 0, 1, 2, or 3 RCyc. In some embodiments, at least one Cyc is C6-10aryl substituted with 1, 2, or 3 RCyc. In some embodiments, at least one Cyc is C6-10aryl substituted with 0 RCyc. In some embodiments, at least one Cyc is phenyl substituted with 1, 2, or 3 RCyc. In some embodiments, at least one Cyc is phenyl substituted with 1 RCyc. In some embodiments, at least one Cyc is phenyl substituted with 0 RCyc. In some embodiments, at least one Cyc is napthyl substituted with 1 RCyc. In some embodiments, at least one Cyc is napthyl substituted with 0 RCyc. In some embodiments, at least one Cyc is phenyl substituted with 1 halogen. In some embodiments, at least one Cyc is phenyl substituted with 1 F. In some embodiments, at least one Cyc is 5-6-membered heterocycle having 1 to 3 ring heteroatoms independently selected from N, 0, and S, substituted with 0, 1, 2, or 3 RCyc. In some embodiments, at least one Cyc is 6-membered heterocycle having 1 to 3 ring heteroatoms independently selected from N, O, and S,Series 1 / 5 33827 / 50003 / PCsubstituted with 0, 1, 2, or 3 RCyc. In some embodiments, at least one Cyc is 5-membered heterocycle having 1 to 3 ring heteroatoms independently selected from N, 0, and S, substituted with 0, 1, 2, or 3 RCyc. In some embodiments, at least one Cyc is 5-6-membered heterocycle having 1 to 3 ring heteroatoms independently selected from N, 0, and S, substituted with 1, 2, or 3 RCyc. In some embodiments, at least one Cyc is 5-6-membered heterocycle having 1 to 3 ring heteroatoms independently selected from N, 0, and S, substituted with 0 RCyc. In some embodiments, at least one Cyc is piperidinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, piperazinyl or pyrrolidinyl, and is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, at least one Cyc is morpholinyl. In some embodiments, at least one Cyc is morpholinyl substituted with 0 RCyc. In some embodiments, at least one Cyc is thiomorpholinyl. In some embodiments, at least one Cyc is thiomorpholinyl substituted with at least one oxo. In some embodiments, at least one Cyc is piperazinyl. In some embodiments, at least one Cyc is piperazinyl substituted with 0 RCyc. In some embodiments, at least one Cyc is piperazinyl substituted with 1 CM alkyl. In some embodiments, at least one Cyc is piperazinyl substituted with 1 -C(O)R4, wherein R4is selected from N(RN)2, phenyl, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, C1-3haloalkyoxy, C1-3hydroxyalkyl, and C1-3hydroxyalkoxy. In some embodiments, at least one Cyc is piperazinyl substituted with 1 -C(O)R4, wherein R4is selected from methyl, NHMe, NMe2, isobutyl, CF3, CH2OH, NHPh, phenyl, and methoxy. In some embodiments, at least one Cyc is piperazinyl substituted with 1 -S(O)2R3, wherein R3is selected from (RN)2, C1-3alkyl, or C3-6cycloalkyl. In some embodiments, at least one Cyc is piperazinyl substituted with 1 -S(O)2R3, wherein R3is selected from methyl, NHMe, NMe2, and NHPh. In some embodiments, at least one Cyc is piperazinyl substituted with 1 C1.4 alkyl. In some embodiments, at least one Cyc is piperazinyl substituted with 1 oxo. In some embodiments, at least one Cyc is piperazinyl substituted with 1 OH. In some embodiments, at least one Cyc is tetrahydropyranyl. In some embodiments, at least one Cyc is tetrahydropyranyl and substituted with 0 RCycIn some embodiments, at least one Cyc is piperidinyl. In some embodiments, at least one Cyc is piperidinyl and substituted with 0 RCycIn some embodiments, at least one Cyc is piperidinyl and substituted with 1 acetyl. In some embodiments, at least one Cyc is piperidinyl and substituted with 1 methyl. In some embodiments, at least one Cyc is 5-6-membered heteroaryl having 1 to 3 ring heteroatoms independently selected from N, 0, and S, substituted with 0, 1, 2, or 3 RCyc. In some embodiments, at least one Cyc is 5-membered heteroaryl having 1 to 3 ring heteroatoms independently selected from N, 0, and S, substituted with 0, 1, 2, or 3 RCyc. In some embodiments, at least one Cyc is 6-membered heteroaryl having 1 to 3 ring heteroatoms independently selected from N, 0, and S, substituted with 0, 1, 2, or 3 RCyc. In some embodiments, at least one Cyc is 5-6-membered heteroaryl having 1 to 3 ring heteroatoms independently selected from N, 0, and S, substituted with 1, 2, or 3 RCyc. In some embodiments, at least one Cyc is 5-6-membered heteroaryl having 1 to 3 ring heteroatoms independently selected from N, 0, and S, substituted with 0 RCyc. In some embodiments, at least one Cyc is pyridinyl or pyrazolyl, and is substituted with 0, 1, 2, or 3 RCyc. In some embodiments, at least one Cyc is pyrazolyl substituted with 1 RCyc. In some embodiments, at least one Cyc is pyrazolyl substituted with 1 C1-3 alkyl. In some embodiments, at least one Cyc is pyrazolyl substituted with 1 methyl. In some embodiments, at least one Cyc is pyridinyl substituted with 0 RCyc. In someSeries 1 / 5 33827 / 50003 / PCembodiments, at least one Cyc is 1 -pyridinyl. In some embodiments, at least one Cyc is 2-pyridinyl. In some embodiments, at least one Cyc is 3-pyridinyl. In some embodiments, Cyc is C3-6cycloalkyl substituted with 0, 1, 2, or 3 RCyc. In some embodiments, Cyc is C3-6cycloalkyl substituted with 1, 2, or 3 RCycIn some embodiments, Cyc is C3-6cycloalkyl substituted with 0 RCycIn some embodiments, Cyc is cyclohexyl substituted with 0, 1, 2, or 3 RCyc. In some embodiments, Cyc is cyclohexyl substituted with 1, 2, or 3 RCyc. In some embodiments, Cyc is cyclohexyl substituted with 0 RCyc. In some embodiments, at least one Cyc is phenyl, pyridinyl or pyrazolyl, and is substituted with 0, 1, 2, or 3 RCyc.
[0076] In some embodiments, at least one RCycis halogen, oxo, OH, C1-4alkyl, C0-2alkylene-C(O)R4, or -S(O)2R3. In some embodiments, at least one RCycis halogen, oxo, OH, or C1-4alkyl. In some embodiments, at least one RCycis halogen. In some embodiments, at least one RCycC1-4alkyl. In some embodiments, at least one RCycis F. In some embodiments, at least one RCycis oxo. In some embodiments, at least one RCycis methyl. In some embodiments, at least one R0^ is C0-2alkylene-C(O)R4, C(O)N(RN)2, or -S(O)2R3. In some embodiments, at least one RCycis C0-2alkylene-C(O)R4, wherein R4is OH, N(RN)2, phenyl, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, C1-3haloalkyoxy, C1-3hydroxyalkyl, or C1-3hydroxyalkoxy. In some embodiments, at least one RCycis C0-1alkylene-C(O)R4, wherein R4is OH, NH2, NHMe, NHPh, NMe2, CF3, CH2OH, phenyl, methyl, and methoxy. In some embodiments, at least one RCycis -S(O)2R3, wherein R3is N(RN)2, C1-3alkyl, or C3-6cycloalkyl In some embodiments, at least one RCycis -S(O)2Me, -S(O)2NHMe, -S(O)2NHPh, -S(O)2NMe2, or -S(O)2NH2. In some embodiments, at least one RCycis -C(O)Me, -C(O)OMe, -C(O)CH2OH, -C(O)iPr, -C(O)CF3, -C(O)Ph, -C(O)NH2, -C(O)NHMe, -C(O)NMe2, -C(O)NHPh, -SO2Me, -SO2NH2, -SO2NHMe, or -SO2NMe2. In some embodiments, one RCycis present and is selected from -C(O)Me, -C(O)OMe, -C(O)CH2OH, -C(O)iPr, -C(O)CF3, -C(O)Ph, -C(O)NH2, -C(O)NHMe, -C(O)NMe2, -C(O)NHPh, -SO2Me, -SO2NH2, -SO2NHMe, and -SO2NMe2.
[0077] In some embodiments, at least one R3is N(RN)2, Ci-3alkyl, or C3-6cycloalkyl. In some embodiments, at least one R3is Me, NHMe, NHPh, NMe2, or NH2. In some embodiments, at least one R3is Me. In some embodiments, at least one R3is NHMe. In some embodiments, at least one R3is NHPh. In some embodiments, at least one is NMe2. In some embodiments, at least one is NH2. In some embodiments, one R3is present and is Me. In some embodiments, one R3is present and is NHMe. In some embodiments, one R3is present and is NHPh. In some embodiments, one R3is present and is NMe2. one R3is present and is NH2.
[0078] In some embodiments, at least one R4is OH, N(RN)2, phenyl, C1.3 alkyl, C1-3 alkoxy, C1-3haloalkyl, Ci.3haloalkyoxy, Ci.3hydroxyalkyl, or C hydroxyalkoxy. In some embodiments, at least one R4is OH, NH2, NHMe, NHPh, NMe2, CF3, CH2OH, phenyl, methyl, and methoxy. In some embodiments, one R4is present and is OH. In some embodiments, one R4is present and is NH2. In some embodiments, one R4is present and is NHMe. In some embodiments, one R4is present and is NHPh. In some embodiments, one R4is present and is NMe2. In some embodiments, one R4is present and is CF3. In some embodiments, one R4is present and is CH2OH. In someSeries 1 / 5 33827 / 50003 / PCembodiments, one R4is present and is phenyl. In some embodiments, one R4is present and is methyl. In some embodiments, one R4is present and is methoxy.
[0079] In some embodiments, at least one RNis H, phenyl, C1-4 alkyl, or -S(O)2Ci.3alkyl. In some embodiments, at least one RNis H. In some embodiments, at least one RNis phenyl. In some embodiments, at least one RNis C1-4 alkyl. In some embodiments, at least one RNis -S(O)2C1-3alkyl. In some embodiments, at least one RNis methyl. In some embodiments, at least one RNis -S(O)2Me. In some embodiments, two RNare present, and both are H. In some embodiments, two RNare present, and both are methyl. In some embodiments, two RNare present, one RNis H, and the other RNis methyl.Het
[0080] The compounds disclosed herein comprise a Het moiety. In some embodiments Het is pyrazolyl. In some embodiments, Het is triazolyl. In some embodiments, Het is pyrazolyl substituted with 0, 1, or 2 halogens. In some embodiments, Het is triazolyl substituted with 0, 1, or 2 halogens. In some embodiments, Het is substituted with 1 or 2 F. In some embodiments, Het is substituted with 0 halogen. In some embodiments, Het has a structure of,, Het has astructure of X.,R2and R2A
[0081] The compounds disclosed herein comprise R2and R2A. In some embodiments, each of R2and R2Ais H.
[0082] In some embodiments, R2and R2Atogether with the atoms to which they are attached form a fused cyclopropyl ring such that the compound has a structure of Formula (I A-0) or (I A-1 ):
[0083] In some embodiments, the disclosure provides compounds having the structure of Formula (IA) or (IA-2):Series 1 / 5 33827 / 50003 / PC
[0084] In some embodiments, the disclosure provides compounds having the structure of Formula (IB-0) or (IB-1'):
[0085] In some embodiments, the disclosure provides compounds having a structure of Formula (IB-1):
[0086] In some embodiments, the disclosure provides compounds having a structure of Formula (IB):
[0087] In some embodiments, the disclosure provides compounds having the structure of Formula (IC-0) or (IC-1):
[0088] In some embodiments, the disclosure provides compounds having a structure of Formula (IC):Series 1 / 5 33827 / 50003 / PC
[0089] In some embodiments, the disclosure provides compounds having a structure listed in Table 1, or a pharmaceutically acceptable salt thereof.Table 1.Series 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PC
[0090] In some embodiments, the disclosure provides compounds of Table 1 (or pharmaceutically acceptable salts thereof) having specific stereochemistry, as shown in the structures listed in Table 2.Table 2.Series 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PC
[0091] In some embodiments, a compound is selected from compound 34, 35, 39, 45, 47, 56, 184, 186, 188, 200, 202, 204, and 214, or a pharmaceutically acceptable salt thereof. In some embodiments, a compound of the disclosure is selected from the group consisting of Compound 34, 35, 45, 47, 184, and 186 or a pharmaceutically acceptable salt thereof.Pharmaceutical Compositions
[0092] The disclosure also provides pharmaceutical compositions comprising the disclosed compounds and a pharmaceutically acceptable excipient, carrier or adjuvant.
[0093] The pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration, and rectal administration, etc. The pharmaceutical compositions can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions). The pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and / or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers, etc.Series 1 / 5 33827 / 50003 / PC
[0094] As used herein, the term "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
[0095] The pharmaceutical composition can be a tablet or capsule comprising the active ingredient together with one or more of: a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and / or polyethyleneglycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and e) absorbents, colorants, flavors and sweeteners. Tablets may be either film coated or enteric coated according to methods known in the art. Suitable compositions for oral administration include an effective amount of a compound of the invention in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
[0096] Certain injectable compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions may be sterilized and / or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating theSeries 1 / 5 33827 / 50003 / PCosmotic pressure and / or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient.
[0097] Suitable compositions for transdermal application include an effective amount of a compound of the invention with a suitable carrier. Carriers suitable for transdermal delivery include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time and means to secure the device to the skin.
[0098] Suitable compositions for topical application, e.g., to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g., for delivery by aerosol or the like. Such topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g, for prophylactic use in sun creams, lotions, sprays and the like. They are thus particularly suited for use in topical applications, including cosmetic formulations well known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives. As used herein, a topical application may also pertain to an inhalation or to an intranasal application. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurized container, pump, spray, atomizer or nebulizer, with or without the use of a suitable propellant.Methods of Use
[0099] The disclosure also provides a method of inhibiting ELOVL1 comprising contacting ELOVL1 with a compound or a pharmaceutical composition, as disclosed herein.
[0100] The disclosure also provides methods of treating disorders, diseases, or conditions associated with, or caused by, the accumulation of Very Long Chain Fatty Acids (VLCFAs) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound as disclosed herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the disease or disorder is selected from1): X-linked adreno-leukodystrophy (X-ALD or ALD), cerebral adrenoleukodystrophy (cALD), childhood onset cerebral adrenoleukodystrophy (CCALD), adolescent onset cerebral adrenoleukodystrophy, adult onset cerebral adrenoleukodystrophy, cerebello-brainstem form of ALD (CBALD), adrenomyeloneuropathy (AMN) or adrenal insufficiency (Addison only) form of ALD;2): disorders, diseases, or conditions associated with, or caused by one or more mutations in the ABCD1;3): Zellweger Spectrum Disorder (ZSD) and presentations thereof, including Zellweger Syndrome (ZSD),Series 1 / 5 33827 / 50003 / PCNeonatal Adreno-leukodystrophy (NALD), Infantile Refsum Disease (IRD), Adult Refsum Disease (ARD), Heimler Syndrome, a mitochondrial disorder, and a peripheral neuropathy; and4): peroxisomal disorders, diseases, or conditions associated or caused by mutations in AC0X1, AC0X2, HSD17B4, AMACR, and PHYH, or a combination thereof.
[0101] Examples of mitochondrial disorders include VLCAD, wherein the accumulation of VLCFA conjugate or derivates is associated with mutations in the gene VLCAD, and very long-chain acyl-CoA dehydrogenase deficiency (VLCADD).
[0102] Examples of peripheral neuropathy include diabetic neuropathy, other forms of distal, length dependent, mixed sensorimotor axonal polyneuropathy, and hereditary sensory and autonomic neuropathy.
[0103] The term "a therapeutically effective amount" of a compound refers to an amount of the compound that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity (e.g., ELOVL1), or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc. In one non-limiting embodiment, the term "a therapeutically effective amount" refers to the amount of the compound that, when administered to a subject, is effective to (1) at least partially alleviating, inhibiting, preventing and / or ameliorating a condition, or a disorder, or a disease or biological process (i) mediated by ELOVL1, or (ii) associated with ELOVL1, or (2) inhibiting the activity of ELOVL1. In another non-limiting embodiment, the term "a therapeutically effective amount" refers to the amount of the compound that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially inhibit ELOVL1.
[0104] As used herein, the term “subject” refers to a "mammal”, for example, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, and mice. In some embodiments, the mammal is a primate. In some embodiments, the mammal is a human.
[0105] As used herein, the term "inhibit", "inhibition" or "inhibiting" refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
[0106] As used herein, the term "treat", "treating" or "treatment" of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment "treat", "treating” or "treatment" refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In yet another embodiment, "treat", "treating" or "treatment" refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
[0107] As used herein, a subject is "in need of" a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.Series 1 / 5 33827 / 50003 / PC
[0108] In some embodiments, the disclosure provides methods for modulating ELOVL1 in a mammal comprising administering to the mammal at least one compound, or pharmaceutically acceptable salt thereof, as disclosed herein in an amount sufficient to modulate ELOVL1 activity in the mammal.
[0109] In some embodiments, the disclosure provides the disclosed compounds or pharmaceutically acceptable salt thereof for use as a medicament. In some embodiments, the disclosure provides use of the disclosed compounds or pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating human carcinoma, as described herein.EMBODIMENTS1. A compound of formula (I'):or a pharmaceutically acceptable salt thereof,whereinRing A is C6-10aryl, 5-6 membered heteroaryl having 1, 2, or 3 ring heteroatoms independently selected from N, 0, and S, indolyl, isoindolyl, indolinyl, or isoindolinyl;n is 0, 1, 2, 3, 4, or 5;each R1is independently halogen, CN, oxo, Cvsalkyl, C1-3alkoxy, C1-3haloalkyl, Ci-3haloalkoxy, -S(O)2R3, C0-2alkylene-C(O)R4, C0-2alkylene-Cyc, C(O)-Cyc, N(RN)2, NRNC(O)-Cyc, or C(O)NRN-Cyc;orone R1taken together with Ring A and the morpholine ring forms(a) a spiro ring moiety having a structure(b) a fused ring moiety having a structureRing A is further substituted with 0 to 4 R1;each of R2and R2Ais H, or R2and R2A, together with the atoms to which they are attached, form a fused cyclopropyl ring;Series 1 / 5 33827 / 50003 / PCCyc is C3-6cycloalkyl, C6-10aryl, 5-6-membered heterocycle or 5-6 membered heteroaryl, wherein the heterocycle and heteroaryl have 1 to 3 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 RCyc;each RCycis independently halogen, oxo, OH, C1.4 alkyl, C0-2alkylene-C(O)R4, or -S(O)2R3;each R3is independently N(RN)2, C1-3alkyl, or C3-6cycloalkyl;each R4is independently OH, N(RN)2, phenyl, C1.3 alkyl, C1-3 alkoxy, C1-3haloalkyl, C1-3haloalkoxy, C1-3hydroxyalkyl, or C1-3hydroxyalkoxy;each RNis independently H, phenyl, C1-4 alkyl, or -S(O)2Ci-3alkyl; andHet is pyrazolyl or triazolyl and is substituted with 0, 1, or 2 halogens,with the proviso that when n is 0, Ring A is phenyl, and R2Aand R2are H, then Het is substituted with 1 or 2 halogens.2. The compound or salt of embodiment 1, wherein Ring A is C6-10aryl.3. The compound or salt of embodiment 2, wherein Ring A is phenyl.4. The compound or salt of embodiment 2, wherein Ring A is naphthyl.5. The compound or salt of embodiment 1, wherein Ring A is 5-6 membered heteroaryl having 1, 2, or 3 ring heteroatoms independently selected from N, 0, and S.6. The compound or salt of embodiment 5, wherein Ring A is pyridinyl.7. The compound or salt of embodiment 5, wherein Ring A is pyrimidinyl.8. The compound or salt of embodiment 5, wherein Ring A is pyrazolyl.9. The compound or salt of embodiment 1, wherein Ring A is indolyl, isoindolyl, indolinyl, or isoindolinyl.10. The compound or salt of any one of embodiments 1 to 9, wherein, at least one R1is a halogen.11. The compound or salt of embodiment 10, wherein at least one R1is F.12. The compound, or salt of embodiment 10 or 11, wherein at least two R1are F.13. The compound, or salt of any one of embodiments 10 to 12, wherein at least one R1is Cl.14. The compound or salt of any one of embodiments 1 to 13, wherein at least one R1is CN.15. The compound, or salt of any one of embodiments 1 to 14, wherein at least one R1is C1-3alkyl.16. The compound or salt of embodiment 15, wherein at least one R1is methyl.17. The compound, or salt of any one of embodiments 1 to 16, wherein at least one R1is C1-3alkoxy.18. The compound, or salt of embodiment 17, wherein at least one R1is methoxy.19. The compound, or salt of any one of embodiments 1 to 18, wherein at least one R1is C1-3haloalkyl.20. The compound, or salt of embodiment 19, wherein at least one R1is fluoromethyl, difluoromethyl, or trifluoromethyl.21. The compound, or salt of any one of embodiments 1 to 20, wherein at least one R1is C1-3haloalkoxy.22. The compound, or salt of embodiment 21, wherein at least one R1is difluoromethoxy or trifluoromethoxy.Series 1 / 5 33827 / 50003 / PC23. The compound, or salt of any one of embodiments 1 to 22, wherein at least one R1is C0-2alkylene-C(O)R4.24. The compound or salt of embodiment 23, wherein at least one R1is C0-2alkylene-C(O)N(RN)2.25. The compound, or salt of embodiment 24, wherein at least one R1is C(O)NHS(O)2Me, C(0)NMe2, C(O)NHMe, or C(O)NH2.26. The compound, or salt of embodiment 24, wherein at least one R1is CH2-C(O)NHS(O)2Me, CH2-C(O)NMe2, CH2-C(O)NHMe, or CH2-C(O)NH2.27. The compound, or salt of any one of embodiments 23 to 26, wherein at least one R1is Co-2alkylene-C02H.28. The compound, or salt of embodiment 27, wherein least one R1is CO2H or CH2CO2H.29. The compound, or salt of any one of embodiments 1 to 28, wherein at least one R1is -SO2R3.30. The compound or salt of embodiment 29, wherein at least one R1is -SO2CH3, -SO2NH2, -SO2NHMe, or - SO2NMe2.31. The compound, or salt of any one of embodiments 1 to 29, wherein at least one R1is C0-2alkylene-Cyc, C(O)-Cyc, or C(O)NH-Cyc.32. The compound, or salt of embodiment 31, wherein at least one R1is Cyc.33. The compound, or salt of embodiment 31, wherein at least one R1is CH2Cyc.34. The compound, or salt of any one of embodiments 31 to 33, wherein at least one R1is C(O)-Cyc.35. The compound, or salt of any one of embodiments 31 to 34, wherein at least one R1is C(O)NH-Cyc.36. The compound, or salt of any one of embodiments 31 to 35, wherein at least one Cyc is C6-10aryl substituted with 0, 1, 2, or 3 RCyc.37. The compound, or salt of embodiment 36, wherein at least one Cyc is phenyl substituted with 1, 2, or 3 Rcvc.38. The compound, or salt of any one of embodiments 31 to 37, wherein at least one Cyc is 5-6-membered heterocycle with 1 to 3 ring heteroatoms independently selected from N, O, and S, and is substituted with 0, 1, 2, or 3 RCyc.39. The compound, or salt of embodiment 38, wherein at least one Cyc is piperidinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, piperazinyl or pyrrolidinyl, and is substituted with 0, 1, 2, or 3 RCyc.40. The compound, or salt of any one of embodiments 31 to 39, wherein at least one Cyc is 5-6-membered heteroaryl with 1 to 3 ring heteroatoms independently selected from N, O, and S, and is substituted with 0, 1, 2, or 3 RCyc.41. The compound, or salt of embodiment 40, wherein at least one Cyc is pyridinyl or pyrazolyl, and is substituted with 0, 1, 2, or 3 RCyc.42. The compound, or salt of any one of embodiments 30 to 41, wherein at least one Cyc is C3-6cycloalkyl substituted with 0, 1, 2, or 3 RCyc.43. The compound, or salt of embodiment 42, wherein at least one Cyc is cyclohexyl substituted with 0, 1, 2, or 3 RCyc.Series 1 / 5 33827 / 50003 / PC44. The compound, or salt of any one of embodiments 1 to 43, wherein at least one RCycis halogen, oxo, OH, or C1-4 alkyl.45. The compound, or salt of embodiment 44, wherein at least one RCycis F.46. The compound, or salt of embodiment 44 or 45, wherein at least one RCycis oxo.47. The compound, or salt of embodiment 44, 45, or 46, wherein at least one RCycis OH.48. The compound, or salt of any one of embodiments 44 to 47, wherein at least one RCycis methyl.49. The compound, or salt of any one of embodiments 1 to 48, wherein at least one RCycis C0-2alkylene-C(O)R4,C(O)N(RN)2, or -S(O)2R350. The compound, or salt of embodiment 49, wherein one RCycis -C(O)Me, -C(O)OMe, -C(O)CH2OH, -C(O)iPr, -C(O)CF3, -C(O)Ph, -C(O)NH2, -C(O)NHMe, -C(O)NMe2, -C(O)NHPh, SO2Me, -SO2NH2, -SO2NHMe, or - SO2NMe2.51. The compound, or salt of any one of embodiments 1 to 50, wherein each of R2and R2Ais H.52. The compound, or salt of any one of embodiments 1 to 50, having a structure of Formula (I A-0)53. The compound, or salt of any one of embodiments 1 to 51, wherein one R1taken together with Ring A andthe morpholine ring forms a spiro ring moiety having a structureRing A is further substituted with 0 to 4 R1.54. The compound, or salt of embodiment 53, whereinhas a structureRing A is further substituted with 0 to 4 R1.55. The compound, or salt of any one of embodiments 1 to 51, wherein one R1taken together with Ring A andthe morpholine ring forms a fused ring moiety having a structureRing A is further substituted with 0 to 4 R1.56. The compound or salt of any one of embodiments 53 to 55, wherein Ring A is further substituted with 0 R1.Series 1 / 5 33827 / 50003 / PC57. The compound, or salt of any one of embodiments 1 to 56, wherein n is 1, 2, or 3.58. The compound, or salt of embodiment 57, wherein n is 1 or 2.59. The compound or salt of any one of embodiments 1 to 58, having a structure of Formula (IB-0):60. The compound or salt of embodiment 59, having a structure of Formula (IC-0):61. The compound or salt of embodiment 59, having a structure of Formula (IB-1’):62. The compound or salt of embodiment 61, having a structure of Formula (IC-1):63. The compound or salt of any one of embodiments 1 to 60, wherein Ring A is 5-6 membered heteroaryl having 1, 2, or 3 ring heteroatoms independently selected from N, 0, and S.64. The compound or salt of any one of embodiments 1 to 63, wherein Het is pyrazolyl.65. The compound or salt of embodiment 64, wherein Het is [pyrazolyl structure image]66. The compound or salt of any one of embodiments 1 to 63, wherein Het is triazolyl.67. The compound or salt of embodiment 66, wherein Het is68. The compound or salt of any one of embodiments 1 to 67, wherein Het is substituted with 1 or 2 halogens.69. The compound, or salt of embodiment 1, having a structure listed in Table 1.Series 1 / 5 33827 / 50003 / PC70. The compound, or salt of embodiment 1, having a structure listed in Table 2.71. The compound, or salt of embodiment 70, selected from the group consisting of Compound 34, 35, 39, 45, 47, 56, 184, 186, 188, 200, 202, 204, and 214.72. The compound, or salt of embodiment 71, selected from the group consisting of Compound 34, 35, 45, 47, 184, and 186.73. A pharmaceutical composition comprising a compound, stereoisomer, or salt of any one of embodiments 1 to 72, and at least one pharmaceutically acceptable excipient.74. A method of inhibiting ELOVL1 comprising contacting ELOVL1 with a compound or salt of any one of embodiments 1 to 72 or composition of embodiment 73.75. A method of treating a condition associated with, or caused by, accumulation of Very Long Chain Fatty Acids (VLCFAs) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound or salt of any one of embodiments 1 to 72 or composition of embodiment 73.76. The method of embodiment 75, wherein the accumulation of VLCFAs is due to a defect in peroxisomal degradation.77. The method of embodiment 75 or 76, wherein the condition is associated with, or caused by, one or more mutations in ABCD1.78. The method of any one of embodiments 75 to 77 wherein the condition is X-linked adreno-leukodystrophy (X-ALD or ALD), cerebral adrenoleukodystrophy (cALD), childhood onset cerebral adrenoleukodystrophy (CCALD), adolescent onset cerebral adrenoleukodystrophy, adult onset cerebral adrenoleukodystrophy, cerebello-brainstem form of ALD (CBALD), adrenomyeloneuropathy (AMN), or adrenal insufficiency (Addison only) form of ALD.79. The method of embodiments 75 or 76, wherein the condition is Zellweger Syndrome, Neonatal Adreno- leukodystrophy (NALD), Infantile Refsum Disease (IRD), Adult Refsum Disease (ARD), Heimler Syndrome, a mitochondrial disorder, or a peripheral neuropathy.FURTHER EMBODIMENTS1A. A compound of formula (I):or a pharmaceutically acceptable salt thereof,whereinSeries 1 / 5 33827 / 50003 / PCeach R1is independently halogen, -CN, C^alkyl, C^alkoxy, C1-3haloalkyl, C1-3haloalkoxy, phenyl, -SO2R3, 5-membered heterocycle having 1 to 3 heteroatoms independently selected from N, 0, and S,or an R1can comprise an C1-3alkylene such that when taken together with the phenyl ring and morpholine ring formsa spiro ring moiety having a structurethe phenyl ring is further substituted with 0 to n-1 R1, oran R1can comprise -O-CH2- such that when taken together with the phenyl ring and morpholine ring forms a moietyhaving a structure othe phenyl is further substituted with 0 to n-1 R1;each of R2and R2Ais H, or R2and R2A, together with the atoms to which they are attached, form a fused cyclopropyl ring;R3is C1-3alkyl or C3-6cycloalkyl;Het is pyrazolyl or triazolyl; andn is 1, 2, 3, 4, or 5.2A. The compound or salt of embodiment 1A, wherein, at least one R1is a halogen.3A. The compound or salt of embodiment 2A, wherein at least one R1is F.4A. The compound, or salt of embodiment 3A, wherein at least two R1are F.5A. The compound, or salt of embodiment 2A, wherein at least one R1is Cl.6A. The compound or salt of any one of embodiments 1A-5A, wherein at least one R1is -CN.7A. The compound, or salt of any one of embodiments 1A-6A, wherein at least one R1is C1-3alkyl.8A. The compound or salt of embodiment 7 A, wherein at least one R1is methyl.9A. The compound, or salt of any one of embodiments 1A-8A, wherein at least one R1is Ci-3alkoxy.10A. The compound, or salt of embodiment 9A, wherein at least one R1is methoxy.11A. The compound, or salt of any one of embodiments 1A-10A, wherein at least one R1is C1-3haloalkyl.12A. The compound, or salt of embodiment 11A, wherein at least one R1is fluoromethyl, difluoromethyl,Series 1 / 5 33827 / 50003 / PCor trifluoromethyl.13A. The compound, or salt of any one of embodiments 1A-12A, wherein at least one R1is C1-3haloalkoxy.14A. The compound, or salt of embodiment 13A, wherein at least one R1is difluoromethoxy or trifluoromethoxy.15A. The compound, or salt of any one of embodiments 1A-14A, wherein at least one R1is -SO2R3.16A. The compound or salt of embodiment 15A, wherein at least one R1is -SO2CH3.17A. The compound, or salt of any one of embodiments 1A-16A, wherein at least one R1is phenyl.18A. The compound, or salt of any one of embodiments 1A-17A, wherein at least one R1is a 5-membered heterocycle having 1 to 3 heteroatoms independently selected from N, O, and S.19A. The compound, or salt of embodiment 18A, wherein at least one R1is pyrrolidinyl.20A. The compound, or salt of any one of embodiments 1A-19A, wherein Het is pyrazolyl.21A. The compound, or salt of any one of embodiments 1A-19A, wherein Het is triazolyl.22A. The compound, or salt of any one of embodiments 1A-21A, wherein each of R2and R2Ais H.23A. The compound, or salt of embodiment 20A, having a structure of Formula (IA)24A. The compound, or salt of any one of embodiments 1A-22A, wherein one R1is C1-3alkylene suchthat when taken together with the phenyl ring and morpholine ring forms a moiety of formulaand the phenyl ring is further substituted with 0 to n-1 R1.25A. The compound, or salt of embodiment 24A, wherein R1is ethylene such that the moiety of formulathe phenyl ring is further substituted with 0 to n-1 R1.Series 1 / 5 33827 / 50003 / PC26A. The compound, or salt of any one of embodiments 1 A-22A, wherein R1is -O-CH2- such that whentaken together with the phenyl ring and morpholine ring forms a moiety of formula, and the phenyl ring is further substituted with 0 to n-1 R1.27A. The compound or salt of any one of embodiments 24A-26A, wherein the phenyl ring is further substituted with 0 R1.28A. The compound, or salt of any one of embodiments 1A-26A, wherein n is 1, 2, or 3.29A. The compound, or salt of embodiment 27A, wherein n is 1 or 2.30A. The compound or salt of any one of embodiments 1A-29A, having a structure of Formula (IB):31 A. The compound or salt of embodiment 30A, having a structure of Formula (IC):32A. The compound, or salt of embodiment 1A, having a structure listed in Table 1.33A. The compound, or salt of embodiment 1A, having a structure listed in Table 2.34A. The compound, or salt of embodiment 33A, selected from the group consisting of Compound 34,35, 45, and 47.35A. A pharmaceutical composition comprising a compound, stereoisomer, or salt of any one of embodiments 1A-34A, and at least one pharmaceutically acceptable excipient.36A. A method of inhibiting ELOVL1 comprising contacting ELOVL1 with a compound or salt of any one of embodiments 1 A-34A or composition of embodiment 35A.Series 1 / 5 33827 / 50003 / PC37A. A method of treating a condition associated with, or caused by, accumulation of Very Long Chain Fatty Acids (VLCFAs) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound or salt of any one of embodiments 1 A-34A or composition of embodiment 35A.38A. The method of embodiment 37 A, wherein the accumulation of VLCFAs is due to a defect in peroxisomal degradation.39A. The method of embodiment 37A or 38A, wherein the condition is associated with, or caused by, one or more mutations in ABCD1.40A. The method of any one of embodiments 37A-39A wherein the condition is X-linked adrenoleukodystrophy (ALD), cerebral adrenoleukodystrophy (cALD), childhood cerebral adrenoleukodystrophy (CCALD), adolescent cerebral adrenoleukodystrophy, or adrenomyeloneuropathy (AMN).41 A. The method of embodiment 37A or 38A, wherein the condition is Zellweger Syndrome, NeonatalAdreno-leukodystrophy (NALD), Infantile Refsum Disease (IRD), Adult Refsum Disease (ARD) or Heimler Syndrome.EXAMPLES
[0110] The following examples are illustrative, but of course, should not be construed as in any way limiting their scope.
[0111] Temperatures are given in degrees centigrade (°C). The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR. Abbreviations used are those conventional in the art.
[0112] All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents and catalysts utilized to synthesize the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art.
[0113] The following abbreviations are used herein: ACN refers to acetonitrile; BINAP refers to 2,2'-bis(diphenylphosphino)-1, T-binaphthyl; Boc refers to fert-butyloxycarbonyl; BTMG refers to 2-fert-butyl-1, 1,3,3-tetramethylguanidine; BuOH refers to butanol; Cbz refers to benzyloxycarbonyl; dba refers to dibenzylideneacetone; DCM refers to dichloromethane; dFppy refers to 2-(2,4-difluorophenyl)pyridine; DIG refers to N, N-diisopropylcarbodiimide; DIEA refers to N, N-diisopropylethylamine; DMAP refers to 4-(dimethylamino)pyridine; DME refers to dimethoxyethane; DMF refers to N, N-dimethylformamide; DMSO refers to dimethylsulfoxide; dppf refers to 1, 1 '-bis(diphenylphosphino)ferrocene; dtbpy or dtbbpy refers to 4,4'-bis(ferf-butyl)-2,2'-bipyridine; e.e. refers to enantiomeric excess; ESI refers to electrospray ionization; EtOAc refers to ethyl acetate; EtOH refers to ethanol; FA refers to formic acid; FEP refers to fluorinated ethylene propylene; HATU refers to O-(7-azabenzotriazol-1-yl)-W, W, W', M'-tetramethyluronium hexafluorophosphate; HMDS refers to hexamethyldisilazane; HPLC refers to highSeries 1 / 5 33827 / 50003 / PCperformance liquid chromatography; [Ir(dF(Me)ppy)₂dtbpy]PF₆ refers to iridium(III) bis[2-(2,4-difluorophenyl)-5-methylpyridine-N,C2']-4,4'-di-tert-butyl-2,2'-bipyridine hexafluorophosphate; LCMS refers to liquid chromatography mass spectrometry; LED refers to light-emitting diode; MeOH refers to methanol; NiBr₂·dtbpy refers to [4,4'-bis(tert-butyl)-2,2'-bipyridine]nickel dibromide; NMR refers to nuclear magnetic resonance; PPI refers to pores per inch; RVC refers to reticulated vitreous carbon; SFC refers to supercritical fluid chromatography; TEA refers to triethylamine; TFA refers to trifluoroacetic acid; THF refers to tetrahydrofuran; TMG refers to 1, 1,3,3-tetramethylguanidine; Tol refers to toluene; TsOH refers to p-toluenesulfonic acid; and TTMSS refers to tris(trimethylsilyl)silane.
[0114] General. All oxygen and / or moisture sensitive reactions were carried out under N2 atmosphere in glassware that was flamed-dried under vacuum (0.5 mmHg) and purged with N2 prior to use. All reagents and solvents were purchased from commercial vendors and used as received unless otherwise noted or synthesized according to known literature procedures. NMR spectra were recorded on a Bruker (400 MHz,1H) spectrometer. Proton and carbon chemical shifts are reported in ppm (d) referenced to residual solvent peak. Data are reported as follows: chemical shifts, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, etc.; couplet constant(s) in Hz). Unless otherwise indicated NMR data were collected at 25 °C. HPLC separations were performed on a Gilson 281 / Shimadzu LC-20AP semi-prep HPLC system. SFC separations were performed on a Waters 150MGM prep SFC system. Mass spectral data were collected on an Agilent system (electrospray ionization (ESI) time-of-flight (TOF)).
[0115] Chromatography - Method A: Agilent 1260& G6125B. Column: Luna C18 3.0x50mm, 5 μm. Ramp from 10% ACN (0.02% TFA) in water (0.04% TFA) to 80% ACN in water in 4.50 min. Flow rate is set at 0.8 mL / min, then hold at 80% ACN for 1.10 min. Flow rate is set at 0.8 mL / min, then ramp from 80% ACN in water to 10% ACN in water in 0.01 min. Flow rate is set at 0.8 mL / min to 1.5 mL / min, then hold at 10% ACN for 0.39 min. Flow rate is set at 1.5 mL / min. Column temperature: 40 °C.
[0116] Chromatography - Method B: Agilent 1260&6125B. Column: Xbridge-C18 2.1*50mm 5 μm. The gradient was 5% B in 0.40 min and 5-95% B at 0.40-3.40 min, hold on 95% B for 0.45 min, and then 95-5% B in 0.01 min, the flow rate was 0.8 mL / min. Mobile phase A was H2O+IO mM NH4HCO3, mobile phase B was Acetonitrile. Column temperature: 40 °C.
[0117] Chromatography - Method C: Agilent 1200&6130. Column: Xbridge-C18 2.1*50 mm 5 μm. The gradient was 5% B in 0.40min and 5-95% B at 0.40-3.40 min, hold on 95% B for 0.45 min, and then 95-5% B in 0.01 min, the flow rate was 0.8 mL / min. Mobile phase A was H2O+IO mM NH4HCO3, mobile phase B was Acetonitrile. Column temperature: 40 °C.
[0118] Chromatography - Method D: Shimadzu LCMS-2020. Column: Xbridge-C18 50*2.1mm, 5mm. Ramp from 30% ACN in water (10 mmol / L NH4HCO3) to 90% ACN in water in 4.80 min. Flow rate is set at 0.4 mL / min; then holdSeries 1 / 5 33827 / 50003 / PCat 90% ACN for 0.70 min. Flow rate is set at 0.4 mL / min; return back to 30% ACN in water and hold for 0.50 min. Flow rate is set at 0.8 mL / min. Column temperature: 40°C.
[0119] Chromatography - Method E: Shimadzu LCMS-2020. Column: Halo C18, 3.0*30mm, 5μm. 0.04% TFA in water (solvent A) and 0.02 % TFA in acetonitrile (solvent B). Initial isocratic elution hold at 5% (solvent B) for 0.40 min, the elution gradient is 5%-95% (solvent B) in 2.60 min, and holding at 95% (solvent B) for 1.00 min, then returning back to 5% (solvent B) and holding for 0.50 min at a flow rate of 1.0 mL / min. Column temperature: 40°C.
[0120] Chromatography - Method F: Agilent 1200&6120B. Column: Xbridge-C18 2.1*50mm, 5μm. 10mM ammonium bicarbonate in water (solvent A) and acetonitrile (solvent B). Initial isocratic elution hold at 5% (solvent B) for 0.40 min, the elution gradient is 5%-95% (solvent B) in 3.00 min, and holding at 95%(solvent B) for 0.45 min, then returning back to 5% (solvent B) and holding for 0.65 min at a flow rate of 0.8 mL / min. Column temperature: 40°C.
[0121] Example 1. Synthesis of 4-((1s,3s)-3-(1 / - / -pyrazol-1 -yl)cyclobutoxy)-6-chloropyrimidine (Int-A).
[0122] Step 1. 3-(1 / 7-Pyrazol-1-yl)cyclobutan-1-one
[0123] To a solution of 3-bromocyclobutan-1-one (6.0 g, 40.3 mmol) and 1 H-pyrazole (3.29 g, 48.3 mmol) in dichloromethane (60 mL) was added TEA (12.2 g, 120 mmol, 16.8 mL) in one portion at 25 °C. After stirring at 25 °C for 12 hours, the mixture was filtered and the filtrate was concentrated under reduced pressure to give 3-(1 / 7-pyrazol-1 -yl)cyclobutan-1 -one (56 g, crude) which was used in the next step directly without further purification.1H NMR (400 MHz, CDCl3) 5 (ppm) 7.61 - 7.56 (m, 1 H), 7.51 (d, J = 2.3 Hz, 1 H), 6.35 - 6.26 (m, 1 H), 5.07 - 4.98 (m, 1 H), 3.83 -3.72 (m, 2H), 3.61 - 3.49 (m, 2H).
[0124] Step 2. (1s,3s)-3-(1 / 7-Pyrazol-1-yl)cyclobutan-1-ol
[0125] To a solution of 3-(1 / 7-pyrazol-1-yl)cyclobutan-1-one (5.6 g, 41.1 mmol) in THF (56 mL) was added L-selectride (1.0 M, 49.4 mL) at -78 °C dropwise under N2. The mixture was stirred at 20°C for 1 hour under N2. The reaction was quenched by addition of H2O (200 mL) slowly at 0 °C and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with saturated aqueous NaCI (50 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give crude (1 s,3s)-3-(1 H-pyrazol-1 -yl)cyclobutan-1 -ol (8.2 g, 35.6 mmol,Series 1 / 5 33827 / 50003 / PC87% yield, 60% purity) which was used for next step directly without purification.1H NMR (400 MHz, DMSO-de) 5 (ppm) 7.74 (d, >1.88 Hz, 1 H), 7.44 (s, 1 H), 6.22 (t, J = 1.81 Hz, 1 H), 5.24 (d, >6.63 Hz, 1 H), 4.28 - 4.36 (m, 1 H), 3.88 - 4.00 (m, 1 H), 2.67 - 2.71 (m, 2 H), 2.30 (dd, >8.63, 2.75 Hz, 2 H).
[0126] Step 3. 4-((1 s,3s)-3-(1 / - / -Pyrazol-1 -yl)cyclobutoxy)-6-chloropyrimidine
[0127] To a solution of (1s,3s)-3-(1 H-pyrazol-1-yl)cyclobutan-1-ol (6.65 g, 28.9 mmol) and 4,6-dichloropyrimidine (4.30 g, 28.9 mmol) in THF (45 mL) was added t-BuOK (1.0 M, 31.8 mL, THF solution) at -70 °C dropwise under N2. The mixture was stirred at 0 °C for 2 hours. The reaction mixture was diluted with H2O (200 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiC>2, Petroleum ether / Ethyl acetate = 1 / 0 to 5 / 1) to give 4-((1 s,3s)-3-(1 H-pyrazol-1 -yl)cyclobutoxy)-6-chloropyrimidine (Int-A) (3.0 g, 9.57 mmol, 33% yield, 80% purity).1H NMR (400 MHz, CDCI3) 5 (ppm) 8.56 (s, 1 H), 7.57 (d, J=1.00 Hz, 1 H), 7.46 (d, >2.25 Hz, 1 H), 6.79 (s, 1 H), 6.27 (t, >1.94 Hz, 1 H), 5.17 (quin, >7.29 Hz, 1 H), 4.48 - 4.61 (m, 1 H), 3.13 (m, 2 H), 2.75 - 2.87 (m, 2 H). LCMS (ESI+): m / z = 251.2 (M+1)+.
[0128] Example 2. Synthesis of (S)-4-(6-((1 s,3R)-3-(1 / - / -pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)-2-(4-fluorophenyl)morpholine (Compound 34).
[0129] Step 1. ferf-Butyl 2-(4-fluorophenyl)morpholine-4-carboxylate
[0130] A solution of 1-bromo-4-fluorobenzene (50 g, 285 mmol), 4-(ferf-butoxycarbonyl)morpholine-2-carboxylic acid (99 g, 428 mmol), phthalimide (42 g, 285 mmol), BTMG (73 g, 428 mmol), [Ir(dF(Me)ppy)₂dtbpy]PF₆ (2.9 g, 2.8 mmol) and NiBr₂·dtbpy (6.9 g, 14.3 mmol) in DMSO (1000 mL) was pumped through a flow photoreactor (FEP coil reactor, 3.175 mm, 55.0 mL, 55.0 °C; flow rate = 0.554 mL / min; light source = 450 nm, 400 W). The reaction solution was re-circulated through the photoreactor and reacted for 24 hours. The resulting mixture was diluted with H2O (500Series 1 / 5 33827 / 50003 / PCmL) and extracted with EtOAc (800 mL x 3). The combined organic phases were washed with brine (800 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. This procedure was repeated seven additional times (420 g of 1-bromo-4-fluorobenzene in total). The combined crude material was purified by column chromatography (SiO₂, hexanes / ethyl acetate=100 / 1 to 20 / 1) to give fert-butyl 2-(4-fluorophenyl)morpholine-4-carboxylate (228 g, 770 mmol).1H NMR (400 MHz, chloroform-d) 5 (ppm) 7.24 - 7.32 (m, 2 H), 6.97 (t, 8.69 Hz, 2 H), 4.32 (dd, >10.44, 1.94 Hz, 1 H), 3.78 - 3.99 (m, 3 H), 3.60 (td, >11.73, 2.69 Hz, 1 H), 2.64 - 3.05 (m, 2 H), 1.41 (s, 9 H).
[0131] Step 2. 2-(4-Fluorophenyl)morpholine
[0132] A solution of tert-butyl 2-(4-fluorophenyl)morpholine-4-carboxylate (60 g, 213 mmol) in HCI / dioxane (2.0M, 600 mL) was stirred at 25 °C for 1 hour. TEA / EtOAc (10:1) was added to the mixture at 25 °C to adjust the pH to 8. After stirring at 25 °C for 0.5 hour, the resulting mixture was filtered, and the filter cake was dried in vacuo to give 2-(4-fluorophenyl)morpholine (38 g, 210 mmol). LCMS (ESI+): m / z = 181.9 (M+H)+.
[0133] Step 3. (S)-2-(4-Fluorophenyl)morpholine
[0134] 2-(4-Fluorophenyl)morpholine (38 g, 210 mmol) was separated by SFC (column: Chiral-IG-50-DAICEL CHIRALPAK IG 250mm*50mm*10pm; mobile phase: [A: CO2; B: MeOH (0.1% NH3H2O)]; B%: 35.00%, 4.30 min; flow rate: 140.00 mL / min) to give (S)-2-(4-fluorophenyl)morpholine (19 g, 88.1 mmol, 84% purity, e.e.= 98.9%).1H NMR (400 MHz, DMSO-ofc) 6 (ppm) 7.39 - 7.47 (m, 2 H), 7.17 - 7.26 (m, 2 H), 4.82 (dd, >11.13, 2.00 Hz, 1 H), 4.04 -4.12 (m, 1 H), 3.97 (td, >12.29, 2.44 Hz, 1 H), 3.35 (br d, >12.26 Hz, 1 H), 3.12 - 3.26 (m, 1 H), 3.04 - 3.11 (m, 1 H), 2.94 (dd, >12.32, 11.44 Hz, 1 H).
[0135] Step 4. (S)-4-(6-((1s,3R)-3-(1 / 7-Pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(4-fluorophenyl)morpholine
[0136] To a solution of (S)-2-(4-fluorophenyl)morpholine (19 g, 88.1 mmol, 84% purity) and Int-A (19.9 g, 79.3 mmol) in n-butanol (190 mL) was added triethylamine (17.8 g, 176 mmol) dropwise at 25°C. The resulting mixture was stirred at 110°C for 12 hours. The reaction was diluted with H2O (500 mL) and extracted with ethyl acetate (3 x 800 mL). The organic phases were combined and concentrated under reduced pressure. The resulting residue was recrystallized with EtOAc / n-hexane (1 / 10, 5 volume). The mixture was filtered, and the filter cake was dried in vacuo to give the title compound (21.5 g, 54.4 mmol, e.e.= 99.8%).1H NMR (400 MHz, DMSO-de) 6 (ppm) 8.27 (s, 1 H), 7.81 (d, >2.13 Hz, 1 H), 7.45 - 7.57 (m, 3 H), 7.21 (t, >8.88 Hz, 2 H), 6.19 - 6.29 (m, 2 H), 5.04 (quin, >7.19 Hz, 1 H), 4.63 (quin, >8.13 Hz, 1 H), 4.52 (dd, >10.57, 2.31 Hz, 1 H), 4.37 (br d, >13.01 Hz, 1 H), 4.25 (br d, >13.26 Hz, 1 H), 4.06 (dd, >11.51, 2.63 Hz, 1 H), 3.66 (td, >11.69, 2.50 Hz, 1 H), 2.94 - 3.08 (m, 3 H), 2.83 (dd, >13.07, 10.69 Hz, 1 H), 2.57 (br d, >8.76 Hz, 2 H). LCMS (ESI+): m / z = 396.2 (M+H)+.
[0137] The following analogs were prepared by following procedures similar to those of Example 2:Series 1 / 5 33827 / 50003 / PC
[0138] Example 3. Synthesis of (S)-4- (6-(( 1 s,3R)-3-(1 H-pyrazol-1 -y l)cy clobu toxy) py ri mi d i n-4-y l)-2- (3-fluorophenyl)morpholine (Compound 35).
[0139] Step 1. tert-Butyl 2-(3-fluorophenyl)morpholine-4-carboxylate
[0140] Asolution of 1-bromo-3-fluorobenzene (10 g, 57.1 mmol), 4-(tert-butoxycarbonyl)morpholine-2-carboxylic acid (19.8 g, 85.7 mmol), phthalimide (12.6 g, 85.7 mmol), BTMG (19.6 g, 114 mmol), [Ir(dF(Me)ppy)₂dtbpy]PF₆ (1.16 g, 1.14 mmol) and NiBr₂·dtbpy (1.39 g, 2.86 mmol) in DMSO (200 mL) was degassed and purged with N2 for three times. The reaction vessel was sealed and irradiated with a blue (455 nm) 400 W LED lamp placed 3 cm away and with cooling water to keep the reaction temperature at 25 °C for 14 hours. The mixture was diluted with water (200 mL) and extracted with ethyl acetate (2 x 150 mL). The combined organic phases were washed with brine (2 x 80 mL), dried with anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (SiO2, hexanes / ethyl acetate=100 / 0 to 9 / 1) to give fert-butyl 2-(4-fluorophenyl)morpholine-4-carboxylate (6.2 g, 19.8 mmol).1H NMR (400 MHz, CDCl3) 5 (ppm) 7.38 - 7.29 (m, 1 H), 7.18 - 7.09 (m, 2 H), 7.05 -6.96 (m, 1 H), 4.42 (dd, J = 1.9, 10.4 Hz, 1 H), 4.18 - 3.91 (m, 3 H), 3.68 (dt, J = 2.6, 11.8 Hz, 1 H), 3.11 - 2.98 (m, 1 H), 2.80 (br s, 1 H), 1.49 (s, 9 H). LCMS (ESI+): m / z = 226.0 (M+H)+.Series 1 / 5 33827 / 50003 / PC
[0141] Step 2. 2-(3-Fluorophenyl)morpholine hydrochloride
[0142] A mixture of tert-butyl 2-(4-fluorophenyl)morpholine-4-carboxylate (3.8 g, 12.2 mmol, 90% purity) in HCI / dioxane (2.0 M, 40 mL) was stirred at 25 °C for 1 hour under an N2 atmosphere. The reaction mixture was concentrated to give 2-(3-fluorophenyl)morpholine hydrochloride (2.66 g, 12.2 mmol). LCMS (ESI+): m / z = 182.1 (M+H)+.
[0143] Step 3. 4-(6-((1 s,3s)-3-(1 H-Pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-fluorophenyl)morpholine
[0144] A mixture of 2-(3-fluorophenyl)morpholine hydrochloride (2.66 g, 12.2 mmol), Int-A (3.04 g, 12.1 mmol) and TEA (3.69 g, 36.4 mmol) in n-butyl alcohol (22 mL) was degassed and purged three times with N2. The mixture was stirred at 110 °C for 3 hours under N2 atmosphere. The mixture was purified by prep-HPLC (Condition: water (NH4HCO3)-ACN; B%: 30%-70%, 15 min) and lyophilized to give 4-(6-((1s,3s)-3-(1 H-pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-fluorophenyl)morpholine (3.15 g, 7.89 mmol).1H NMR (400 MHz, CDCI3) 5 (ppm) 8.32 (d, J = 0.6 Hz, 1 H), 7.56 (d, J = 1.6 Hz, 1 H), 7.47 (d, J = 2.1 Hz, 1 H), 7.38 - 7.33 (m, 1 H), 7.21 - 7.16 (m, 2 H), 7.06 - 7.00 (m, 1 H), 6.27 (t, J = 2.1 Hz, 1 H), 5.87 (d, J = 0.6 Hz, 1 H), 5.15 (quin, J = 7.3 Hz, 1 H), 4.56 - 4.51 (m, 2 H), 4.36 (br d, J= 12.9 Hz, 1 H), 4.17 (td, J = 1.7, 11.6 Hz, 1 H), 4.11 (br d, J= 12.5 Hz, 1 H), 3.80 (dt, J = 2.8, 11.7 Hz, 1 H), 3.19 - 3.14 (m, 1 H), 3.13 - 3.08 (m, 2 H), 2.89 (dd, J= 10.6, 13.2 Hz, 1 H), 2.79 - 2.72 (m, 2 H). LCMS (ESI+): m / z = 396.0 (M+H)+.
[0145] Step 4. (S)-4-(6-((1s,3R)-3-(1 / 7-Pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-fluorophenyl)morpholine
[0146] 4-(6-((1 s,3s)-3-(1 H-Pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-fluorophenyl)morpholine (3.15 g, 7.89 mmol) was separated by SFC (Chiral-AS-40-DAICEL CHIRALPAK AS-H (250 mm*40 mm, 5 m); mobile phase: CO2-EtOH (0.1% NH3H2O); B%:28%, 6 min, isocratic elution mode) to give the title compound (1.31 g, 3.27 mmol, e.e. = 100%).1H NMR (400 MHz, DMSO-d6) 3 (ppm) 8.27 (s, 1 H), 7.81 (d, J= 2.1 Hz, 1 H), 7.49 (d, J= 1.4 Hz, 1 H), 7.43 (dt, J = 6.1, 8.0 Hz, 1 H), 7.31 - 7.26 (m, 2 H), 7.15 (dt, J = 2.4, 8.6 Hz, 1 H), 6.26 (s, 1 H), 6.24 (t, J= 1.9 Hz, 1 H), 5.09 - 5.02 (m, 1 H), 4.64 (t, J= 7.8 Hz, 1 H), 4.55 (dd, J = 2.5, 10.5 Hz, 1 H), 4.40 (br d, J= 13.0 Hz, 1 H), 4.27 (br d, J = 12.4 Hz, 1 H), 4.07 (dd, J = 2.6, 11.6 Hz, 1 H), 3.67 (dt, J = 2.6, 11.7 Hz, 1 H), 3.09 - 3.02 (m, 1 H), 3.00 -2.93 (m, 2 H), 2.84 (dd, J = 10.8, 13.0 Hz, 1 H), 2.61 - 2.54 (m, 2 H). LCMS (ESI+): m / z = 396.2 (M+H)+.
[0147] The following analogs were prepared by following procedures similar to those of Example 3:Series 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PC
[0148] Example 4. Synthesis of (S)-4-(6-((1s,3R)-3-(1 / - / -pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(3,4-difluorophenyl)morpholine (Compound 45).
[0149] Step 1. terf-Butyl 2-(3,4-difluorophenyl)morpholine-4-carboxylate
[0150] A solution of 4-bromo-1,2-difluorobenzene (1.0 g, 5.18 mmol), 4-(fe / f-butoxycarbonyl)morpholine-2-carboxylic acid (1.8 g, 7.79 mmol), phthalimide (1.14 g, 7.77 mmol), TMG (895 mg, 7.77 mmol),[Ir(dF(Me)ppy)₂dtbpy]PF₆ (525 mg, 0.518 mmol) and NiBr₂·dtbpy (126 mg, 0.259 mmol) in DMSO (10 mL) was degassed and placed under an nitrogen atmosphere. The reaction vessel was sealed and irradiated with a 10 W blue LED lamp placed 3 cm away and with cooling water to keep the reaction temperature at 25 °C for 14 hours. The mixture was diluted with water (30 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic phase was dried with anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (SiO2, hexanes / ethyl acetate=100 / 1 to 1 / 1) to give fert-butyl 2-(3,4-difluorophenyl)morpholine-4-carboxylate (940 mg, 2.83 mmol).1H NMR (400 MHz, DMSO-d6) 6 (ppm) 7.49 - 7.38 (m, 2H), 7.25 (m, 1H), 4.43 (dd, J = 2.5, 10.5 Hz, 1H), 4.06 - 3.83 (m, 2H), 3.78 (br d, J = 13.1 Hz, 1H), 3.54 (dt, J = 2.7, 11.7 Hz, 1H), 3.07 - 2.64 (m, 2H), 1.44 - 1.39 (m, 9H).
[0151] Step 2. 2-(3,4-Difluorophenyl)morpholineSeries 1 / 5 33827 / 50003 / PC
[0152] To a solution of tert-butyl 2-(3,4-difluorophenyl)morpholine-4-carboxylate (940 mg, 3.14 mmol) in dichloromethane (10 mL) was added trifluoroacetic acid (2 mL) dropwise at 25 °C The mixture was stirred at 25 °C for 12 hours. The reaction mixture was concentrated under reduced pressure to give 2-(3,4-difluorophenyl)morpholine (1.2 g, 1.81 mmol, crude). LCMS (ESI+): m / z = 200.2 (M+H)+.
[0153] Step 3. 4-(6-((1s,3s)-3-(1H-Pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(3,4-difluorophenyl)morpholine
[0154] A mixture of 2-(3,4-difluorophenyl)morpholine (175 mg, 0.878 mmol), Int-A (200 mg, 0.798 mmol) and TEA (242 mg, 2.39 mmol) in n-butyl alcohol (2 mL) was stirred at 110 °C for 12 hours. The mixture was concentrated under reduced pressure to give a residue. Purification by prep-HPLC (Condition: water (NH4HCO3-ACN; B%: 30%-65%, 15 min) and lyophilization gave 4-(6-((1s,3s)-3-(1 / 7-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(3,4-difluorophenyl)morpholine (180 mg, 0.431 mmol). LCMS (ESI+): m / z = 414.2 (M+H)+.
[0155] Step 4. (S)-4-(6-((1s,3R)-3-(1 / 7-Pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(3,4-difluorophenyl)morpholine
[0156] 4- (6-(( 1 s,3s)-3-( 1 H-Py razol-1 -y l)cycl obu toxy ) py ri m idi n-4-y l)-2-(3, 4-d if I uoro pheny I) morphol i ne (180 mg,0.422 mmol) was separated by SFC (Chiral-AD-30-DAICEL CHIRALPAK AD (250 mm*30 mm, 10 pm); mobile phase: CO2-MeOH / ACN (7:3 with 0.1% NH3H2O); B%:60%, isocratic elution mode) to give the title compound (first-eluting peak, 52.9 mg, 0.127 mmol, e.e. = 100%).1H NMR (400 MHz, DMSO-d6) 5 (ppm) 8.27 (s, 1H), 7.81 (d, J = 2.0 Hz, 1 H), 7.58 - 7.40 (m, 3H), 7.32 (br s, 1 H), 6.29 - 6.21 (m, 2H), 5.05 (quin, J = 7.2 Hz, 1 H), 4.64 (quin, J = 8.1 Hz, 1H), 4.58 - 4.50 (m, 1H), 4.43 - 4.20 (m, 2H), 4.11 - 4.01 (m, 1 H), 3.73 - 3.59 (m, 1H), 3.10 - 2.92 (m, 3H), 2.89 -2.77 (m, 1 H), 2.62 - 2.53 (m, 2H); (400 MHz, CDCI3) 5 (ppm) 8.32 (s, 1 H), 7.57 (d, J = 1.4 Hz, 1 H), 7.47 (d, J = 1.8 Hz, 1H), 7.32 - 7.28 (m, 1H), 7.22 - 7.10 (m, 2H), 6.28 (t, J = 1.9 Hz, 1H), 5.87 (s, 1H), 5.15 (quin, J = 7.3 Hz, 1H), 4.59 - 4.45 (m, 2H), 4.37 (br d, J = 13.1 Hz, 1 H), 4.20 - 4.01 (m, 2H), 3.79 (dt, J = 2.8, 11.7 Hz, 1 H), 3.24 - 3.03 (m, 3H), 2.90 - 2.70 (m, 3H). LCMS (ESI+): m / z = 414.2 (M+H)+.
[0157] The following analog was prepared by following procedures similar to those of Example 4:
[0158] Example 5. Synthesis of (S)-4-(6-((1 s,3R)-3-(1 H-Pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)-2-(3,5-difluorophenyl)morpholine (Compound 47).Series 1 / 5 33827 / 50003 / PC
[0159] Step 1. tert-Butyl 2-(3,5-difluorophenyl)morpholine-4-carboxylate
[0160] A solution of 1-bromo-3,5-difluorobenzene (5.0 g, 25.9 mmol), 4-(tert-butoxycarbonyl)morpholine-2-carboxylic acid (9.0 g, 38.9 mmol), phthalimide (5.7 g, 38.9 mmol), TMG (4.5 g, 38.9 mmol), [Ir(dF(Me)ppy)2dtbpy]PF6(263 mg, 0.259 mmol) and NiBr2‘dtbpy (631 mg, 1.3 mmol) in DMSO (100 mL) was degassed and placed under an nitrogen atmosphere. The reaction vessel was sealed and irradiated with a 10 W blue LED lamp placed 3 cm away and with cooling water to keep the reaction temperature at 25 °C for 14 hours. The mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 x 300 mL). The combined organic phases were dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (SiO2, hexanes / ethyl acetate=100 / 0 to 9 / 1) to give fe / t-butyl 2-(3,5-difluorophenyl)morpholine-4-carboxylate (3.5 g, 11.8 mmol).1H NMR (400 MHz, DMSO-d6) 5 (ppm) 6.96 - 6.88 (m, 2H), 6.78 - 6.69 (m, 1 H), 4.40 (br d, J = 10.3 Hz, 1H), 4.12 (q, J = 7.1 Hz, 1 H), 4.01 (br d, J = 11.3 Hz, 1 H), 3.94 (br d, J = 6.8 Hz, 1 H), 3.65 (br d, J = 9.4 Hz, 1 H), 3.03 (br t, J = 10.9 Hz, 1H), 2.76 (br s, 1H), 1.49 (s, 9H). LCMS (ESI+): m / z 300.1 (M+H)+.
[0161] Step 2. 2-(3,5-Difluorophenyl)morpholine
[0162] To a solution of fert-butyl 2-(3,5-difluorophenyl)morpholine-4-carboxylate (3.5 g, 11.8 mmol) in dichloromethane (30 mL) was added trifluoroacetic acid (6 mL) dropwise at 25 °C. The mixture was stirred at 25°C for 12 hours. The reaction mixture was concentrated under reduced pressure to give 2-(3,5-difluorophenyl)morpholine (2.34 g, 11.7 mmol, crude). LCMS (ESI+): m / z = 200.1 (M+H)+.
[0163] Step 3. 4-(6-((1s,3s)-3-(1 / 7-Pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(3,5-difluorophenyl)morpholine
[0164] A mixture of 2-(3,5-difluorophenyl)morpholine (795 mg, 3.99 mmol), Int-A (1.0 g, 3.99 mmol) and TEA (1.2 mg, 12 mmol) in n-butyl alcohol (10 mL) was stirred at 110 °C for 12 hours. The mixture was concentrated under reduced pressure to give a residue which was purification by prep-HPLC (Condition: water (NH4HCO3)-ACN; B%:Series 1 / 5 33827 / 50003 / PC40%-70%, 11 min) and lyophilized to give 4-(6-((1 s,3s)-3-(1 H-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(3,5-difluorophenyl)morpholine. Separation by SFC (Chiral-AD-30-DAICEL CHIRALPAK AD (250 mm*30 mm, 10 urn); mobile phase: CO2-MeOH / ACN (4:1 with 0.1% NH3H2O); B%:60%, isocratic elution mode) afforded the title compound (508 mg, 1.23 mmol, e.e. = 99.1%).1H NMR (400 MHz, DMSO-d6) δ (ppm) 8.28 (s, 1H), 7.80 (d, J= 2.3 Hz, 1H), 7.49 (d, J= 1.4 Hz, 1H), 7.28 - 7.12 (m, 3H), 6.36 - 6.18 (m, 2H), 5.05 (quin, J = 7.3 Hz, 1H), 4.68 - 4.55 (m, 2H), 4.46 - 4.23 (m, 2H), 4.08 (dd, J = 2.7, 11.6 Hz, 1 H), 3.66 (dt, J = 2.5, 11.7 Hz, 1 H), 3.06 - 2.93 (m, 3H), 2.83 (dd, J = 10.7, 12.9 Hz, 1H), 2.61 - 2.53 (m, 2H). LCMS (ESI+): m / z = 414.2 (M+H)+.
[0165] The following analog was prepared by following procedures similar to those of Example 5:
[0166] Example 6. Synthesis of 1-[(1R,3s)-3-{6-[(S)-2-(3,5-difluorophenyl)-4-morpholinyl]-4-pyrimidinyloxy}cyclobutyl]-1 H-1,2,3-triazole (Compound 186).
[0167] Step 1. fert-Butyl 2-(3,5-difluorophenyl)-4-morpholinecarboxylate
[0168] Reaction solution 1: 1-Bromo-3,5-difluorobenzene (50.0 g, 259 mmol), 4-fert-butoxycarbonyl-2-morpholinecarboxylic acid (89.9 g, 389 mmol), phthalimide (38.1 g, 259 mmol), (fert-butylimino)bis(dimethylamino)methane (66.6 g, 389 mmol), Ir [dF(Me)ppy]2dtbpy (PFg) (263 g, 2.59 mmol) and NICl2-dtbpy (5.16 g, 13.0 mmol) in dimethyl sulfoxide (1 L). The reaction solution 1 was pumped (0.554mL / min) to flow reactor (FEP, Coils reactor, 3.175(1 / 8”)mm, 55 mL, 55°C). The solution was recirculated through a photoreactor (450 nm, 400 W) and reacted for 90 min. The reaction mixture was diluted with H2O (1500 mL) and extracted with ethyl acetate (800 mL x 3). The combined organic phases were washed with brine (800 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. This procedure was repeated seventeen times. The crude material was purified by silica gel column chromatography (hexanes / ethyl acetate = 100 / 1 to 20 / 1) to giveSeries 1 / 5 33827 / 50003 / PCfe / t-butyl 2-(3,5-difluorophenyl)-4-morpholinecarboxylate (334 g, 1.00 mol).1H NMR (400 MHz, CDCI3) 6 (ppm) 6.98 -6.86 (m, 2H), 6.75 (tt, J= 2.3, 8.9 Hz, 1H), 4.40 (dd, J = 2.4, 10.4 Hz, 1H), 4.16 - 3.85 (m, 3H), 3.67 (dt, J = 2.8, 11.7 Hz, 1 H), 3.04 (br t, J = 11.0 Hz, 1 H), 2.76 (br d, J = 0.8 Hz, 1 H), 1.50 (s, 9H).
[0169] Step 2. 2-(3,5-Difluorophenyl)morpholine
[0170] A solution of fert-butyl 2-(3,5-difluorophenyl)-4-morpholinecarboxylate (192 g, 577 mmol) in HCI / ethyl acetate (1.45 L) was stirred for 1 hour at 25°C. TEA / ethyl acetate (10:1) was added to the mixture at 25°C to adjust pH to 8 and stirred for 1 hour. The resulting mixture was filtered, and the filter cake was dried in vacuo to give 2-(3,5-difluorophenyl)morpholine (115 g, 577 mmol).
[0171] Step 3. (S)-2-(3,5-Difluorophenyl)morpholine
[0172] The racemic mixture of 2-(3,5-difluorophenyl)morpholine (115 g, 577 mmol) was separated by SFC (column: Chiral-OD-30-DAICEL CHIRALCEL OD (250mm*30mm,10um); mobile phase: MeOH (0.1% NH3H2O) / CO2 = 40%) to give (S)-2-(3,5-difluorophenyl)morpholine (45.5 g, 206 mmol).1H NMR (400 MHz, DMSO-d6) δ (ppm) 7.31 - 7.08 (m, 3H), 4.86 (dd, J = 2.1, 11.1 Hz, 1 H), 4.11 (dd, J = 3.4, 12.6 Hz, 1 H), 3.96 (dt, J = 2.3, 12.4 Hz, 1 H), 3.47 (br d, J = 11.9 Hz, 1H), 3.22 (br d, J = 12.5 Hz, 1H), 3.02 - 2.89 (m, 2H).19F NMR (377 MHz, DMSO-d6) δ (ppm) -109.20 (s, 2F). SFC e.e. = 97.0%.
[0173] Step 4. 1-[(1R,3s)-3-{6-[(S)-2-(3,5-Difluorophenyl)-4-morpholinyl]-4-pyrimidinyloxy}cyclobutyl]-1 / 7-1,2,3-tri azole
[0174] To a solution of (S)-2-(3,5-difluorophenyl)morpholine (3.00 g, 13.6 mmol) and 1-[(1s,3s)-3-(6-chloro-4-pyrimidinyloxy)cyclobutyl]-f / - / -1,2,3-triazole (3.24 g, 12.9 mmol) in n-butanol (30 mL) was added triethylamine (2.74 g, 27.1 mmol) dropwise at 25°C. The reaction was stirred at 100°C for 12 hours. The resultant mixture was diluted with H2O (50 mL) and extracted with ethyl acetate (80 mL x 3). The combined organic phases were concentrated under reduced pressure to give a residue. The residue was recrystallized from ethyl acetate / n-hexane (1 / 10, 5V) at 25°C. The product was collected by filtration, and the filter cake was dried in vacuo to give 1-[(1R,3s)-3-{6-[(S)-2-(3,5-difluorophenyl)-4-morpholinyl]-4-pyrimidinyloxy}cyclobutyl]-f / - / -1,2,3-triazole (3.83 g, 9.18 mmol).1H NMR (400 MHz, DMSO-d6) 5 (ppm) 8.29 (d, J = 2.9 Hz, 2H), 7.75 (s, 1H), 7.27 - 7.11 (m, 3H), 6.30 (s, 1H), 5.11 (quin, J= 7.2 Hz, 1 H), 4.95 (quin, J = 8.2 Hz, 1 H), 4.58 (dd, J = 2.1, 10.3 Hz, 1 H), 4.46 - 4.24 (m, 2H), 4.08 (br dd, J = 2.3, 11.6 Hz, 1H), 3.66 (dt, J= 2.3, 11.7 Hz, 1H), 3.17 - 2.97 (m, 3H), 2.83 (dd, J = 10.8, 13.0 Hz, 1H), 2.70 - 2.57 (m, 2H).19F NMR (376 MHz, DMSO-d6) 5 (ppm) -109.65 (s, 2F). LCMS (ESI+): m / z=415.2 (M+H)+. SFC e.e. = 100%.
[0175] The following analogs were prepared by following procedures similar to those of Example 6:Series 1 / 5 33827 / 50003 / PC
[0176] Example 7. Synthesis of (1S,3S,6 / ?)-5-(6-((1s,3S)-3-(1H-1,2,3-triazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-3-(4-fluorophenyl)-2-oxa-5-azabicyclo[4.1.0]heptane (Compound 198) and (1R,3R,6S)-5-(6-((1s,3R)-3-(1 / 7-1,2,3-triazol-1-Series 1 / 5 33827 / 50003 / PCyl)cyclobutoxy)pyrimidin-4-yl)-3-(4-fluorophenyl)-2-oxa-5-azabicyclo[4.1.0]heptane (Compound 199).
[0177] Step 1. 2-(4-Fluorophenyl)oxirane
[0178] To a mixture of trimethylsulfoxonium iodide (17.7 g, 80.6 mmol) in DMSO (50 mL) and THF (20 mL) was added potassium 2-methyl-2-propanolate (9.04 g, 80.6 mmol) in portions at 20°C. The mixture was stirred at 40°C for 1 hour. The solution was then cooled to 0°C and 4-fluorobenzaldehyde (5.00 g, 40.3 mmol) was added dropwise. The reaction mixture was stirred at 0°C for 1 hour. The resultant mixture was diluted with water (100 mL) and extracted with hexane (3 x 60 mL). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give 2-(4-fluorophenyl)oxirane (3.80 g, 24.8 mmol).1H NMR (400 MHz, CDCl3) 5 (ppm) 7.15 - 7.19 (m, 2H), 6.94 - 7.00 (m, 2H), 3.78 (dd, J=3.8, 2.8 Hz, 1H), 3.07 (dd, J=5.3, 4.1 Hz, 1H), 2.70 (dd, J=5.4, 2.6 Hz, 1H).
[0179] Step 2. 2-(Benzyl(2,2-dimethoxyethyl)amino)-1-(4-fluorophenyl)ethan-1-ol
[0180] To a solution of 2-(4-fluorophenyl)oxirane (3.80 g, 27.5 mmol) in EtOH (38 mL) was added W-benzyl (2,2-dimethoxyethyl)amine (5.37 g, 27.5 mmol) in one portion at 25°C. The reaction was stirred at 80°C for 12 hours. TheSeries 1 / 5 33827 / 50003 / PCcooled reaction mixture was concentrated under reduced pressure to give 2-(benzyl (2,2-dimethoxyethyl)amino)-1 -(4-fluorophenyl)ethan-1-ol (9.00 g, 21.6 mmol). LCMS (ESI+): m / z = 334.2 (M+H)+.
[0181] Step 3. 4-Benzyl-2-(4-fluorophenyl)-6-methoxymorpholine
[0182] A mixture of 2-(benzyl(2,2-dimethoxyethyl)amino)-1-(4-fluorophenyl)ethan-1-ol (9.00 g, 21.6 mmol) and TsOH’ W (1.64 g, 8.64 mmol) was stirred at 115°C for 12 hours. The reaction mixture was diluted with NaHCOa solution (100 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were dried over NaaSCu, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (hexanes / ethyl acetate = 1 / 0 to 15 / 1) to give 4-benzyl-2-(4-fluorophenyl)-6-methoxymorpholine (4.10 g, 12.9 mmol).1H NMR (400 MHz, CDCl3) 6 (ppm) 7.19 - 7.34 (m, 7H), 6.85 - 7.02 (m, 2H), 4.42 - 5.09 (m, 2H), 3.39 -3.56 (m, 4H), 3.35 (s, 1 H), 2.71 - 2.96 (m, 2H), 2.02 - 2.30 (m, 1 H), 1.91 - 1.99 (m, 1 H).
[0183] Step 4. Benzyl 2-(4-fluorophenyl)-2,3-dihydro-4H-1,4-oxazine-4-carboxylate
[0184] To a solution of 4-benzyl-2-(4-fluorophenyl)-6-methoxymorpholine (4.10 g, 12.9 mmol) in dichloromethane (40 mL) was added phenylmethyl chloroformate (3.53 g, 20.7 mmol) dropwise at 25°C. The reaction mixture was stirred at 25°C for 12 hours. The solvents were removed under reduced pressure, and the residue was dissolved in toluene (306 mL). p-Toluenesulfonic acid (890 mg, 5.17 mmol) was added to the reaction in one portion at 25°C. The reaction was stirred at 110°C with a Dean-Stark apparatus for 2 hours. The cooled reaction mixture was quenched by addition of saturated aqueous sodium bicarbonate solution (50 mL) and extracted with EtOAc (50 mL x 3). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (hexane / ethyl acetate = 1 / 0 to 5 / 1) to give benzyl 2-(4-fluorophenyl)-2,3-dihydro-4H-1,4-oxazine-4-carboxylate (2.40 g, 7.28 mmol).1H NMR (400 MHz, CDCI3) 5 (ppm) 7.29 - 7.41 (m, 7H), 7.08 (td, J=8.2, 3.8 Hz, 2H), 6.30 - 6.52 (m, 1 H), 6.03 - 6.25 (m, 1 H), 5.12 - 5.28 (m, 2H), 4.76 - 4.91 (m, 1H), 4.07 -4.33 (m, 1H), 3.15 - 3.37 (m, 1H). LCMS (ESI+): m / z = 314.2 (M+Na)+.
[0185] Step 5. Benzyl 3-(4-fluorophenyl)-2-oxa-5-azabicyclo[4.1.0]heptane-5-carboxylate.
[0186] To a solution of benzyl 2-(4-fluorophenyl)-2,3-dihydro-4H-1,4-oxazine-4-carboxylate (2.40 g, 7.66 mmol) in toluene (32 mL) were added diiodomethane (16.4 g, 61.3 mmol) and diethylzinc (61.3 mL, 61.3 mmol, 1.0 M) dropwise at 0°C. The mixture was stirred at 25°C for 2 hours. The reaction was quenched with aqueous saturated NaHCOs (100 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (hexane / ethyl acetate = 1 / 0 to 20 / 1) to give benzyl 3-(4-fluorophenyl)-2-oxa-5-azabicyclo[4.1.0]heptane-5-carboxylate (2.10 g, 6.09 mmol).1H NMR (400 MHz, CDCI3) 5 (ppm) 7.33 - 7.48 (m, 7H), 7.00 - 7.13 (m, 2H), 5.14 - 5.34 (m, 2H), 4.51 - 4.61 (m, 1 H), 3.72 - 3.99 (m, 2H), 2.81 - 3.09 (m, 2H), 0.89 -1.04 (m, 2H). LCMS (ESI+): m / z = 328.1 (M+H)+.Series 1 / 5 33827 / 50003 / PC
[0187] Step 6. (1 S,3S,6R)-3-(4-Fluorophenyl)-2-oxa-5-azabicyclo[4.1.0]heptane
[0188] To a solution of benzyl 3-(4-fluorophenyl)-2-oxa-5-azabicyclo[4.1,0]heptane-5-carboxylate (1.9 g, 5.8 mmol) in dichloromethane (80 mL) was added triethylamine (2.9 g, 29 mmol), palladium bis(acetate) (650 mg, 2.9 mmol) and triethylsilane (10 g, 87 mmol) dropwise at 0°C. The mixture was stirred at 0°C for 2 hours. The reaction was quenched with H2O (50 ml) and extracted with DCM / MeOH (10 / 1) (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (CH2Cl2 / MeOH = 1 / 0 to 10 / 1) to give (1S,3S,6R)-3-(4-fluorophenyl)-2-oxa-5-azabicyclo[4.1.0]heptane (650 mg, 3.0 mmol).1H NMR (400 MHz, CDCI3) 5 (ppm) 7.34 (dd, J=8.1, 5.8 Hz, 2H), 7.05 (br t, >8.7 Hz, 2H), 4.50 (dd, >9.2, 3.4 Hz, 1 H), 3.67 (td, >6.7, 3.9 Hz, 1 H), 2.71 - 2.93 (m, 2H), 2.43 (td, >6.9, 4.3 Hz, 1H), 0.83 - 0.93 (m, 1H), 0.75 (q, >7.1 Hz, 1H). LCMS (ESI+): m / z = 194.0 (M+H)+.
[0189] Step 7. (1 S,3S,6R)-5-(6-((1s,3S)-3-(1 / 7-1,2,3-Triazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-3-(4-fluorophenyl)-2-oxa-5-azabicyclo[4.1.0]heptane
[0190] A solution of (1S,3S, 6R)-3-(4-fluorophenyl)-2-oxa-5-azabicyclo[4.1.0]heptane (100 mg, 466 mol) and 4,6-dichloropyrimidine (69.4 mg, 466 mol) in dimethyl sulfoxide (1 mL) was stirred at 90°C for 1 hour. (1s,3s)-3-(1 / 7-1,2,3-triazol-1-yl)cyclobutanol (130 mg, 932 pimol) was added in one portion at 15°C. t-BuOK (0.93 mL, 1.0 M) was added dropwise at 15°C. The reaction was stirred at 25°C for 12 hours. The resultant mixture was filtered, and the filtrate was concentrated to give a residue. The residue was purified by prep-HPLC (31 - 51% ACN / H2O (10 mM NH4HCO3) to give (1S,3S,6R)-5-(6-((1s,3S)-3-(1 / 7-1,2,3-triazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-3-(4-fluorophenyl)-2-oxa-5-azabicyclo[4.1.0]heptane (30.0 mg, 69.8 mol).1H NMR (400 MHz, DMSO-d6) δ (ppm) 8.31 (d, >14.9 Hz, 2H), 7.77 (s, 1H) 7.38 - 7.50 (m, 2H), 7.22 (t, >8.8 Hz, 2H), 6.15 (s, 1H), 5.10 - 5.20 (m, 1H), 4.92 - 5.05 (m, 1H), 4.55 - 4.67 (m, 1H), 4.32 - 4.52 (m, 1H), 4.04 - 4.17 (m, 1H), 3.09 - 3.19 (m, 2H), 2.78 - 2.95 (m, 2H), 2.64 - 2.68 (m, 2H), 0.84 - 1.02 (m, 2H). LCMS (ESI+): m / z = 409.3 (M+H)+.
[0191] Step 8. (1 S,3S,6R)-5-(6-((1s,3S)-3-(1 H-1,2,3-Triazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-3-(4-fluorophenyl)-2-oxa-5-azabicyclo[4.1.0]heptane and (1 R,3R,6S)-5-(6-((1s,3 / ?)-3-(1 H-1,2,3-triazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-3-(4-fluorophenyl)-2-oxa-5-azabicyclo[4.1.0]heptane
[0192] The racemic mixture of (1S,3S,6R)-5-(6-((1s,3S)-3-(1 / 7-1,2,3-triazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-3-(4-fluorophenyl)-2-oxa-5-azabicyclo[4.1.0]heptane (30.0 mg, 69.8 mol) was separated by SFC (column: Chiral-OJ-30-DAICEL CHIRALCEL OJ (250 mm*30 mm, 10 urn); mobile phase: 40% MeOH / CO2) to give (1S,3S,6R)-5-(6-((1s,3S)-3-(1 / 7-1,2,3-triazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-3-(4-fluorophenyl)-2-oxa-5-azabicyclo[4.1.0]heptane (8.3 mg, 20 pimol, Compound 198) and (1R,3R,6S)-5-(6-((1s,3R)-3-( / / - / -1,2,3-triazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-3-(4-fluorophenyl)-2-oxa-5-azabicyclo[4.1.0]heptane (6.9 mg, 17 mol, Compound 199).Compound 198:1H NMR (400 MHz, DMSO-d6) δ (ppm) 8.33 (s, 1H), 8.29 (s, 1H), 7.77 (d, >0.9 Hz, 1H), 7.45 (dd,Series 1 / 5 33827 / 50003 / PC>8.4, 5.7 Hz, 2H), 7.22 (t, >8.9 Hz, 2H), 6.15 (s, 1 H), 5.15 (quin, >7.2 Hz, 1 H), 4.90 - 5.05 (m, 1 H), 4.55 - 4.67 (m, 1 H), 4.36 - 4.50 (m, 1 H), 4.09 (br d, J=3.9 Hz, 1 H), 3.05 - 3.18 (m, 2H), 2.74 - 2.98 (m, 2H), 2.60 - 2.70 (m, 2H), 0.99 (q, >6.6 Hz, 1H), 0.89 (dt, >6.8, 4.4 Hz, 1H).19F NMR (400 MHz, DMSO-d6) 5 (ppm) -114.21 (s, 1 F). LCMS (ESI+): m / z=409.2 (M+H)+.Compound 199:1H NMR (400 MHz, DMSO-d6) 5 (ppm) 8.32 (s, 1H), 8.28 (s, 1H), 7.76 (s, 1H), 7.44 (dd, >8.1, 5.8 Hz, 2H), 7.21 (t, >8.8 Hz, 2H), 6.14 (s, 1H), 5.14 (quin, >7.2 Hz, 1H), 4.97 (t, >8.1 Hz, 1H), 4.59 (br d, >8.8 Hz, 1H), 4.24 - 4.51 (m, 1H), 4.08 (br d, >3.1 Hz, 1H), 3.05 - 3.18 (m, 2H), 2.73 - 2.91 (m, 2H), 2.61 - 2.70 (m, 2H), 0.93 - 1.03 (m, 1H), 0.82 - 0.92 (m, 1H).19F NMR (400 MHz, DMSO-d6) 5 (ppm) -114.21 (s, 1 F). LCMS (ESI+): m / z=409.2 (M+H)+.
[0193] The following analogs were prepared by following procedures similar to those of Example 7:
[0194] Example 8. Synthesis of (R)-4-(6-((1 s,3S)-3-(1 H-pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)-2-(pyrimidin-2-yl)morpholine (Compound 212) and (S)-4-(6-((1 s,3R)-3-(1 H-pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)-2-(pyrimidin-2-yl)morpholine (Compound 213).Series 1 / 5 33827 / 50003 / PC212 213
[0195] Step 1. 4-(fert-Butyl) 2-(1,3-dioxoisoindolin-2-yl) morpholine-2,4-dicarboxylate
[0196] To a solution of 4-(fert-butoxycarbonyl)morpholine-2-carboxylic acid (2.00 g, 8.65 mmol) and 2-hydroxy-1,3-isoindolinedione (1.55 g, 9.51 mmol) in dichloromethane (30 mL) was added DMAP (106 mg, 865 pimol) and DIG (1.31 g, 10.4 mmol) at 0°C. The reaction was stirred at 25°C for 3 hours. The resultant mixture was filtered, and the filtrate was concentrated to give a residue. The residue was purified by silica gel column chromatography (ethyl acetate / hexane = 0%-20%) to give 4-(tert-butyl) 2-(1,3-dioxoisoindolin-2-yl) morpholine-2,4-dicarboxylate (2.65 g, 6.34 mmol).1H NMR (400 MHz, DMSO-cfe) 6 (ppm) 7.91 (dd, J = 3.2, 5.1 Hz, 2H), 7.81 (dd, J = 3.1, 5.3 Hz, 2H), 4.55 (dd, J = 3.1, 8.8 Hz, 1 H), 4.08 (br d, J = 11.4 Hz, 1 H), 3.65 - 3.78 (m, 2H), 3.50 (br d, J = 4.3 Hz, 1 H), 3.27 (ddd, J = 3.2, 9.6, 13.1 Hz, 1H), 1.50 (s, 9H). LCMS (ESI+): m / z = 399.0 (M+Na)+.
[0197] Step 2. fert-Butyl 2-(5-bromopyrimidin-2-yl)morpholine-4-carboxylate
[0198] To an oven dried 50 mL Electra Syn 2.0 vial were added 5-bromo-2-iodopyrimidine (2.04 g, 7.17 mmol), 4-(terf-butyl) 2-(1,3-dioxoisoindolin-2-yl) morpholine-2,4-dicarboxylate (2.00 g, 4.78 mmol), NICW^O (227 mg, 957 pimol) and 2,2'-bipyridyl (149 mg, 957 pimol). Anhydrous dimethylformamide (30 mL) was then added via syringe.The contents of the vial were allowed to stir until all solids were dissolved (~10 minutes). AgNOs (406 mg, 2.39 mmol) was then added. The vial was equipped with an Electra Syn 2.0 vial cap with a magnesium sacrificial anode and a cylindrical 100 ppi RVC at 20°C. The vial was then placed on an IKA Electra Syn 2.0 stir plate and electrolysis was set to 100 mA, 0.5 mmol, 2.5 F / mol (open to air). The resulting mixture was diluted with water (50 mL) and extractedSeries 1 / 5 33827 / 50003 / PCwith ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (ACN / water (with FA) 15%-40%) and lyophilized to give tert-butyl 2-(5-bromopyrimidin-2-yl)morpholine-4-carboxylate (270 mg, 722 pmol).1H NMR (400 MHz, CDCl3) 5 (ppm) 8.83 (s, 2H), 4.66 (dd, >10.5, 2.8 Hz, 1H), 4.24 - 4.47 (m, 1H), 4.13 (br d, >10.6 Hz, 1H), 3.91 - 4.05 (m, 1H), 3.75 (td, J=11.6, 2.5 Hz, 1H), 3.02 - 3.15 (m, 2H), 1.49 (s, 9H). LCMS (ESI+): m / z = 365.9 (M+Na)+.
[0199] Step 3. tert-Butyl 2-(pyrimidin-2-yl)morpholine-4-carboxylate
[0200] To a mixture of Pd / C (63.3 mg, 10% w / w) in methanol (10 mL) was added TEA (54.1 mg, 535 μmol) and tert-butyl 2-(5-bromopyrimidin-2-yl)morpholine-4-carboxylate (200 mg, 535 μmol) under N2 atmosphere. The suspension was degassed and purged three times with H2. The mixture was stirred at 25°C for 1 hour under H2 (15 Psi). The reaction mixture was filtered, and the filter cake was washed with MeOH (20 mL). The filtrate was concentrated to give a residue. The residue was purified by silica gel column chromatography (ethyl acetate / hexane = 0%-50%) to give tert-butyl 2-(pyrimidin-2-yl)morpholine-4-carboxylate (100 mg, 358 μmol).1H NMR (400 MHz, DMSO-d6) 5 (ppm) 8.80 (d, >4.9 Hz, 2H), 7.28 - 7.30 (m, 1H), 4.70 (dd, 10.5, 2.8 Hz, 1H), 4.38 (br d, >3.3 Hz, 1H), 4.13 - 4.20 (m, 1H), 3.99 (br s, 1H), 3.79 (td, >11.7, 2.8 Hz, 1H), 3.13 (br s, 2H), 1.51 (s, 9H).
[0201] Step 4. 2-(Pyrimidin-2-yl)morpholine
[0202] A mixture of tert-butyl 2-(py rimidin-2-yl)morpholine-4-carboxylate (90.0 mg, 322 μmol) in HCl / dioxane (2.0 mL, 2.0 M) was degassed and purged three times with N2. The mixture was stirred at 25°C for 1 hour. The reaction mixture was concentrated to give 2-(pyrimidin-2-yl)morpholine (65.0 mg, 322 μmol). LCMS (ESI+): m / z = 166.0 (M+H)+.
[0203] Step 5. 4-(6-((1s,3s)-3-(1 / 7-Pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(pyrimidin-2-yl)morpholine
[0204] A mixture of 4-((1s,3s)-3-( 1 / 7-pyrazol-1 -yl)cyclobutoxy)-6-chloropyrimidine (80.0 mg, 322 μmol), 2-(pyrimidin-2-yl)morpholine (65.0 mg, 322 μmol) and TEA (163 mg, 1.63 mmol) in n-butanol (2 mL) was degassed and purged three times with N2. The mixture was stirred at 110°C for 12 hours under N2 atmosphere. The mixture was purified by prep-HPLC (ACN / water (NH4HCO3) = 5%-35%) and lyophilized to give 4-(6-((1s,3s)-3-(1 / 7-pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)-2-(pyrimidin-2-yl)morpholine (70.0 mg, 175 μmol). LCMS (ESI+): m / z = 380.1 (M+H)+.
[0205] Step 6. (R)-4-(6-((1s,3S)-3-(1 / 7-Pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(pyrimidin-2-yl)morpholine and (S)-4-(6-((1 s,3R)-3-(1 / - / -pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)-2-(pyrimidin-2-yl)morpholine
[0206] The racemic mixture of 4-(6-((1s,3s)-3-(f / - / -pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(pyrimidin-2-yl)morpholine (70.0 mg) was separated by SFC (column: Chiral-IG-30-Daicel ChiralPak IG (250*30 mm, 10 urn); mobile phase: IPA / CO2 = 50%) to give (R)-4-(6-((1s,3S)-3-(1H-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(pyrimidin-2-yl)morpholine (24.0 mg, 63.1 μmol, Compound 212) and (S)-4-(6-((1s,3R)-3-(1 / 7-pyrazol-1 -yl)cyclobutoxy)pyrimidin-Series 1 / 5 33827 / 50003 / PC4-yl)-2-(pyrimidin-2-yl)morpholine (18.6 mg, 48.9 mol, Compound 213).Compound 212:1H NMR (400 MHz, DMSO-d6) δ (ppm) 8.85 (d, >4.9 Hz, 2H), 8.27 (s, 1H), 7.81 (d, J=2.1 Hz, 1H),7.46 - 7.55 (m, 2H), 6.24 (t, J=1.9 Hz, 1 H), 6.18 (s, 1 H), 5.00 - 5.07 (m, 1 H), 4.55 - 4.65 (m, 3H), 4.15 (br d, J=12.6 Hz, 1 H), 4.04 (br d, >11.5 Hz, 1 H), 3.66 - 3.73 (m, 1 H), 3.26 - 3.30 (m, 1 H), 3.10 - 3.17 (m, 1 H), 2.93 - 2.99 (m, 2H), 2.55 - 2.60 (m, 2H). LCMS (ESI+): m / z=380.2 (M+H)+.Compound 213:1H NMR (400 MHz, DMSO-d6) δ (ppm) 8.85 (d, >4.9 Hz, 2H), 8.26 (s, 1H), 7.81 (d, >2.1 Hz, 1H),7.47 - 7.52 (m, 2H), 6.24 (t, 1.8 Hz, 1H), 6.18 (s, 1H), 5.04 (t, >7.2 Hz, 1H), 4.55 - 4.65 (m, 3H), 4.15 (br d, >12.1 Hz, 1H), 4.04 (br d, >11.5 Hz, 1H), 3.70 (td, J=11.4, 2.6 Hz, 1H), 3.26 - 3.30 (m, 1H), 3.14 (br t, >10.5 Hz, 1H), 2.93 - 2.99 (m, 2H), 2.55 - 2.60 (m, 2H). LCMS (ESI+): m / z=380.2 (M+H)+.
[0207] Example 9. Synthesis of (S)-4-(6-((1 s,3R)-3-(1 H-pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)-2-(1 -methyl-1 H-pyrazol-4-yl)morpholine (Compound 216) and (R)-4-(6-((1s,3S)-3-(1 / 7-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(1 -methyl-1 / 7-pyrazol-4-yl)morpholine (Compound 217).
[0208] Step 1. 1-Methyl-4-vinyl-1 / 7-pyrazole
[0209] A mixture of 4-iodo-1 -methyl- 1 / 7-pyrazole (5.0 g, 24 mmol), potassium vinyltrifluroborate (3.5 g, 26 mmol), Pd(dppf)Cl2 (980 mg, 1.2 mmol) and K2CO3 (6.6 g, 48 mmol) in 1,4-dioxane (60 mL) and water (6 mL) was degassed and purged 3 times with N2. The mixture was stirred at 90°C for 3 hours under N2 atmosphere. The resultant mixture was filtered, and the filtrate was concentrated to give a residue. The residue was purified by silica gel columnSeries 1 / 5 33827 / 50003 / PCchromatography (ethyl acetate / hexane = 0% - 40%) to give 1-methyl-4-vinyl-1 / 7-pyrazole (1.0 g, 8.5 mmol).1H NMR (400 MHz, CDCl3) 5 (ppm) 7.56 (s, 1H), 7.36 (s, 1H), 6.52 (dd, J=17.6, 11.0 Hz, 1H), 5.44 (dd, J=17.7, 1.3 Hz, 1H), 5.05 (dd, J=11.0, 1.3 Hz, 1H), 3.87 (s, 3H). LCMS (ESI+): m / z=109.2 (M+H)+.
[0210] Step 2. 2-(1 -Methyl-1 / 7-pyrazol-4-yl)morpholine
[0211] To a 15 mL vial equipped with a stir bar was added 1-methyl-4-vinyl-1H-pyrazole (500 mg, 4.62 mmol), 2-((5λ4-dibenzo[b,d]thiophen-5-ylidene)amino)ethan-1-ol (2.25 g, 9.25 mmol), Ir(dFppy)3(70.5 mg, 92.5 μmol) and Bi(OTf)3(6.07 g, 9.25 mmol) in DME (2 mL). The vial was sealed and placed under nitrogen. The reaction mixture was stirred and irradiated with a blue 10 W LED lamp (3 cm away) with cooling water to keep the reaction temperature at 25°C for 14 hours. The residue was purified by silica gel column chromatography (CH2Cl2 / MeOH = 10 / 1) and further purified by prep-HPLC (ACN / H2O (10 mM NH4HCO3) = 1 - 20%) to give 2-(1-methyl-1H-pyrazol-4-yl)morpholine (400 mg, 2.39 mmol).1H NMR (400 MHz, DMSO-d6) 5 (ppm) 7.75 (s, 1H), 7.45 (s, 1H), 4.65 (dd, J = 1.9, 11.1 Hz, 1H), 4.00 (br dd, J= 2.9, 12.7 Hz, 1H), 3.45-3.65 (m, 4H), 3.30-3.40 (br d, J = 12.0 Hz, 1H), 3.15-3.30 (br d, J = 12.0 Hz, 1H), 3.08 - 3.00 (m, 2H). LCMS (ESI+): m / z = 168.2 (M+H)+.
[0212] Step 3. 4-(6-((1s,3s)-3-(1 / 7-Pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(1 -methyl-1 / 7-pyrazol-4-yl)morpholine
[0213] A mixture of 4-((1s,3s)-3-(f / 7-pyrazol-1-yl)cyclobutoxy)-6-chloropyrimidine (100 mg, 399 μmol), 2-(1-methyl-1H-pyrazol-4-yl)morpholine (100 mg, 598 μmol) and triethylamine (121 mg, 1.2 mmol) in n-BuOH (1 mL) was stirred at 110°C for 3 hours. The reaction mixture was concentrated to give a residue. The residue was purified by prep-HPLC (ACN / H2O (10mM NH4HCO3) = 15 - 45%) to give 4-(6-((1s,3s)-3-(1H-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(1-methyl-1H-pyrazol-4-yl)morpholine (100 mg, 262 μmol). LCMS (ESI+): m / z = 382.1 (M+H)+.
[0214] Step 4. (S)-4-(6-((1 s,3R)-3-(1 / 7-Pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(1 -methyl-1 / 7-pyrazol-4-yl)morpholine and (R)-4-(6-((1s,3S)-3-(1 / 7-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(1-methyl-1 / 7-pyrazol-4-yl)morpholine
[0215] The racemic mixture of 4-(6-((1s,3s)-3-(1H-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(1-methyl-1H-pyrazol-4-yl)morpholine (75 mg) was separated by SFC (column: Chiral-AS-30-D AICEL CHIRALPAK AS (250 mm * 30 mm, 10 urn); mobile phase: IPA-ACN (7:3) / CO2 = 40%) to give (S)-4-(6-((1s,3R)-3-(1H-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(1-methyl-1H-pyrazol-4-yl)morpholine (22.8 mg, 57.9 μmol, Compound 216) and (R)-4-(6-((1s,3S)-3-(1H-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(1-methyl-1H-pyrazol-4-yl)morpholine (23.5 mg, 59.7 μmol, Compound 217).Compound 216:1H NMR (400 MHz, DMSO-d6) 5 (ppm) 8.26 (s, 1H), 7.81 (d, J = 2.1 Hz, 1H), 7.72 (s, 1H), 7.49 (d, J = 1.4 Hz, 1 H), 7.44 (s, 1 H), 6.24 (t, J = 2.0 Hz, 1 H), 6.20 (s, 1 H), 5.04 (quin, J = 7.3 Hz, 1 H), 4.68 - 4.59 (m, 1 H), 4.45 (dd, J = 2.5, 10.4 Hz, 1 H), 4.32 (br d, J = 12.4 Hz, 1 H), 4.17 (br d, J = 13.3 Hz, 1 H), 3.95 (dd, J = 1.8, 11.6 Hz, 1 H), 3.81 (s, 3H), 3.60 (dt, J = 2.6, 11.5 Hz, 1 H), 3.06 - 2.91 (m, 4H), 2.60 - 2.52 (m, 2H). LCMS (ESI+): m / z=382.2Series 1 / 5 33827 / 50003 / PC(M+H)+.Compound 217:1H NMR (400 MHz, DMSO-d6) δ (ppm) 8.26 (s, 1H), 7.81 (d, J = 2.1 Hz, 1H), 7.72 (s, 1H), 7.49 (d, J = 1.4 Hz, 1 H), 7.44 (s, 1 H), 6.24 (t, J = 2.0 Hz, 1 H), 6.20 (s, 1 H), 5.04 (quin, J = 7.2 Hz, 1 H), 4.63 (quin, J = 8.2 Hz, 1H), 4.45 (dd, J = 2.5, 10.4 Hz, 1H), 4.32 (br d, J= 12.6 Hz, 1H), 4.17 (brd, J= 12.3 Hz, 1H), 3.99 - 3.91 (m, 1H), 3.81 (s, 3H), 3.60 (dt, J = 2.6, 11.5 Hz, 1 H), 3.07 - 2.89 (m, 4H), 2.61 - 2.52 (m, 2H). LCMS (ESI+): m / z=382.2 (M+H)+.The following analogs were prepared by following procedures similar to those of Example 9:
[0216] Example 10. Synthesis of (S)-4-(6-((1 s,3R)-3-(1 H-pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-(pyrrolidin-1 -yl)phenyl)morpholine (Compound 80) and (R)-4-(6-((1s,3S)-3-(1 / - / -pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-(pyrrolidin-1 -yl)phenyl)morpholine (Compound 81).
[0217] Step 1. ferf-Butyl 2-(3-bromophenyl)morpholine-4-carboxylate
[0218] . To an oven dried 10 mL ElectraSyn 2.0 vial were added m-bromoiodobenzene (1.05 g, 3.72 mmol), 4- (terf-butyl) 2-(1,3-dioxoisoindolin-2-yl) morpholine-2,4-dicarboxylate (2.00 g, 3.72 mmol), NICI2-6H2O (177 mg, 744Series 1 / 5 33827 / 50003 / PCμmol), and 2,2'-bipyridyl (116 mg, 744 μmol). Anhydrous dimethylformamide (23.3 mL) was then added and the contents of the vial were allowed to stir until all solids were dissolved (-10 minutes). AgNO3(316 mg, 1.86 mmol) was then added to the reaction mixture. The vial was equipped with an ElectraSyn 2.0 vial cap with a magnesium sacrificial anode and a cylindrical 100 ppi RVC at 20°C. The vial was then placed on an IKA ElectraSyn 2.0 stir plate and electrolysis was set to 100 mA, 0.5 mmol, 2.5 F / mol (open to air). The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The resultant mixture was diluted with water (3 mL) and extracted with ethyl acetate (2 x 30 mL). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (ethyl acetate / hexane = 0-10%) to give fert-butyl 2-(3-bromophenyl)morpholine-4-carboxylate (500 mg, 1.24 mmol).1H NMR (400 MHz, CDCl3) 5 (ppm) 7.56 (s, 1H), 7.43 (d, 1H), 7.22-7.31 (m, 2H), 4.35-4.45 (d, 1H), 3.6-4.3 (m, 3H), 3.60-3.75 (m, 1H), 2.95-3.15 (m, 1H), 2.60-2.95 (m, 1H), 1.49 (s, 9H). LCMS (ESI+): m / z=241.9 (M+H)+.
[0219] Step 2. fert-Butyl 2-(3-(pyrrolidin-1 -yl)phenyl)morpholine-4-carboxylate
[0220] A mixture of fert-butyl 2-(3-bromophenyl)morpholine-4-carboxylate (500 mg, 1.24 mmol), Pd2(dba)3(114 mg, 124 μmol), BINAP (155 mg, 248 μmol) and sodium 2-methyl-2-propanolate (477 mg, 4.97 mmol) in toluene (5.67 mL) was degassed and purged 3 times with N2. Pyrrolidine (353 mg, 4.97 mmol) was then added dropwise at 25°C. The reaction was stirred at 80°C for 1 hour under N2 atmosphere. The resultant mixture was concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (ethyl acetate / hexane = 0-10%) to give fert-butyl 2-(3-(pyrrolidin-1-yl)phenyl)morpholine-4-carboxylate (465 mg, 1.33 mmol).1H NMR (400 MHz, CDCl3) 5 (ppm) 7.21 (t, J=7.9 Hz, 1 H), 6.66 (br d, J=7.5 Hz, 1 H), 6.42 - 6.61 (m, 2H), 4.37 (br d, J=9.6 Hz, 1 H), 3.76 - 4.11 (m, 3H), 3.68 (td, J= 11.7, 2.6 Hz, 1 H), 3.30 (br t, J=6.5 Hz, 4H), 2.80 - 3.12 (m, 2H), 1.92 - 2.05 (m, 4H), 1.49 (s, 9H). LCMS (ESI+): m / z = 333.1 (M+H)+.
[0221] Step 3. 2-(3-(Pyrrolidin-1-yl)phenyl)morpholine
[0222] A solution of fert-butyl 2-(3-(pyrrolidin-1-yl)phenyl)morpholine-4-carboxylate (150 mg, 406 pimol) in HCI / dioxane (2.0 mL, 2.0 M) was stirred at 25°C for 1 hour. The reaction mixture was concentrated under reduced pressure to give 2-(3-(pyrrolidin-1-yl)phenyl)morpholine (120 mg, 402 μmol). LCMS (ESI+): m / z = 233.1 (M+H)+.
[0223] Step 4. 4-(6-((1 s,3s)-3-(1 H-Pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-(pyrrolidin-1 -yl)phenyl)morpholine
[0224] To a solution of 2-(3-(pyrrolidin-1-yl)phenyl)morpholine (120 mg, 402 μmol) and TEA (122 mg, 1.21 mmol) in n-BuOH (3.59 mL) was added 4-((1s,3s)-3-(1H-pyrazol-1-yl)cyclobutoxy)-6-chloropyrimidine (101 mg, 402 μmol) in one portion at 25°C. The mixture was stirred at 110°C for 12 hours under N2 atmosphere. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (ACN / water (NH4HCO3) = 20% - 50%) and lyophilized to give 4-(6-((1s,3s)-3-( 1 / 7-pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-Series 1 / 5 33827 / 50003 / PC(pyrrolidin-1-yl)phenyl)morpholine (150 mg, 319 μmol).1H NMR (400 MHz, CDCl3) 5 (ppm) 8.26 (s, 1H), 7.81 (d, J=1.9 Hz, 1H), 7.49 (d, J=1.5 Hz, 1H), 7.14 (t, >7.8 Hz, 1H), 6.64 (d, >7.6 Hz, 1H), 6.58 (s, 1H), 6.47 (dd, J=8.1, 1.9 Hz, 1H), 6.24 (t, J=2.0 Hz, 1H), 6.19 (s, 1H), 5.04 (quin, J=7.3 Hz, 1H), 4.58 - 4.68 (m, 1H), 4.29 - 4.44 (m, 2H),4.13 - 4.26 (m, 1 H), 4.05 (dd, >11.6, 2.4 Hz, 1 H), 3.64 (td, >11.7, 2.7 Hz, 1 H), 3.19 - 3.26 (m, 4H), 3.01 - 3.09 (m, 1H), 2.91 - 2.99 (m, 2H), 2.85 (dd, 13.0, 10.6 Hz, 1H), 2.54 - 2.61 (m, 2H), 1.89 - 1.99 (m, 4H). LCMS (ESI+): m / z = 447.6 (M+H)+.
[0225] Step 5. (S)-4-(6-((1s,3R)-3-(1 / 7-Pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-(pyrrolidin-1-yl)phenyl)morpholine and (R)-4-(6-((1s,3S)-3-(1 / 7-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-(pyrrolidin-1-yl)phenyl)morpholine
[0226] The racemic mixture of 4-(6-((7s, 3s)-3-(7 / 7-pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-(pyrrolidin-1 -yl)phenyl)morpholine (0.1 g, 213 μmol) was separated by SFC (column: Chiral-AD-30-DAICEL CHIRALPAK AD (250 mm*30 mm, 10 urn); mobile phase: IPA: MeCN (7:3) / CO2 = 47%) to give (S)-4-(6-((1s,3R)-3-(1H-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-(pyrrolidin-1-yl)phenyl)morpholine (17.6 mg, 39.4 μmol, Compound 80) and (R)-4-(6-((1s,3S)-3-(1H-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-(pyrrolidin-1-yl)phenyl)morpholine (11.5 mg, 28.9 μmol, Compound 81).Compound 80:1H NMR (400 MHz, DMSO-de) 6 (ppm) 8.26 (s, 1H), 7.80 (s, 1H), 7.49 (s, 1H), 7.14 (t, 7.8 Hz, 1H),6.64 (br d, >7.4 Hz, 1H), 6.58 (s, 1H), 6.47 (br d, >8.0 Hz, 1H), 6.24 (d, >1.6 Hz, 1H), 6.19 (s, 1H), 5.04 (br t, >7.2 Hz, 1 H), 4.63 (br t, >8.1 Hz, 1 H), 4.28 - 4.46 (m, 2H), 4.21 (br d, >11.9 Hz, 1 H), 4.05 (br d, >11.5 Hz, 1 H),3.64 (br t, >11.4 Hz, 1 H), 3.22 (br s, 4H), 2.92 - 3.10 (m, 3H), 2.85 (br t, >11.8 Hz, 1 H), 2.57 (br d, >9.8 Hz, 2H), 1.94 (br s, 4H). LCMS (ESI+): m / z=447.3 (M+H)+.Compound 81:1H NMR (400 MHz, DMSO-d6) 5 (ppm) 8.26 (s, 1H), 7.80 (d, >2.1 Hz, 1H), 7.49 (d, >1.4 Hz, 1H),7.14 (t, >7.9 Hz, 1H), 6.64 (d, >7.5 Hz, 1H), 6.58 (s, 1H), 6.47 (dd, >8.1, 1.8 Hz, 1H), 6.24 (t, >2.0 Hz, 1H), 6.19 (s, 1H), 5.04 (quin, >7.3 Hz, 1H), 4.59 - 4.68 (m, 1H), 4.29 - 4.45 (m, 2H), 4.14 - 4.26 (m, 1H), 4.05 (br dd, >11.6, 2.3 Hz, 1H), 3.67 (br s, 1H), 3.22 (br t, >6.5 Hz, 4H), 2.94 - 3.08 (m, 3H), 2.85 (dd, >13.1, 10.6 Hz, 1H), 2.55 - 2.60 (m, 2H), 1.87 - 1.99 (m, 4H). LCMS (ESI+): m / z=447.2 (M+H)+.
[0227] The following analogs were prepared by following procedures similar to those of Example 10:Series 1 / 5 33827 / 50003 / PC
[0228] Example 11. Synthesis of (R)-4-(6-((1 s,3S)-3-(1 H-py razol -1 -y I )cy clobu toxy)py ri mid i n-4-y I )-2- (py r i mi d in-4-yl)morpholine (Compounds 226) and (S)-4-(6-((1s,3R)-3-(1 H-pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)-2-(pyrimidin-4-yl)morpholine (Compounds 227).Series 1 / 5 33827 / 50003 / PC
[0229] Step 1. 4-(tert-Butyl) 2-ethyl 2-(2-chloropyrimidin-4-yl) morpholi ne-2,4-dicarboxy late
[0230] To a solution of 4-(tert-butyl) 2-ethyl morpholine-2,4-dicarboxylate (870 mg, 2.35 mmol) and 2,4-dichloropyrimidine (500 mg, 3.36 mmol) in tetrahydrofuran (5 mL) was added sodium bis(trimethylsilyl)amide (1.68 mL, 1.0M THF, 1.68 mmol) dropwise at 0°C under N2 atmosphere. The reaction was stirred at 25°C for 3 hours. The mixture was diluted with saturated ammonium chloride (20 mL), extracted with ethyl acetate (20mL x 3), washed with brine (20 mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (ethyl acetate / hexane = 0-20%) to give 4-(tert-butyl) 2-ethyl 2-(2-chloropyrimidin-4-yl) morpholine-2,4-dicarboxylate (330 mg, 843 pimol).1H NMR (400 MHz, CDCI3) 5 (ppm) 8.87 (d, J = 5.1 Hz, 1 H), 7.74 (d, J = 5.1 Hz, 1 H), 4.70 - 4.32 (m, 1 H), 4.15 (q, J = 6.6 Hz, 2H), 3.88 (td, J = 3.3, 12.1 Hz, 1 H), 3.77 - 3.63 (m, 2H), 3.60 - 3.38 (m, 1H), 3.11 (ddd, J = 3.7, 10.1, 13.5 Hz, 1H), 1.41 (s, 9H), 1.16 - 1.11 (m, 3H).
[0231] Step 2. fe / t-Butyl 2-(2-chloropyrimidin-4-yl) morpholine-4-carboxylate
[0232] To a solution of 4-(tert-butyl) 2-ethyl 2-(2-chloropyrimidin-4-yl) morpholine-2,4-dicarboxylate (300 mg, 766 pimol) in THF (2.85 mL) was added NaOH (1.9 mL, 2.0 M in H2O, 4.0 mmol) dropwise at 25°C. The reaction was stirred at 25°C for 4 hours. The resultant mixture was treated HCI (1.9 mL, 2.0 M in H2O, 4.0 mmol) to reach pH = 6-7 and stirred at 40°C for 12 hours. The resultant mixture was diluted with saturated ammonium chloride (20 mL), extracted with ethyl acetate (20 mL x 3). The combined organics phases were washed with brine (20 mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (ethyl acetate / hexane = 0-20%) to give tert-butyl 2-(2-chloropyrimidin-4-yl) morpholine-4-carboxylate (199 mg, 631 pmol).1H NMR (400 MHz, CDCI3) 5 (ppm) 8.65 (d, J= 5.0 Hz, 1H), 7.49 (br d, J = 4.8 Hz, 1 H), 4.48 (m, J = 2.8, 10.4 Hz, 2H), 4.09 - 3.92 (m, 2H), 3.70 (dt, J = 2.8, 11.7 Hz, 1H), 3.02 (br t, J = 11.2 Hz, 1 H), 2.78 (br s, 1H), 1.50 (s, 9H). LCMS (ESI+): m / z= 300.0 (M+H)+.
[0233] Step 3. tert-Butyl 2-(2-chloropyrimidin-4-yl) morpholine-4-carboxylate
[0234] To a solution of tert-butyl 2-(2-chloropyrimidin-4-yl) morpholine-4-carboxylate (199 mg, 631 pimol) in methanol (4.73 mL) was added Pd / C (71.0 mg, 10% w / w, 667 μmol) under Ar atmosphere. The suspension was degassed and purged 3 times with H2. The reaction was stirred at 25°C for 1 hour under H2 (15 Psi). The resultant mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (ethyl acetate / hexane = 0-50%) to give tert-butyl 2-(pyrimidin-4-yl) morpholine-4-carboxylate (135 mg, 483 μmol).1H NMR (400 MHz, CDCl3) 5 (ppm) 9.18 (d, J = 0.6 Hz, 1H), 8.76 (d, J = 5.1 Hz, 1 H), 7.52 (br d, J = 3.8 Hz, 1 H), 4.56 - 4.30 (m, 2H), 4.13 - 3.91 (m, 2H), 3.72 (dt, J = 2.8, 11.7 Hz, 1 H), 3.04 (br d, J = 9.4 Hz, 1 H), 2.80 (br t, J = 11.9 Hz, 1 H), 1.50 (s, 9H). LCMS (ESI+): m / z= 266.1 (M+H)+.
[0235] Step 4. 2-(Pyrimidin-4-yl) morpholine
[0236] A solution of tert-butyl 2-(pyrimidin-4-yl) morpholine-4-carboxylate (100 mg, 358 μmol) in hydrogen chlorideSeries 1 / 5 33827 / 50003 / PC(2.0 mL, 2.0 M in dioxane, 1.0 mmol) was stirred at 25°C for 2 hours. The reaction mixture was concentrated under reduced pressure to give 2-(pyrimidin-4-yl) morpholine (80.0 mg, 357 μmol). LCMS (ESI+): m / z= 166.1 (M+H)+.
[0237] Step 5. 4-(6-((1s,3s)-3-(1 / 7-Pyrazol-1-yl) cyclobutoxy) pyrimidin-4-yl)-2-(pyrimidin-4-yl) morpholine
[0238] To a solution of 2-(pyrimidin-4-yl) morpholine (90 mg, 424 μmol) and 4-((1s,3s)-3-(1H-pyrazol-1-yl) cyclobutoxy)-6-chloropyrimidine (101 mg, 403 μmol) in n-BuOH (3.79 mL) was added TEA (129 mg, 1.27 mmol) at 25°C. The reaction was stirred at 110°C for 12 hours under N2 atmosphere. The resultant mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (ACN / water (NH4HCO3) = 20 -50%) and lyophilized to give 4-(6-((1s,3s)-3-(1H-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(pyrimidin-4-yl)morpholine (100 mg, 250 μmol).1H NMR (400 MHz, CDCl3) 5 (ppm) 9.19 (d, J = 1.0 Hz, 1H), 8.86 (d, J = 5.1 Hz, 1H), 8.30 (s, 1H), 7.81 (d, J= 2.1 Hz, 1H), 7.62 (d, J= 5.1 Hz, 1H), 7.49 (d, J= 1.3 Hz, 1H), 6.24 (t, J= 1.9 Hz, 1H), 6.19 (s, 1H), 5.05 (quin, J = 7.2 Hz, 1H), 4.78 (br d, J= 10.9 Hz, 1H), 4.69 - 4.56 (m, 2H), 4.20 - 4.03 (m, 2H), 3.75 (dt, J = 2.8,11.6 Hz, 1H), 3.15 - 3.05 (m, 1H), 3.02 - 2.84 (m, 3H), 2.61 - 2.54 (m, 2H). LCMS (ESI+): m / z= 380.0 (M+H)+.
[0239] Step 6. (R)-4-(6-((1s,3S)-3-(1 / 7-Pyrazol-1-yl)cyclobutoxy) pyrimidin-4-yl)-2-(pyrimidin-4-yl) morpholine and (S)-4-(6-((1s,3R)-3-(1 / 7-pyrazol-1-yl)cyclobutoxy) pyrimidin-4-yl)-2-(pyrimidin-4-yl) morpholine
[0240] The racemic mixture of 4-(6-((7s, 3s)-3-(7 / 7-pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)-2-(pyrimidin-4-yl)morpholine (100 mg, 213 μmol) was purified by SFC (column: Chiral-AY-30-DAICEL CHIRALPAK AY-H (250 mm* 30 mm, 10 um); mobile phase: IPA / CO2 = 50%). The fractions were concentrated under reduced pressure to give (R)-4-(6-((1s,3S)-3-(1 / 7-pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)-2-(pyrimidin-4-yl) morpholine (17.1 mg, 45 μmol, Compounds 226) and (S)-4-(6-((1s,3R)-3-(1H-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(pyrimidin-4-yl) morpholine (11.7 mg, 30.7 μmol, Compounds 227).Compounds 226:1H NMR (400 MHz, DMSO-d6) δ (ppm) 9.19 (d, J= 1.0 Hz, 1H), 8.86 (d, J = 5.3 Hz, 1H), 8.30 (s, 1H), 7.81 (d, J = 2.1 Hz, 1H), 7.62 (d, J = 5.1 Hz, 1H), 7.49 (d, J= 1.3 Hz, 1H), 6.24 (t, J = 2.0 Hz, 1H), 6.19 (s, 1H), 5.05 (t, J = 7.2 Hz, 1 H), 4.78 (br d, J = 11.3 Hz, 1 H), 4.68 - 4.56 (m, 2H), 4.20 - 4.06 (m, 2H), 3.75 (dt, J = 2.7, 11.7 Hz, 1H), 3.15 - 3.06 (m, 1H), 3.01 - 2.85 (m, 3H), 2.62 - 2.54 (m, 2H). LCMS (ESI+): m / z= 380.2 (M+H)+.Compounds 227:1H NMR (400 MHz, DMSO-d6) 6 (ppm) 9.19 (d, J= 1.1 Hz, 1H), 8.86 (d, J = 5.1 Hz, 1H), 8.30 (s, 1H), 7.81 (d, J = 2.1 Hz, 1H), 7.62 (d, 3= 5.1 Hz, 1H), 7.49 (d, 3= 1.4 Hz, 1H), 6.24 (t, 3 = 2.0 Hz, 1H), 6.19 (s, 1H), 5.05 (quin, J = 7.2 Hz, 1 H), 4.78 (br d, J = 13.9 Hz, 1 H), 4.69 - 4.57 (m, 2H), 4.22 - 4.07 (m, 2H), 3.75 (dt, J = 2.7,11.7 Hz, 1H), 3.16 - 3.04 (m, 1H), 3.02 - 2.84 (m, 3H), 2.62 - 2.53 (m, 2H). LCMS (ESI+): m / z= 380.2 (M+H)+.
[0241] Example 12. Synthesis of (S)-4-(6-((1 s,3R)-3-(1 H-1,2,3-triazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-(pyridin-2-yl)phenyl)morpholine (Compounds 243).Series 1 / 5 33827 / 50003 / PC
[0242] A mixture of (S)-4-(6-((1s,3 / ?)-3-( / H-1,2,3-triazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-bromophenyl)morpholine (50.0 mg, 109 μmol), 2-(tributylstannyl)pyridine (121 mg, 328 μmol), bis(triphenylphosphine) palladium(II) dichloride (7.7 mg, 10.9 μmol) and lithium chloride (46.3 mg, 1.09 mmol) in toluene (1.25 mL) was degassed and purged 3 times with N2. The mixture was stirred at 80°C for 2 hours under N2 atmosphere. The reaction mixture was concentrated in vacuo to give a residue. The crude product was purified by prep-HPLC (ACN / H2O (10 mM NH4HCO3) = 23 - 53%) and lyophilized to give (S)-4-(6-((1s,3R)-3-(1H-1,2,3-triazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-(pyridin-2-yl)phenyl)morpholine (9.78 mg, 19.8 μmol).1H NMR (400 MHz, DMSO-d6) 5 ppm 8.68 (dd, 0 = 0.8, 4.7 Hz, 1 H), 8.31 - 8.27 (m, 2H), 8.18 (s, 1 H), 8.05 - 7.97 (m, 2H), 7.90 (dt, J = 1.8, 7.7 Hz, 1H), 7.75 (d, J = 0.8 Hz, 1H), 7.54 - 7.49 (m, 2H), 7.37 (ddd, 0 = 0.9, 4.8, 7.4 Hz, 1H), 6.27 (s, 1H), 5.17 - 5.06 (m, 1H), 4.95 (quin, 0 = 8.2 Hz, 1H), 4.61 (dd, 0= 2.4, 10.6 Hz, 1H), 4.47 (br dd, 0 = 2.8, 12.3 Hz, 1H), 4.33 - 4.22 (m, 1H), 4.11 (dd, 0 = 2.4, 11.4 Hz, 1H), 3.71 (dt, 0 = 2.6, 11.7 Hz, 1H), 3.16 - 3.07 (m, 3H), 2.91 (dd, 0= 10.7, 13.1 Hz, 1H), 2.67 - 2.59 (m, 2H). LCMS (ESI+): m / z= 456.2 (M+H)+.
[0243] The following analogs were prepared by following procedures similar to those of Example 12:
[0244] Example 13. Synthesis of 1-(4-(3-((S)-4-(6-((1s,3R)-3-(1 A / -pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)phenyl)piperazin-1 -yl)ethan-1-one (Compound 260).Series 1 / 5 33827 / 50003 / PC260
[0245] A solution of (S)-4-(6-((fs,3R)-3-(fH-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-bromophenyl)morpholine (70.0 mg, 153 pmol), 1 -(1 -piperazinyl)-1-ethanone (19.7 mg, 153 pimol), 2,2'-bis(diphenylphosphino)-1,1 '-binaphthyl (9.6 mg, 15.3 pimol), Pd2(dba)s (14.0 mg, 15.3 pimol) and sodium 2-methyl-2-propanolate (2.0 M in THF, 0.14 mL) in toluene (0.3 mL) was degassed and purged 3 times with N2. The reaction was stirred at 100°C for 2 hours under N2 atmosphere. The resultant mixture was filtered and concentrated in vacuo. The residue was purified by prep-HPLC (ACN / H2O(10mM NH4HCO3) = 23-53%) and lyophilized to give 1-(4-(3-((S)-4-(6-((1s,3R)-3-(1H-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)phenyl)piperazin-1 -yl)ethan-1 -one (4.7 mg, 9.1 pimol).1H NMR (400 MHz, DMSO-d6) 5 (ppm) 8.27 (d, 3 = 0.8 Hz, 1H), 7.81 (d, 3= 1.8 Hz, 1H), 7.49 (d, 3= 1.6 Hz, 1H), 7.23 (t, 3= 7.9 Hz, 1 H), 7.02 (s, 1 H), 6.94 - 6.82 (m, 2H), 6.30 - 6.15 (m, 2H), 5.05 (quin, 3 = 7.2 Hz, 1 H), 4.71 - 4.57 (m, 1 H), 4.45 (dd, 3= 2.5, 10.4 Hz, 1H), 4.38 - 4.16 (m, 2H), 4.06 (dd, 3 = 2.6, 11.5 Hz, 1H), 3.65 (dt, 3 = 2.3, 11.6 Hz, 1H), 3.60 -3.52 (m, 4H), 3.22 - 3.09 (m, 4H), 3.05 (br dd, 3 = 3.7, 12.9 Hz, 1 H), 3.02 - 2.92 (m, 2H), 2.85 (dd, 3 = 10.6, 13.1 Hz, 1H), 2.59 - 2.53 (m, 2H), 2.04 (s, 3H), LCMS (ESI+): m / z = 504.3 (M+H)+.
[0246] The following analogs were prepared by following procedures similar to those of Example 13.Series 1 / 5 33827 / 50003 / PC
[0247] Example 14. Synthesis of 2-(3-((S)-4-(6-((1s,3R)-3-(1 / 7-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)pheny Qacetic acid (Compound 274).
[0248] Step 1. terf-Butyl 2-(3-((S)-4-(6-((1 s,3R)-3-(1 / 7-pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)phenyl)acetate
[0249] To a 15 mL vial equipped with a stir bar were added (S)-4-(6-((1s,3R)-3-(1 / - / -pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-(3-bromophenyl)morpholine (500 mg, 1.10 mmol), tert-butyl 2-chloroacetate (248 mg, 1.64 mmol), Ir[dF(CF3)ppy]2(dtbpy)(PF6) (12.3 mg, 11.0 mol), NiCh dtbbpy (21.8 mg, 54.8 pimol), 2,6-dimethylpyridine (294 mg, 2.74 mmol) and tris(trimethylsilyl)silane (615 mg, 1.64 mmol) in DME (5 mL). The vial was sealed and placed under nitrogen. The reaction was stirred and irradiated with a 10 W blue (455 nm) LED lamp (3 cm away) with cooling water to keep the reaction temperature at 25°C for 14 hours. The reaction mixture was filtered, and filtrate was concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (ethyl acetate / hexane = 0-50%) and prep-HPLC (ACN / water (FA) = 50-60%). The fractions were diluted with water (50 mL), extracted with ethyl acetate (50 mL x3), washed with brine (50 mL x3), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford tert-butyl 2-(3-((S)-4-(6-((fs,3R)-3-(f / 7-pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)phenyl)acetate (220 mg, 425 pimol).1H NMR (400 MHz, CDCl3) 5 (ppm) 8.32 (s, 1 H), 7.57 (s, 1 H), 7.48 (d, J = 1.4 Hz, 1 H), 7.37 - 7.30 (m, 3H), 7.25 (br d, J = 2.0 Hz, 1 H), 6.28 (t, 3= 2.1 Hz, 1H), 5.86 (s, 1H), 5.14 (quin, J= 7.2 Hz, 1H), 4.59 - 4.48 (m, 2H), 4.31 (br d, J = 12.5 Hz, 1H), 4.18 - 4.13 (m, 2H), 3.80 (dt, J = 2.9, 11.8 Hz, 1H), 3.56 (s, 2H), 3.19 - 3.08 (m, 3H), 2.93 (dd, J= 10.6, 13.1 Hz, 1H), 2.82 - 2.69 (m, 2H), 1.46 (s, 9H). LCMS (ESI+): m / z= 492.7 (M+H)+.Series 1 / 5 33827 / 50003 / PC
[0250] Step 2. 2-(3-((S)-4-(6-((1s,3R)-3-(1 / 7-Pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)phenyl)acetic acid
[0251] To a solution of tert-butyl 2-(3-((S)-4-(6-((ts,3R)-3-(1 / 7-pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl) morpholin-2-yl)phenyl)acetate (20.0 mg, 40.7 mol) in dichloromethane (1 mL) was added trifluoroacetic acid (4.6 mg, 41 mol) dropwise at 0°C. The resultant mixture was stirred at 25°C for 1 hour under N2 atmosphere. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (ACN / water (FA) = 20-50%) and lyophilized to give 2-(3-((S)-4-(6-((1s,3R)-3-(1 / 7-pyrazol-1-yl) cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)phenyl)acetic acid (7.9 mg, 18 pmol).1H NMR (400 MHz, DMSO-d6) 5 (ppm) 12.93 - 11.90 (m, 1H), 8.28 (s, 1H), 7.81 (d, J = 2.1 Hz, 1 H), 7.49 (d, J = 1.5 Hz, 1 H), 7.39 - 7.28 (m, 3H), 7.26 - 7.15 (m, 1 H), 6.27 - 6.18 (m, 2H), 5.05 (quin, J = 72 Hz, 1H), 4.63 (quin, J= 8.1 Hz, 1H), 4.49 (dd, J = 2.4, 10.4 Hz, 1H), 4.41 (br d, J= 12.9 Hz, 1H), 4.29 -4.18 (m, 1H), 4.11 - 4.02 (m, 1H), 3.67 (dt, J = 2.6, 11.8 Hz, 1H), 3.59 (s, 2H), 3.05 (dt, J = 3.7, 12.6 Hz, 1H), 2.97 (dtd, J = 2.9, 7.0, 9.5 Hz, 2H), 2.83 (dd, J = 10.8, 12.9 Hz, 1H), 2.61 - 2.55 (m, 2H). LCMS (ESI+): m / z= 436.2 (M+H)+.
[0252] The following analog was prepared by following procedures similar to those of Example 14:
[0253] Example 15. Synthesis of 2-(3-((S)-4-(6-((1s,3R)-3-(1 / 7-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)phenyl)-W, W-dimethylacetamide (Compound 277).277
[0254] . To a solution of 2-(3-((S)-4-(6-((1s,3R)-3-(1 / 7-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)phenyl)acetic acid (350 mg, 72.3 pmol) in dimethylformamide (0.63 mL, 8.20 mmol) was added dimethylamine hydrochloride (17.7 mg, 217 pimol), DIEA (28.0 mg, 217 pimol) and HATU (41.3 mg, 108 mol). The reaction was stirred at 25°C for 1 hour. The resultant mixture was concentrated under reduced pressure to give a residue. The reaction mixture was purified by prep-HPLC (ACN / H2O (10mM NH4HCO3) = 23-53%) and lyophilized to give 2-(3-((S)-4-(6-((1s,3R)-3-(1 / 7-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)phenyl)-W, W-dimethylacetamide (17.9 mg, 38.3 mol).1H NMR (400 MHz, DMSO-cfe) 5 (ppm) 8.27 (s, 1H), 7.81 (d, J = 1.9 Hz, 1H), 7.49 (d, J= 1.3 Hz, 1 H), 7.33 - 7.26 (m, 3H), 7.21 - 7.14 (m, 1 H), 6.26 - 6.18 (m, 2H), 5.05 (quin, J = 7.2 Hz, 1 H), 468 - 4.58 (m, 1 H), 4.48 (dd, J = 2.3, 10.4 Hz, 1 H), 4.40 (br d, J = 12.3 Hz, 1 H), 4.23 (br d, J = 12.9 Hz, 1 H), 4.06 (br dd, J = 2.5, 11.6Series 1 / 5 33827 / 50003 / PCHz, 1H), 3.70 (s, 2H), 3.68 - 3.61 (m, 1H), 3.11 - 3.03 (m, 1H), 3.00 (s, 3H), 2.99 - 2.91 (m, 2H), 2.87 - 2.77 (m, 4H), 2.61 - 2.54 (m, 2H). LCMS (ESI+): m / z= 463.3 (M+H)+.
[0255] The following analogs were prepared by following procedures similar to those of Example 15:
[0256] Example 16. Synthesis of 3-(( / ?)-4-(6-((1s,3S)-3-(1H-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)-5-fluorobenzoic acid (Compound 312) and 3-((S)-4-(6-((1s,3 / ?)-3-(1 / - / -pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)-5-fluorobenzoic acid (Compound 313).
[0257] Step 1. fert-Butyl 2-(3-fluoro-5-methoxycarbonylphenyl)-4-morpholinecarboxylate
[0258] Reaction solution 1: Methyl 3-bromo-5-fluorobenzoate (5.00 g, 21.5 mmol), 4-terf-butoxycarbonyl-2-morpholinecarboxylic acid (7.44 g, 32.2 mmol), phthalimide (3.16 g, 21.5 mmol), BTMG (5.51 g, 32.2 mmol),Series 1 / 5 33827 / 50003 / PClr[dF(CF3)ppy]2(dtbbpy)PF6 (481 mg, 429 pmol) and NiCh’dtbpy (427 mg, 1.07 mmol) in dimethyl sulfoxide (100 mL). Reaction solution 1 was pumped (0.565 mL / min) to flow reactor (FEP, Coils reactor, 3.175(1 / 8") mm, 50.868 mL, 50.0°C; light source: 450 nm, 400W; residence time = 90 min). The reaction mixture was diluted with water (300 mL) and extracted with ethyl acetate (150 mL x 3). The combined organic phases were washed with brine (100 mL x 2), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 10:1) to afford tert-butyl 2-(3-fluoro-5-methoxycarbonylphenyl)-4-morpholinecarboxylate (2.60 g, 6.13 mmol).1H NMR (400 MHz, CDCl3) 5 ppm 7.85 (s, 1H), 7.66 (br dd, J= 1.1, 7.8 Hz, 1 H), 7.34 (br d, J = 9.1 Hz, 1 H), 4.47 (br dd, J = 2.1, 10.4 Hz, 1 H), 4.04 (br dd, J = 2.6, 11.5 Hz, 2H), 3.94 (s, 4H), 3.69 (dt, J = 2.6, 11.7 Hz, 1H), 3.14 - 2.96 (m, 1H), 2.89 - 2.66 (m, 1H), 1.50 (s, 9H).
[0259] Step 2. Methyl 5-fluoro-3-(2-morpholinyl)benzoate hydrochloride
[0260] A mixture of tert-butyl (S)-2-(3-fluoro-5-methoxycarbonylphenyl)-4-morpholinecarboxylate (2.6 g, 6.5 mmol) in hydrogen chloride / dioxane (2.0 M, 26 mL) was stirred at 20°C for 2 hours. The reaction was concentrated under reduced pressure to give methyl 5-fluoro-3-(2-morpholinyl)benzoate hydrochloride (2.0 g, 5.8 mmol). LCMS (ESI+): m / z = 240.0 (M+H)+.
[0261] Step 3. Methyl 5-fluoro-3-(4-{6-[(1 s,3s)-3-(1-pyrazolyl)cyclobutoxy]-4-pyrimidinyl}-2-morpholinyl)benzoate
[0262] To a solution of 4-((1s,3s)-3-(1H-pyrazol-1-yl)cyclobutoxy)-6-chloropyrimidine (1.0 g, 4.0 mmol) and methyl 5-fluoro-3-(2-morpholinyl)benzoate hydrochloride (1.5 g, 4.4 mmol) in n-butanol (10 mL) was added triethylamine (2.0 g, 20 mmol) at 20°C. The mixture was stirred at 110°C for 12 hours. The resultant mixture was concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (ethyl acetate / hexane = 0%-30%) to give methyl 5-fluoro-3-(4-{6-[( 1s,3s)-3-(1 -pyrazolyl)cyclobutoxy]-4-pyrimidinyl}-2-morpholinyl)benzoate (650 mg, 1.3 mmol). LCMS (ESI+): m / z = 454.2 (M+H)+.
[0263] Step 4. 5-Fluoro-3-(4-{6-[(1 s,3s)-3-(1-pyrazolyl)cyclobutoxy]-4-pyrimidinyl}-2-morpholinyl)benzoic acid
[0264] To a solution of methyl 5-fluoro-3-(4-{6-[(fs,3s)-3-(1 -pyrazolyl)cyclobutoxy]-4-pyrimidinyl}-2-morpholinyl)benzoate (0.60 g, 1.32 mmol) in tetrahydrofuran (3 mL) was added dropwise a solution of lithium hydroxide monohydrate (167 mg, 3.97 mmol) in water (3 mL) at 0°C. The reaction was stirred at 20°C for 2 hours. The resultant mixture was concentrated in vacuo to give a residue. The residue was purified by prep-HPLC (ACN / H2O (0.23% FA) = 23-53%). The product fractions were extracted with ethyl acetate (20 mL x 4). The combined organic layers were dried over Na2SO4, filtered, and the filtrate was concentrated under reduced pressure to give 5-fluoro-3-(4-{6-[(fs,3s)-3-(1 -pyrazolyl)cyclobutoxy]-4-pyrimidinyl}-2-morpholinyl)benzoic acid (0.40 g, 900 mol).1H NMR (400 MHz, CDCI3) 5 ppm 8.35 (s, 1 H), 7.95 (s, 1 H), 7.74 (br d, J = 8.1 Hz, 1 H), 7.62 (s, 1 H), 7.53 - 7.38 (m, 2H), 6.29 (br s, 1H), 5.90 (s, 1H), 5.16 (quin, J = 7.2 Hz, 1H), 4.68 - 4.49 (m, 2H), 4.41 (br d, J= 12.9 Hz, 1H), 4.20 -4.15 (m, 1H), 4.04 (br d, J = 13.0 Hz, 1H), 3.87 - 3.75 (m, 1H), 3.32 - 3.19 (m, 1H), 3.18 - 3.07 (m, 2H), 3.01 - 2.89Series 1 / 5 33827 / 50003 / PC(m, 1 H), 2.85 - 2.73 (m, 2H). LCMS (ESI+): m / z = 440.1 (M+H)+.
[0265] Step 5. 3-((R)-4-(6-((1 s,3S)-3-(1 / - / -Pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)-5-fluorobenzoic acid and 3-((S)-4-(6-((1s,3 / ?)-3-(1 / 7-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)-5-fluorobenzoic acid
[0266] 5-Fluoro-3-(4-{6-[(7s,3s)-3-(1 -pyrazolyl)cyclobutoxy]-4-pyrimidinyl}-2-morpholinyl)benzoic acid (0.40 g, 910 pmol) was purified by SFC (column: Chiral-IK-30-DAICEL CHIRAL IK (250 mm*30 mm, 10 urn); mobile phase: EtOH (0.1% NH3H2O) / CO2= 32%) and concentrated under reduced pressure to give 3-((R)-4-(6-((1s,3S)-3-(1 / 7-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)-5-fluorobenzoic acid (116 mg, 257 mol, Compound 312) and 3-((S)-4-(6-((1s,3 / ?)-3-(1 / 7-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)-5-fluorobenzoic acid (111 mg, 249 mol, Compound 313).Compound 312:1H NMR (400 MHz, DMSO-d6) 5 ppm 8.28 (s, 1H), 7.89 (s, 1H), 7.80 (d, J = 2.1 Hz, 1H), 7.67 - 7.53 (m, 2H), 7.49 (d, J = 1.4 Hz, 1 H), 6.28 (s, 1 H), 6.24 (t, J = 1.9 Hz, 1 H), 5.10 - 5.00 (m, 1 H), 4.69 - 4.57 (m, 2H), 4.50 -4.38 (m, 1 H), 4.29 (br d, J = 12.9 Hz, 1 H), 4.09 (br dd, J = 24, 11.6 Hz, 1 H), 3.68 (dt, J = 2.5, 11.7 Hz, 1 H), 3.09 -2.93 (m, 3H), 2.83 (dd, J = 10.8, 13.0 Hz, 1H), 2.63 - 2.53 (m, 2H).19F NMR (400 MHz, DMSO-d6) 5 ppm -112.56 (br s, 1F). LCMS (ESI+): m / z = 440.2 (M+H)+.Compound 313:1H NMR (400 MHz, DMSO-d6) 6 ppm 8.28 (s, 1H), 7.89 (s, 1H), 7.80 (d, J= 1.6 Hz, 1H), 7.59 (br dd, J = 9.4, 15.1 Hz, 2H), 7.49 (s, 1H), 6.28 (s, 1H), 6.24 (s, 1H), 5.05 (quin, J = 7.2 Hz, 1H), 4.70 - 4.57 (m, 2H), 4.44 (br d, J = 12.5 Hz, 1 H), 4.29 (br d, J = 12.0 Hz, 1 H), 4.09 (br dd, J = 1.9, 11.4 Hz, 1 H), 3.68 (br dd, J = 9.5, 11.8 Hz, 2H), 3.10 - 2.93 (m, 3H), 2.83 (br dd, J = 10.9, 12.7 Hz, 1H), 2.62 - 2.54 (m, 2H).19F NMR (400 MHz, DMSO-d6) 5 ppm -112.59 (br s, 1F). LCMS (ESI+): m / z = 440.2 (M+H)+.
[0267] The following analogs were prepared by following procedures similar to those of Example 16:
[0268] Example 17. Synthesis of 3-((S)-4-(6-((1s,3R)-3-(1 / - / -pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)-5-fluoro-A / , A / -dimethylbenzamide (Compound 317).Series 1 / 5 33827 / 50003 / PC
[0269] . To a solution of dimethylamine hydrochloride (27.8 mg, 341 pmol) and DIEA (88.2 mg, 683 pmol) in dimethylformamide (0.6 mL) was added 3-((S)-4-(6-((1s,3R)-3-( 1 / 7-pyrazol-1 -yl)cyclobutoxy)pyrimidin-4-yl)morpholin- 2-yl)-5-fluorobenzoic acid (30.0 mg, 68.3 pmol) and HATU (38.9 mg, 102 pmol) at 25°C. The reaction was stirred at 50°C for 1 hour The mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (ACN / H2O (10 mM NH4HCO3) = 27-57%) and lyophilized to give 3-((S)-4-(6-((1s,3R)-3-(1H-pyrazol-1- yl)cyclobutoxy)pyrimidin-4-yl)morpholin-2-yl)-5-fluoro-N, N-dimethylbenzamide (5.5 mg, 12 pmol).1H NMR (400 MHz, DMSO-c / e) 6 ppm 8.27 (s, 1 H), 7.80 (d, J = 2.1 Hz, 1 H), 7.49 (d, J = 1.4 Hz, 1 H), 7.40 - 7.30 (m, 2H), 7.25 - 7.18 (m, 1H), 6.28 (s, 1H), 6.24 (t, J = 2.0 Hz, 1H), 5.10 - 5.00 (m, 1H), 4.69 - 4.55 (m, 2H), 4.41 (br d, J= 13.0 Hz, 1H), 4.29 (br d, J = 13.0 Hz, 1 H), 4.08 (br dd, J = 2.5, 11.5 Hz, 1 H), 3.67 (dt, J = 2.6, 11.7 Hz, 1 H), 3.09 - 2.94 (m, 6H), 2.89 (br s, 3H), 2.87 - 2.80 (m, 1 H), 2.62 - 2.54 (m, 2H).19F NMR (400 MHz, DMSO-d6) 5 ppm -112.50 (s, 1 F). LCMS (ESI+): m / z = 467.2 (M+H)+.
[0270] The following analogs were prepared by following procedures similar to those of Example 17:Series 1 / 5 33827 / 50003 / PC
[0271] Example 18. HEK293 VLCFA-LPC IC50Determination
[0272] HEK293-EBNA1 (HEK293E) cells were treated with compounds, such as those listed in Tables 1 and 2, using the representative manual protocols described below.
[0273] Cell Culture Growth Conditions:
[0274] HEK293E cells were maintained in Freestyle F17 media (Gibco A13835) supplemented with PenStrep (0.5%, Gibco # 15140122), Glutamax (2%, Gibco #35050-061), and PluronicTM F-68 (0.1%, Gibco #24040-032) (“supplemented media”). Suspension cultures were grown in disposable Erlenmeyer flasks at about 120 rpm, 37 °C., 5% C02, and 80% humidity. Cell densities were kept between about 0.5 and 3 million cells per mL, in 500 mL per flask for routine expansion for use in screening as described below.
[0275] Treatment of Cells with Compounds Provided Herein:
[0276] The cells were treated with compounds in 96-well format in a total of 900 pL cell media. Cells were grown in 96-well V-Bottom Deep Well Plates (Corning #3960) and sealed with Airpore Tape Sheets (Qiagen #19571). In brief, for each well, 450 pL of growth media of HEK293E cells at 1 E6 / mL (final concentration 4.5E5 / well) was supplemented with 180 pLof growth media supplemented with 1mg / ml C-13 sodium acetate (Sigma #282014) in which a dilution series of compound in DMSO had been added, along with 270 pL of growth media supplementedSeries 1 / 5 33827 / 50003 / PCwith 1 mg / mL (final concentration 0.5 mg / mL) C-13 sodium acetate. After sealing and plating, cells are placed into a shaking incubator at 225 rpm shaking incubator at 225 rpm, 37 °C, 5% C02, and >80% humidity for 48 hours. Following incubation, treated cells were harvested by centrifugation at 8000xg for 10 minutes. The supernatant was then discarded, and cell pellets were frozen at -80 °C.
[0277] Extraction from Cell Pellet Material for LC-MS Analysis:
[0278] Analytes were then extracted from thawed cell pellets with 200 pL hexane-isopropanol (60:40) by mixing and manually pipetting for 3 times and shaking at 800 rpm for 30 minutes at room temperature. Samples are centrifuged at max speed. 50 pL of supernatant is then added 200 pL internal standard (C13:0 lysophosphatidylcholine in n-butanol at 25 ng / mL). The samples are mixed, then centrifuged at 5800 rpm for 10 minutes. 5 pL of this material was then injected for analysis.
[0279] UHPLC / Mass Spectrometry:
[0280] The organic extraction was analyzed with an UHPLC (Waters ACQUITY UPLC system) coupled to a Triplequadrupole 6500 MS system: SCIEX, API6500 mass spectrometer. Separation of the13C2-labeled C24:0 lysophosphatidylcholine and internal standard C13:0 LPC was achieved using Waters ACQUITY BEH HILIC Column (2.1x100 mm, 1.7 μm). The UHPLC mobile phases consisted of 100% water with 20 mM ammonium formate (solvent A) and acetonitrile (90%) / water (10%) with 20 mM ammonium formate (solvent B).
[0281] The peak area for the mass spectrometry transition monitoring13C2-labeled C24:0 lysophosphatidylcholine and the internal standard C13:0 LPC are described below:
[0282] Data Analysis
[0283] The peak area ratio of13C2-C24:0 LPC vs. the internal standard (13C2-labeled C24:0 LPC peak area / IS C13:0) was used to quantify species in each sample. Percentage Inhibition was calculated as (Cmax- Experimental Sarnple) / (Cmax - Cmin) x 100, where Cmaxis the mean peak area ratio for DMSO treated controls and Cmin is the mean area ratio for controls without sodium acetate13C2 added (n=4-8). The percentage inhibition values measured in technical duplicate were then used to estimate I C50 values using an 8-point concentration curve. IC50 estimations were made by fitting the data to a four-parameter dose response (Y = Bottom + (Top - Bottom) / (1 + 10A((Log IC50-X) * Hill Slope))).Table 3: HEK IC50 ResultsSeries 1 / 5 33827 / 50003 / PCSeries 1 / 5 33827 / 50003 / PC
[0284] Example 19. Ion Channel Inhibition
[0285] Compound 34 was tested for inhibition of 5 seizure-related ion channel targets: hNaV1.2, hKv2.1, hKv7.2 / 7.3, GABA α1β2γ2, and NMDA 1 / 2A. The following reference compounds as known agonist / antagonist of the channels were used in the study: tetrodotoxin (TTX); 10, 10-bis(4-pyridinylmethyl)-9(10H)-anthracenone (XE991) is a known Kv7 (KCNQ) channel blocker; quinidine; bicuculline; and memantine. Six-point concentration-response curves were tested at concentrations up to 100 piM on the automated patch-clamp platform, QPatch II. The activity of Compound 34 was compared against known compound “Reference Compound 22":(Reference Compound 22).
[0286] Compounds were solubilized and tested according to Table 4. 6-Point concentration-response curves were generated using approximately 3-fold serial dilutions from the top test concentration.
[0287] Electrophysiological recordings were made from a Chinese Hamster Ovary or Human Embryonic Kidney cell lines stably expressing the full-length ion channel. Single cell ionic currents were measured in whole-cell configuration at room temperature (25 °C) using a QPatch II (Sophion Biosciences). The internal solution for all potassium channels contained (mM): 60 KF, 50 KCI, 20EGTA, 10 HEPES and 10 NaCI was buffered to pH 7.3. TheSeries 1 / 5 33827 / 50003 / PCinternal solution for all sodium channels contained (mM): 140 CsF, 1 EGTA, 10 NaCI, 10 HEPES and was buffered to pH 7.3. The internal solution for all ligand-gated ion channels contained (mM): 130 KCI, 1 MgCI2, 5 Mg-ATP, 10 HEPES, 5 EGTA, buffered to pH 7.3 with KOH. The external solution (HEPES-buffered saline, HBSS) contained (mM): 138 NaCI, 4.5 KCI, 1.8 CaCI2, 1.0 MgCI2, 10 HEPES, 10 glucose, buffered to pH 7.4. Cells were clamped at a holding potential of -90mV before a depolarizing step appropriate for each channel.
[0288] Table 4. Compound stocks and top test concentrations.
[0289] Concentration-response curves were generated by cumulative addition of compound with concentrations low to high. Cells were repeatedly pulsed during this time at frequencies given in Table 6. In all cases, steady-state inhibition was achieved before the next concentration of compound was added. For each ion channel, a positive control compound was tested in parallel as a six-point concentration-response curve (listed in Table 4). For voltagegated sodium channels, to investigate any use-dependence, an 8-pulse voltage protocol is applied at a frequency of 3 Hz. Inhibition is compared at pulse 1 (P1) and pulse 8 (P8). Any difference in the potency of a compound at P8 versus P1 would be typical of use-dependent block.
[0290] IC50 values were obtained from a 4-parameter logistic fit of the concentration-response data (Table 5). Greater than values indicate where inhibition did not reach 50% so an estimate of IC50 could not be made.Table 5. Seizure ion channel panel IC50S and % inhibition at top test concentration* Compounds showed potentiation of the GABA current. Displayed as negative inhibition at the concentration showing maximal activity.
[0291] Compound 34, 47, 186, and Ref. Compound 22 were tested against 5 ion channels related to seizure:Series 1 / 5 33827 / 50003 / PChNaV1.2, hKv2.1, hKv7.2 / 7.3, GABA α1β2γ2, and NMDA 1 / 2A. The compounds showed a range of activities as shown in Table 5. Most significantly, inhibition of hKv2.1 and positive allosteric modulation of GABAα1β2γ2.
[0292] The following QC conditions were applied:
[0293] (1) Individual cells with any of the following properties were excluded from subsequent analysis (1) seal resistances <500 MQ (2) ion channel currents <100 pA (3) seal resistances that changed by >50% during the experiment; and
[0294] (2) Assay plates in which the IC50 of the reference compound was outside of the expected range were failed.
[0295] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein
[0296] The use of the terms “a” and "an” and "the” and “at least one” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term “at least one” followed by a list of one or more items (for example, “at least one of A and B”) is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (for example, “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
Claims
Series 1 / 5 33827 / 50003 / PCWHAT IS CLAIMED:
1. A compound of formula (I'):or a pharmaceutically acceptable salt thereof,whereinRing A is C6-10aryl, 5-6 membered heteroaryl having 1, 2, or 3 ring heteroatoms independently selected from N, 0, and S, indolyl, isoindolyl, indolinyl, or isoindolinyl;n is 0, 1, 2, 3, 4, or 5;each R1is independently halogen, CN, oxo, Ci-salkyl, Cioalkoxy, C1-3haloalkyl, C-i-shaloalkoxy, -S(O)2R3, C0-2alkylene-C(O)R4, C0-2alkylene-Cyc, C(O)-Cyc, N(RN)2, NRNC(O)-Cyc, or C(O)NRN-Cyc;orone R1taken together with Ring A and the morpholine ring forms(a) a spiro ring moiety having a structure(b) a fused ring moiety having a structureRing A is further substituted with 0 to 4 R1;each of R2and R2Ais H, or R2and R2A, together with the atoms to which they are attached, form a fused cyclopropyl ring;Cyc is C3-6cycloalkyl, C6-10aryl, 5-6-membered heterocycle or 5-6 membered heteroaryl, wherein the heterocycle and heteroaryl have 1 to 3 ring heteroatoms independently selected from N, 0, and S, and Cyc is substituted with 0, 1, 2, or 3 R®c;each RCycis independently halogen, oxo, OH, C1-4alkyl, C0-2alkylene-C(O)R4, or -S(O)2R3;each R3is independently N(RN)2, C1-3alkyl, or C3-6cycloalkyl;each R4is independently OH, N(RN)2, phenyl, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, C1-3haloalkyoxy, C1-3hydroxyalkyl, or C1-3hydroxy alkoxy;each RNis independently H, phenyl, C1-4 alkyl, or -S(O)2Ci-3alkyl; andSeries 1 / 5 33827 / 50003 / PCHet is pyrazolyl or triazolyl and is substituted with 0, 1, or 2 halogens,with the proviso that when n is 0, Ring A is phenyl, and R2Aand R2are H, then Het is substituted with 1 or 2 halogens.
2. The compound or salt of claim 1, wherein Ring A is C6-10aryl.
3. The compound or salt of claim 2, wherein Ring A is phenyl.
4. The compound or salt of claim 2, wherein Ring A is naphthyl.
5. The compound or salt of claim 1, wherein Ring A is 5-6 membered heteroaryl having 1, 2, or 3 ring heteroatoms independently selected from N, 0, and S.
6. The compound or salt of claim 5, wherein Ring A is pyridinyl.
7. The compound or salt of claim 5, wherein Ring A is pyrimidinyl.
8. The compound or salt of claim 5, wherein Ring A is pyrazolyl.
9. The compound or salt of claim 1, wherein Ring A is indolyl, isoindolyl, indolinyl, or isoindolinyl.
10. The compound or salt of any one of claims 1 to 9, wherein, at least one R1is a halogen.
11. The compound or salt of claim 10, wherein at least one R1is F.
12. The compound, or salt of claim 10 or 11, wherein at least two R1are F.
13. The compound, or salt of any one of claims 10 to 12, wherein at least one R1is Cl.
14. The compound or salt of any one of claims 1 to 13, wherein at least one R1is CN.
15. The compound, or salt of any one of claims 1 to 14, wherein at least one R1is C1-3alkyl.
16. The compound or salt of claim 15, wherein at least one R1is methyl.
17. The compound, or salt of any one of claims 1 to 16, wherein at least one R1is C1-3alkoxy.
18. The compound, or salt of claim 17, wherein at least one R1is methoxy.
19. The compound, or salt of any one of claims 1 to 18, wherein at least one R1is C1-3haloalkyl.
20. The compound, or salt of claim 19, wherein at least one R1is fluoromethyl, difluoromethyl, or trifluoromethyl.
21. The compound, or salt of any one of claims 1 to 20, wherein at least one R1is C1-3haloalkoxy.
22. The compound, or salt of claim 21, wherein at least one R1is difluoromethoxy or trifluoromethoxy.
23. The compound, or salt of any one of claims 1 to 22, wherein at least one R1is C0-2alkylene-C(O)R4.
24. The compound or salt of claim 23, wherein at least one R1is C0-2alkylene-C(O)N(RN)2.
25. The compound, or salt of claim 24, wherein at least one R1is C(O)NHS(O)2Me, C(O)NMe2, C(O)NHMe, or C(O)NH226. The compound, or salt of claim 24, wherein at least one R1is CH2-C(O)NHS(O)2Me, CH2-C(O)NMe2, CH2- C(O)NHMe, or CH2-C(O)NH2.
27. The compound, or salt of any one of claims 23 to 26, wherein at least one R1is Co-2alkylene-C02H.
28. The compound, or salt of claim 27, wherein least one R1is CO2H or CH2CO2H.
29. The compound, or salt of any one of claims 1 to 28, wherein at least one R1is -SO2R3.Series 1 / 5 33827 / 50003 / PC30. The compound or salt of claim 29, wherein at least one R1is -SO2CH3, -SO2NH2, -SO2NHMe, or -SO2NMe2.
31. The compound, or salt of any one of claims 1 to 29, wherein at least one R1is C0-2alkylene-Cyc, C(O)-Cyc, or C(O)NH-Cyc.
32. The compound, or salt of claim 31, wherein at least one R1is Cyc.
33. The compound, or salt of claim 31, wherein at least one R1is CH2Cyc.
34. The compound, or salt of any one of claims 31 to 33, wherein at least one R1is C(O)-Cyc.
35. The compound, or salt of any one of claims 31 to 34, wherein at least one R1is C(O)NH-Cyc.
36. The compound, or salt of any one of claims 31 to 35, wherein at least one Cyc is C6-10aryl substituted with 0,1, 2, or 3 R*.
37. The compound, or salt of claim 36, wherein at least one Cyc is phenyl substituted with 1, 2, or 3 R*.
38. The compound, or salt of any one of claims 31 to 37, wherein at least one Cyc is 5-6-membered heterocycle with 1 to 3 ring heteroatoms independently selected from N, 0, and S, and is substituted with 0, 1, 2, or 3 RCyc39. The compound, or salt of claim 38, wherein at least one Cyc is piperidinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, piperazinyl or pyrrolidinyl, and is substituted with 0, 1, 2, or 3 R*.
40. The compound, or salt of any one of claims 31 to 39, wherein at least one Cyc is 5-6-membered heteroaryl with 1 to 3 ring heteroatoms independently selected from N, O, and S, and is substituted with 0, 1, 2, or 3 RCyc41. The compound, or salt of claim 40, wherein at least one Cyc is pyridinyl or pyrazolyl, and is substituted with 0, 1, 2, or 3 R*.
42. The compound, or salt of any one of claims 30 to 41, wherein at least one Cyc is C3-6cycloalkyl substituted with 0, 1, 2, or 3 R*.
43. The compound, or salt of claim 42, wherein at least one Cyc is cyclohexyl substituted with 0, 1, 2, or 3 R*.
44. The compound, or salt of any one of claims 1 to 43, wherein at least one R* is halogen, oxo, OH, or C1-4 alkyl.
45. The compound, or salt of claim 44, wherein at least one R* is F.
46. The compound, or salt of claim 44 or 45, wherein at least one R* is oxo.
47. The compound, or salt of claim 44, 45, or 46, wherein at least one R* is OH.
48. The compound, or salt of any one of claims 44 to 47, wherein at least one R* is methyl.
49. The compound, or salt of any one of claims 1 to 48, wherein at least one R* is C0-2alkylene-C(O)R4, C(O)N(RN)2, or -S(O)2R350. The compound, or salt of claim 49, wherein one R* is -C(O)Me, -C(0)0Me, -C(O)CH2OH, -C(O)iPr, - C(O)CF3, -C(O)Ph, -C(O)NH2, -C(O)NHMe, -C(O)NMe2, -C(O)NHPh, SO2Me, -SO2NH2, -SO2NHMe, or - SO2NMe2.Series 1 / 5 33827 / 50003 / PC51. The compound, or salt of any one of claims 1 to 50, wherein each of R2and R2Ais H.
52. The compound, or salt of any one of claims 1 to 50, having a structure of Formula (IA-0)53. The compound, or salt of any one of claims 1 to 51, wherein one R1taken together with Ring A and themorpholine ring forms a spiro ring moiety having a structureRing A is further substituted with 0 to 4 R1.is further substituted with 0 to 4 R1.
55. The compound, or salt of any one of claims 1 to 51, wherein one R1taken together with Ring A and themorpholine ring forms a fused ring moiety having a structureRing A is further substituted with 0 to 4 R1.
56. The compound or salt of any one of claims 53 to 55, wherein Ring A is further substituted with 0 R1.
57. The compound, or salt of any one of claims 1 to 56, wherein n is 1, 2, or 3.
58. The compound, or salt of claim 57, wherein n is 1 or 2.
59. The compound or salt of any one of claims 1 to 58, having a structure of Formula (IB-0):
60. The compound or salt of claim 59, having a structure of Formula (IC-0):Series 1 / 5 33827 / 50003 / PC61. The compound or salt of claim 59, having a structure of Formula (IB-1'):Het(IB-1’).
62. The compound or salt of claim 61, having a structure of Formula (IC-1):
63. The compound or salt of any one of claims 1 to 60, wherein Ring A is 5-6 membered heteroaryl having 1, 2, or 3 ring heteroatoms independently selected from N, 0, and S.
64. The compound or salt of any one of claims 1 to 63, wherein Het is pyrazolyl.YNN65. The compound or salt of claim 64, wherein Het isZ / 66. The compound or salt of any one of claims 1 to 63, wherein Het is triazolyl.
67. The compound or salt of claim 66, wherein Het is •68. The compound or salt of any one of claims 1 to 67, wherein Het is substituted with 1 or 2 halogens.
69. The compound, or salt of claim 1, having a structure listed in Table 1.
70. The compound, or salt of claim 1, having a structure listed in Table 2.
71. The compound, or salt of claim 70, selected from the group consisting of Compound 34, 35, 39, 45, 47, 56, 184, 186, 188, 200, 202, 204, and 214.
72. The compound, or salt of claim 71, selected from the group consisting of Compound 34, 35, 45, 47, 184, and 186.
73. A pharmaceutical composition comprising a compound, stereoisomer, or salt of any one of claims 1 to 72, and at least one pharmaceutically acceptable excipient74. A method of inhibiting ELOVL1 comprising contacting ELOVL1 with a compound or salt of any one of claims 1 to 72 or composition of claim 73.Series 1 / 5 33827 / 50003 / PC75. A method of treating a condition associated with, or caused by, accumulation of Very Long Chain Fatty Acids (VLCFAs) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound or salt of any one of claims 1 to 72 or composition of claim 73.
76. The method of claim 75, wherein the accumulation of VLCFAs is due to a defect in peroxisomal degradation.
77. The method of claim 75 or 76, wherein the condition is associated with, or caused by, one or more mutations in ABCD1.
78. The method of any one of claims 75 to 77 wherein the condition is X-linked adreno-leukodystrophy (X-ALD or ALD), cerebral adrenoleukodystrophy (cALD), childhood onset cerebral adrenoleukodystrophy (CCALD), adolescent onset cerebral adrenoleukodystrophy, adult onset cerebral adrenoleukodystrophy, cerebello- brainstem form of ALD (CBALD), adrenomyeloneuropathy (AMN), or adrenal insufficiency (Addison only) form of ALD.
79. The method of claim 75 or 76, wherein the condition is Zellweger Syndrome, Neonatal Adreno- leukodystrophy (NALD), Infantile Refsum Disease (IRD), Adult Refsum Disease (ARD), Heimler Syndrome, a mitochondrial disorder, or a peripheral neuropathy.
